Cell Signaling Regulatory Mechanisms Controlling Epithelial-Mesenchymal Transition in Carcinoma by Buonato, Janine Marie
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
1-1-2015
Cell Signaling Regulatory Mechanisms Controlling
Epithelial-Mesenchymal Transition in Carcinoma
Janine Marie Buonato
University of Pennsylvania, hjanine@seas.upenn.edu
Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the Biomedical Commons, Cell Biology Commons, and the Molecular Biology
Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/1628
For more information, please contact libraryrepository@pobox.upenn.edu.
Recommended Citation
Buonato, Janine Marie, "Cell Signaling Regulatory Mechanisms Controlling Epithelial-Mesenchymal Transition in Carcinoma" (2015).
Publicly Accessible Penn Dissertations. 1628.
http://repository.upenn.edu/edissertations/1628
Cell Signaling Regulatory Mechanisms Controlling Epithelial-
Mesenchymal Transition in Carcinoma
Abstract
Epithelial-mesenchymal transition (EMT) is a cellular program normally engaged during development and
wound healing that is hijacked in many cancers to drive metastasis and resistance to therapy. The clinical
implications of EMT in cancer progression have driven efforts to understand the cellular processes controlling
EMT induction. Transforming growth factor-beta (TGFβ) and expression of related transcription factors
potentiate EMT induction through complex and incompletely understood mechanisms. In this thesis, we
investigated specific intracellular signaling pathways controlling maintenance of mesenchymal characteristics
and EMT induction in response to growth factors in lung and pancreatic carcinoma cells. In lung carcinoma
cells, extracellular signal-regulated kinase-1/2 (ERK1/2) pathway activation, which promotes cell survival
and proliferation, was required for complete EMT induction. Furthermore, chronic ERK1/2 inhibition
reversed baseline mesenchymal traits while simultaneously augmenting cellular sensitivity to a clinically
approved small molecule EGFR inhibitor in cell lines with multiple clinically relevant modes of therapy
resistance. In both lung and pancreatic carcinoma cell lines, TGFβ-mediated EMT was enhanced by co-
treatment with epidermal growth factor (EGF), as had been noted in other contexts. We demonstrated that
the ability of EGF to enhance TGFβ-mediated EMT depended on SH2 domain-containing phosphatase-2
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ABSTRACT 
 
CELL SIGNALING REGULATORY MECHANISMS CONTROLLING EPITHELIAL-
MESENCHYMAL TRANSITION IN CARCINOMA 
 
Janine M. Buonato 
Matthew J. Lazzara 
 
 Epithelial-mesenchymal transition (EMT) is a cellular program normally engaged during 
development and wound healing that is hijacked in many cancers to drive metastasis and 
resistance to therapy. The clinical implications of EMT in cancer progression have driven efforts 
to understand the cellular processes controlling EMT induction. Transforming growth factor-beta 
(TGFβ) and expression of related transcription factors potentiate EMT induction through complex 
and incompletely understood mechanisms. In this thesis, we investigated specific intracellular 
signaling pathways controlling maintenance of mesenchymal characteristics and EMT induction in 
response to growth factors in lung and pancreatic carcinoma cells. In lung carcinoma cells, 
extracellular signal-regulated kinase-1/2 (ERK1/2) pathway activation, which promotes cell 
survival and proliferation, was required for complete EMT induction. Furthermore, chronic ERK1/2 
inhibition reversed baseline mesenchymal traits while simultaneously augmenting cellular 
sensitivity to a clinically approved small molecule EGFR inhibitor in cell lines with multiple 
clinically relevant modes of therapy resistance. In both lung and pancreatic carcinoma cell lines, 
TGFβ-mediated EMT was enhanced by co-treatment with epidermal growth factor (EGF), as had 
been noted in other contexts. We demonstrated that the ability of EGF to enhance TGFβ-
mediated EMT depended on SH2 domain-containing phosphatase-2 (SHP2) activation through 
tyrosine phosphorylated adapter binding, which is required for complete ERK1/2 activation. 
Though SHP2 was not directly engaged and activated by TGFβ, SHP2 was required for TGFβ-
mediated effects. Incomplete or transient effects of ERK inhibition and SHP2 depletion motivated 
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subsequent systematic evaluation of cell signaling processes engaged during EMT induction to 
identify other pathways that control mesenchymal dedifferentiation in pancreatic carcinoma cells. 
We thus developed a data-driven computational model to predict the relationships between 
multivariate signaling events and EMT-associated phenotypes in response to combinations of 
TGFβ, EGF, and hepatocyte growth factor (HGF). Signaling intermediates that co-varied most 
with mesenchymal traits provided novel potential targets to inhibit EMT phenotype acquisition or 
restore epithelial traits in carcinoma. Together, this thesis enhanced mechanistic understanding 
of EMT regulation by SHP2, identified novel strategies to reverse EMT phenotypes in carcinoma 
cells, and generated a quantitative model to understand mesenchymal dedifferentiation, which 
can be leveraged in the future to improve clinical outcomes for cancer patients. 
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CHAPTER 1: Introduction  
 
1-1 THE EPITHELIAL-MESENCHYMAL TRANSITION  
 Epithelial-mesenchymal transition (EMT) is a cellular program that allows fully 
differentiated epithelial cells to undergo a series of modifications ultimately leading to acquisition 
of a less differentiated mesenchymal phenotype. During this process, epithelial cells lose their 
distinctive morphology with strong cell-cell adhesions, patterned organization, and apical-basal 
polarity to acquire a more invasive and migratory phenotype with front-back polarity [1]. EMT is 
engaged during specific stages of normal development including embryonic implantation, 
gastrulation, and migration from the neural crest as well as in wound healing in mature organisms 
[2, 3]. In these contexts, EMT induction is necessary for proper development and homeostasis. 
However, EMT can also produce unfavorable outcomes in disease including fibrosis at sites of 
inflammation and cancer metastasis [3, 4]. These central roles for EMT in both development and 
disease have motivated extensive research to characterize and understand the details of this 
series of coordinated complex alterations within and among cells. 
As illustrated in Figure 1-1, EMT induction causes shifts in cellular morphology, 
dissolution of cell-cell adhesions, and invasion into the basement membrane. These phenotypic 
outcomes are accompanied by corresponding shifts in expression of proteins that make up the 
cytoskeleton, compose junctional complexes, and allow degradation of and invasion into the 
surrounding stroma [5]. Epithelial cells are characterized by expression of junctional proteins E-
cadherin and zona occludens-1 (ZO-1) as well as cytokeratin. As cell-cell adhesions dissolve 
during EMT, expression of these epithelial markers decreases in favor of mesenchymal cell 
markers, which include vimentin, fibronectin, and N-cadherin [2]. Expression of the zinc-finger 
binding transcription factors Snail1 or Snail2 (also known as Slug) or one of the basic helix-loop-
helix factors Twist1 or ZEB-1 can induce EMT by repressing transcription of genes involved in 
cell-cell adhesion or promoting transcription of mesenchymal-associated genes [2]. These 
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transcription factors are upregulated during EMT and are often considered master-regulators of 
EMT because overexpression of Twist1 [6, 7] or Snail [7] alone, for example, can induce the 
complex array of EMT processes. In addition to shifts in protein and transcription factor 
expression, cells undergoing EMT display changes in extracellular matrix (ECM) protein 
deposition and interaction [5], alternative splicing of mRNA [8], and microRNA expression [9], 
further highlighting the complexity of EMT.  
 
 
Figure 1-1: Epithelial-mesenchymal transition. 
Fully differentiated epithelial cells have strong cell-cell contacts, apical-basal polarity, and express 
the proteins E-cadherin, ZO-1, and cytokeratin. In response to certain cues (e.g., TGFβ), cells 
lose these traits, undergoing an epithelial-mesenchymal transition (EMT). EMT promotes invasion 
into the surrounding stroma and expression of vimentin, N-cadherin, and transcription factors 
including Snail and Twist. Full EMT induction results in complete loss of E-cadherin expression 
and eliminates all cell-cell contacts. Partial EMT states are observed where cells express both 
epithelial and mesenchymal proteins. 
 
 
EMT is initiated by exposure to growth factors of the transforming growth factor-beta 
(TGFβ) super family. Within this family Nodal, Vg1/GDF-1, and bone morphogenic proteins drive 
EMT during different stages of embryogenesis [2]. The title family member, TGFβ-1, is more 
commonly the driver of EMT in inflammation, fibrosis, and wound healing [2, 4]. TGFβ1 itself 
(hereafter referred to as TGFβ), however, has complex biological roles, producing outcomes of 
both EMT and apoptosis depending on the cell context [4, 10]. For in vitro cell culture models, 
recombinant TGFβ can be used to induce EMT in immortalized epithelial cell lines. Because of its 
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pro-apoptotic effects, TGFβ is often combined with other stimulatory growth factors in these 
culture models to enhance EMT induction [11]. For example, addition of epidermal growth factor 
(EGF) with TGFβ in cell culture has been shown to favor EMT induction over apoptotic outcomes 
[12, 13] and enhance EMT phenotype acquisition compared to TGFβ alone [12-14].  This thesis is 
focused specifically on identifying and quantitatively describing the molecular mechanisms 
controlling EMT in cancer cells in response to different growth factor treatments or at baseline. 
Translation of these advances into therapeutic strategies could contribute to improved patient 
outcomes for multiple reasons, but first a more detailed description of the existing knowledge 
surrounding EMT must be established to reveal gaps in our understanding. 
 
 
Figure 1-2: Cancer initiation and progression in epithelial tissues. 
Healthy epithelial cells form acinar structures with a hollow lumen and are surrounded by stroma 
which contains other cell types including fibroblasts. A tumorigenic event (e.g., oncogenic 
mutation) causes cell transformation and unchecked proliferation which results in occlusion of the 
lumen. Further growth and progression leads to rupture of the epithelial structure and 
dissemination of cells into the stroma and bloodstream. 
  
1-2 EMT IN CANCER 
 In addition to its established roles in development, EMT has been implicated in cancer 
progression, particularly for solid tumors originating from epithelial tissues. In healthy tissues, 
epithelial cells exist in highly ordered configurations, often surrounding ducts where they form 
acinar structures with a hollow lumen surrounded by ECM [15, 16]. As shown in Figure 1-2, 
unchecked cellular proliferation during cancerous progression leads to occlusion of the lumen [15, 
17]. The ability of cells to disseminate from the primary tumor site into the bloodstream requires 
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cells to invade the surrounding ECM and has therefore been hypothesized to depend upon EMT. 
This dissemination is required for metastasis, which causes an estimated 90% of cancer-related 
deaths [18, 19], making deciphering this process of prime importance. 
 The overlap between traits required for metastatic dissemination and traits conferred to 
epithelial cells during EMT led investigators over the last 15 years to draw a causal link between 
these processes with support of in vitro and in vivo models [3]. There have been detractors of this 
model, however, due to the lack of direct evidence of cancer cells ‘in the act’ of undergoing EMT 
to invade the surrounding matrix in histological tumor analysis [20]. Additionally, tumor 
metastases often display epithelial characteristics similar to the primary tumor cells rather than a 
mesenchymal phenotype, which further complicated the EMT model [2]. However, in 2012 a 
mouse model of pancreatic ductal adenocarcinoma provided direct evidence of EMT leading to 
metastasis, where epithelial-derived cells genetically labeled with a fluorescent protein were seen 
in the stroma surrounding pancreatic ducts, though apart from their fluorescence they were 
indistinguishable from stromal fibroblasts [21]. Somewhat surprisingly, EMT induction, invasion, 
and detection of pancreatic-derived cells in the liver were seen at very early stages of progression 
from premalignant lesions. Disseminated cells also displayed EMT plasticity consistent with the 
histological similarity between primary and metastatic tumors as well as observations from 
previous studies that metastatic colonization requires a mesenchymal-epithelial transition (MET) 
[22, 23]. Although this establishes concrete evidence for EMT during cancer progression, many 
questions remain regarding precise cues controlling initial EMT induction and MET reversion. 
 Further incentive to investigate EMT in the context of carcinoma progression has 
emerged over the last ten years as accumulating evidence has linked mesenchymal traits to 
therapeutic resistance across cancer types [24]. Mesenchymal dedifferentiation has been 
associated with resistance to chemotherapy and targeted therapeutics in cancers including those 
of the lung [25-28], bladder [29], head and neck [30, 31], pancreas [32], and breast [28, 33]. EMT 
or EMT-like phenotype switching has also been linked to the ability of initially therapy-sensitive 
cells to become resistant in lung cancer [28, 34, 35] and melanoma [36]. A more detailed 
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mechanistic understanding of the processes controlling EMT determination in cancer could thus 
be leveraged to improve patient response and increase efficacy of targeted drugs and 
chemotherapeutics. 
 Another framework for understanding certain features of tumor initiation and progression 
that has emerged in parallel with EMT investigations is the observation of cancer stem cells 
(CSCs). CSCs can be defined functionally by proliferative and self-renewal capabilities and the 
ability of a single cell to seed new tumors that recapitulate the cellular heterogeneity of the 
original tumor. CSCs have been characterized in acute myeloid leukemia [37] as well as in solid 
tumors including breast and colon carcinomas [38, 39]. The undifferentiated nature of stem cells 
and the requirement that disseminated cancer cells (the product of EMT) must be able to form 
metastatic lesions from a single cell, have linked the concepts of CSCs to EMT [24]. Indeed there 
has been evidence that after undergoing EMT, cells display certain properties of CSCs, such as 
tumor-initiating capacity and surface expression of stem cell markers [40]. However, as the CSC 
concept has matured in the literature, additional properties have been attributed to CSCs that are 
sometimes in opposition to each other, for example both dormancy and proliferation [41, 42]. 
Additionally, the inability to purify a stem cell population displaying all attributed CSC surface 
markers and phenotypic traits has motivated a shift toward characterizing stemness as a property 
of certain cancer cells rather than focusing on the absolute definition of a CSC population [41]. 
Thus, rather than defining CSC populations, examining certain stem cell characteristics and 
attributes will prove useful references to characterize EMT-associated transformations in this 
work and elsewhere. 
 
1-3 CELL SIGNALING AND EMT  
 Cellular decision making and acquisition of phenotypes in response to extracellular 
stimuli, such as EMT in response to TGFβ or death in response to therapy, is controlled by 
networks of intracellular signaling pathways. Transmission of information through such signaling 
networks often originates from transmembrane receptor proteins including receptor tyrosine 
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kinases (RTKs) and receptor serine/threonine kinases. Receptor extracellular domain binding to 
soluble or immobilized ligand can lead to receptor dimerization and activation of the intracellular 
kinase domain [43]. In the case of RTKs, the induced catalytic activity of the kinase domain leads 
to covalent attachment of phosphates onto tyrosine residues on the receptor itself and/or 
downstream substrates. Phosphorylated tyrosine residues serve as binding sites for downstream 
adapters containing SRC-homology-2 (SH2) or phosphotyrosine binding (PTB) domains [44]. 
Recruitment of such adapter proteins leads to further protein modifications and protein 
interactions resulting in the activation of downstream signaling pathways such as the mitogen 
activated protein kinase (MAPK), signal transducer and activator of transcription (STAT), and 
phosphoinositide 3-kinase (PI3K)/AKT pathways. Signals originating at the plasma membrane 
ultimately impact cell behavior through transcriptional effects mediated in the cell nucleus. 
Systematic evaluation of the precise signaling pathways activated in response to cellular stimuli 
and resulting phenotypic effects can thus reveal mechanisms that predict or control cellular 
outcomes.  
As implied by the complex nature of the EMT program, the signaling networks engaged 
during EMT downstream of TGFβ, for example, are extensive and complex [45, 46]. Dimers of 
TGFβ bind, and thus bring together, two pairs of receptor serine/threonine kinases [10]. Each pair 
contains one type I and one type II receptor, and upon binding to TGFβ, the type II receptor 
phosphorylates the type I receptor leading to recruitment and phosphorylation of SMAD 
transcription factors [4]. Due to this direct activation by TGFβ receptors, the SMAD signaling 
pathways are often considered ‘canonical’ TGFβ signaling pathways. There are, however, many 
other pathways activated downstream of TGFβ including the extracellular signal-regulated kinase 
(ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK pathways [47]. Though the type I and II 
TGFβ receptors are well-characterized serine/threonine kinases, the type II receptor displays a 
low level of autophosphorylation on tyrosine residues [48] and can be tyrosine phosphorylated by 
the cytosolic kinase SRC [49]. This tyrosine phosphorylation can lead to recruitment of adapter 
proteins in the MAPK cascades, specifically SHC, GRB2, and SOS [50, 51]. The JNK and p38 
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pathways are also activated downstream of TRAF6 recruitment to TGFβ receptor complexes [47]. 
Additionally, PI3K/AKT pathway activation has been reported downstream of TGFβ in multiple 
cell types through less fully described mechanisms [46]. Of these non-SMAD pathways 
downstream of TGFβ, there is evidence that ERK activation in particular is necessary for EMT 
induction [14, 45, 52]. In certain cell types, other growth factors including EGF [53], fibroblast 
growth factor (FGF) [54], and hepatocyte growth factor (HGF) [54] can induce EMT. The EGF 
receptor (EGFR) can also be activated in a SRC-dependent manner by TGFβ receptors, 
promoting ERK activation [55, 56]. EGFR activation through this intracellular mechanism or by 
EGF treatment often enhances EMT outcomes in vitro compared to TGFβ treatment alone [12-
14, 57]. 
 In addition to displaying differential activation of signaling pathways during EMT 
induction, cells that have undergone EMT through transcription factor expression, growth factor 
treatment, or other mechanisms display altered signaling networks. For example, inducible 
expression of Twist or Snail in the non-small cell lung cancer (NSCLC) cell line H358 reduced 
basal AKT phosphorylation through downregulation of the EGFR-family member ERBB3 [58]. 
Similarly, EMT driven by expression of Twist, Snail, or Slug in mammary epithelial cells was 
accompanied by decreased EGFR and increased platelet-derived growth factor receptor 
(PDGFR) expression [7]. Additional models of mesenchymal dedifferentiation have also found 
upregulation of PDGFR [26, 59] as well as other receptors including c-MET (the receptor for 
HGF) [59], lysophosphatic acid receptor [59], FGF receptor (FGFR) [26], and AXL [28]. 
 
1-4 EPIDERMAL GROWTH FACTOR RECEPTOR IN CANCER 
 Epidermal growth factor receptor (EGFR) kinases are activated upon ligand binding to 
the EGFR extracellular domain, which promotes receptor dimerization and trans-
autophosphorylation on multiple tyrosine residues in the receptor C-terminal tail (Figure 1-3, 
reviewed in [43, 60, 61]). Phosphorylated EGFR dimers then recruit downstream signaling 
adapters through phosphotyrosine-SH2 and -PTB domain interactions. These interactions 
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ultimately lead to activation of pathways that promote cell survival, proliferation, and growth 
including AKT, ERK, and STAT3.  
 
 
Figure 1-3: Epidermal growth factor receptor activation. 
Epidermal growth factor receptor (EGFR) activation is initiated by binding of EGF to the 
extracellular domain of the receptor, inducing receptor dimerization. Asymmetrical interaction of 
intracellular kinase domains activates their catalytic activity, leading to ATP-dependent 
phosphorylation (p) of tyrosine residues (Y) on the C-terminal tail in trans. The small molecule 
gefitinib is an ATP analog, which inhibits this receptor autophosphorylation mechanism. 
 
EGFR overexpression occurs with high frequency in many cancer types including 70-
80% of NSCLC [62] and ~50% of glioblastoma multiforme (GBM) [63, 64] tumors. Additionally, 
EGFR-activating mutations are detected at 10-20% and 25-30% overall in NSCLC and GBM, 
respectively. Due to these high rates of overexpression and mutation, a number of small molecule 
inhibitors (e.g., gefitinib) and monoclonal antibodies (e.g., cetuximab) targeting EGFR have been 
developed and approved for various cancers [65]. Despite their ability to specifically inhibit EGFR 
signaling these drugs generally confer little clinical advantage, with rare notable exceptions. For 
example, in NSCLC the subset of tumors expressing kinase-activated mutants of EGFR display 
significant initial response to small molecule EGFR inhibitors [66-68]. However, though initial 
response is often dramatic, these patients almost invariably develop resistance to EGFR 
inhibition, often through acquisition of the EGFR ‘gatekeeper’ mutation (T790M) [69, 70]. Up-
regulation of c-MET [71] and ERK2 amplification [72] are other mechanisms leading to adaptive 
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resistance to EGFR inhibition. Interestingly, in addition to EGFR inhibitor response, expression of 
kinase activated EGFR mutants is correlated with enhanced epithelial characteristics compared 
to wild type expressing cells [73], and EMT phenotype acquisition is a mechanism of acquired 
resistance in these cells [35]. 
The NSCLC-associated EGFR mutants that confer inhibitor sensitivity display elevated 
kinase activity and impaired endocytosis compared to wild type EGFR, indicating constitutive 
receptor-mediated signaling from the plasma membrane. Corresponding phosphorylation of 
downstream signaling components such as AKT and STAT3/5 is elevated in cells harboring these 
EGFR mutations [67]. Interestingly however, the same EGFR mutants also lead to suppressed 
ERK phosphorylation relative to wild type EGFR, which is linked to the enhanced cellular 
response to EGFR inhibition [74]. Recent work identified a mechanism for this ERK suppression 
through functional impairment of the proto-oncogene SH2-domain containing phosphatase-2 
(SHP2) [75], a cytosolic protein tyrosine phosphatase (PTP), which is recruited to receptor-bound 
signaling complexes to promote full ERK activation (Figure 1-4). In the context of wild type 
receptor activation, ligand-bound EGFR dimers trans-autophosphorylate, leading to recruitment of 
downstream signaling intermediates growth factor receptor-bound protein 2 (GRB2) and GRB2-
associated binding protein 1 (GAB1) [76]. GAB1 is then phosphorylated on multiple tyrosine 
residues which are recognized by SH2 domains on SHP2, leading to relief of intramolecular 
SHP2 inhibition and access of the phosphatase domain to substrates (Figure 1-4, refs [77-79]). In 
the context of kinase-activated EGFR mutants, SHP2 is constitutively associated with GAB1 and 
endocytosis-impaired EGFR in a way that suppresses its ability to promote ERK activation [75]. 
As implied by its designation as a proto-oncogene, SHP2-activating mutations have been 
causally linked to multiple cancers including juvenile myelomonocytic leukemia and acute 
myelogenous leukemia [80, 81], and SHP2 activity through regulating the ERK pathway has been 
shown to promote tumorigenesis in models of breast cancer and GBM [82, 83]. 
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Figure 1-4: ERK pathway signaling downstream of EGFR activation. 
In cells at rest, EGFR and SHP2 exist in inactive conformations stabilized through intramolecular 
interactions. EGF-induced EGFR kinase activation and phosphorylation (P) leads to recruitment 
of the signaling adapters GRB2 and GAB1. Phosphorylation of GAB1 on multiple tyrosine 
residues recruits binding of SHP2’s SH2 domains, which activates SHP2 by relieving an inhibitory 
interaction of the N-terminal SH2 and PTP domains. SHP2 phosphatase activity promotes ERK 
pathway activation through multiple routes including dephosphorylation of a binding site on GAB1 
for the RAS-inhibitory molecule RASGAP.  
  
1-5 ERK PATHWAY PERTURBATIONS IN CANCER AND EMT 
 ERK1 and ERK2 are the terminal MAPK proteins in a cascade that originates at the 
plasma membrane with the small GTPase RAS. RAS is activated downstream of many RTKs, as 
shown for EGFR in Figure 1-4. RAS promotes dimerization and activation of the RAF MAPK-
kinase-kinases, which in turn phosphorylate the MAPK-kinases MEK1/2, which phosphorylate 
ERK1/2. The ERK pathway is well established as promoting cellular survival and proliferation, 
and mutations within the RAS-RAF-MEK-ERK signaling cascade occur with high frequency in 
many cancers [84, 85]. The most common mutations in this cascade (and of all oncogenes) are 
found in the RAS family genes – KRAS (which represents a large majority of RAS mutations), 
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NRAS, and HRAS – with high overall RAS mutation incidence in pancreatic (~95%), colorectal 
(~50%), and lung (~30%) adenocarcinomas and notable mutational populations in many other 
malignancies, including uterine, thyroid, gastric, and cervical carcinomas [86]. BRAF mutations 
also occur with high frequency in certain malignancies including melanoma (~70%), papillary 
thyroid cancer (~50%), and colon cancer (~10%) [86]. Since the discovery of RAS mutations in 
human cancer in 1982 [87, 88], ongoing research efforts have been devoted to characterizing and 
targeting RAS and RAF proteins, but few advances have been made that confer significant 
clinical benefit. Particular challenges have arisen due to the complex function and difficult-to-
target nature of RAS signaling [86], as well as the importance of negative feedback loops within 
the cascade particularly downstream of mutant BRAF [89, 90]. Significant efforts have thus 
focused on targeting proteins downstream of RAS such as MEK [84, 85]. Trametinib recently 
became the first FDA-approved MEK inhibitor after improved overall survival was demonstrated in 
metastatic melanoma patients with BRAF mutation [91, 92]. 
This same signaling cascade has been linked to EMT with several studies demonstrating 
a requirement for ERK1/2 pathway activity for TGFβ-induced EMT in multiple non-transformed 
cellular backgrounds [14, 45, 52]. The activity of ERK2 specifically induces EMT in non-
transformed mammary epithelial cells [93] and has been implicated as the mediator of oncogenic 
KRAS-induced invasion in pancreatic cancer cells [94]. Furthermore, phosphatases within the 
ERK cascade including SHP2, PTPN14, and MKP3 have been implicated in EMT induction [95-
97]. In some cell contexts TGFβ alone is able to induce ERK activation and subsequent EMT [51, 
56, 98], while in others EGF addition is needed to activate the ERK pathway and promote TGFβ-
driven EMT [14, 57]. The molecular interactions responsible for these effects have not been 
described, but would provide important insight into routes for controlling EMT.  
 
1-6 THESIS SUMMARY 
 Clinical intervention strategies to reduce or eliminate the invasive capacity of tumor cells 
and enhance therapy response have the potential to substantially impact cancer patient 
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prognosis. With these aims in mind, this thesis focuses on approaches to understand and control 
EMT induction in cancer cells. In Chapter 2, we studied how suppressing ERK activation using a 
MEK inhibitor affected EMT induction and baseline mesenchymal characteristics in NSCLC cells. 
We found that MEK inhibition impaired EMT in response to the combination of TGFβ and EGF in 
lung cancer cells. MEK inhibition in the absence of EMT-inducing growth factors also promoted 
acquisition of epithelial characteristics in cells with either wild type or mutant EGFR expression on 
a timescale (multiple days) which was much longer than that for ERK pathway suppression 
(several minutes). Further investigation revealed that prolonged MEK inhibition continued to 
promote epithelial marker expression while significantly enhancing cell death in response to the 
EGFR inhibitor gefitinib. This strategy of staggered exposure to MEK- and EGFR-targeted 
inhibitors led to enhanced cell death response in multiple cell lines with de novo or acquired 
gefitinib resistance, suggesting potential efficacy in different clinical populations of lung 
carcinoma. The concurrent acquisition of epithelial traits from MEK inhibition and enhanced 
sensitivity also provided basic validation of the concept that targeting EMT could augment 
therapeutic response. 
 The striking effect of MEK inhibition on EMT induction motivated further investigation into 
upstream components in the ERK pathway. Given previous knowledge about its importance in 
ERK pathway activation and determining gefitinib response, the role of the cytosolic phosphatase 
SHP2 in EMT induction was explored in Chapter 3. Specifically, we investigated how the 
presence and activation of SHP2 contributed to the ability of EGF to enhance EMT induction by 
TGFβ. EGF has been shown to augment TGFβ-mediated EMT in multiple cell settings, which we 
observed and quantified in lung and pancreatic cancer cell lines. In these cells, EGF significantly 
enhanced TGFβ-mediated downregulation of E-cadherin, upregulation of vimentin, and increased 
migration. We found that basal SHP2 activity is required for EMT in response to TGFβ alone and 
that the augmented EMT from EGF addition resulted from induced SHP2 activity through SHP2 
SH2-domain binding to tyrosine phosphorylated GAB1. These results suggested that SHP2 is a 
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key effector in EMT induction whose degree of activation is associated with the extent of EMT 
observed in response to various stimuli. 
 In Chapter 4, motivated by the ability to reverse EMT with chronic MEK inhibition, we took 
a broader view of EMT-relevant signaling networks to identify other targets for inhibiting or 
reversing mesenchymal dedifferentiation in pancreatic cancer cells. We combined high-
throughput temporal protein phosphorylation measurements and quantitative EMT phenotype 
measurements in response to EMT-inducing growth factor treatments in a partial least squares 
regression (PLSR) computational model to identify the protein phosphorylation events that are 
most predictive of EMT induction. We found that different combinations of EGF, HGF, and TGFβ 
produced quantitatively different EMT states, which was captured in the reduced dimension 
principal component space from the PLSR model. Additionally, we specifically identified early and 
late phosphorylation events that are most predictive of EMT induction. This model will motivate 
further investigation into additional targets for reversing mesenchymal phenotypes to produce 
clinically impactful outcomes similar to those observed in Chapters 2 and 3 for ERK pathway 
inhibition. 
In Chapter 5 we discussed the implications of our findings, which have enhanced our 
understanding of EMT regulation and offered several approaches to improve clinical outcomes 
through impairing mesenchymal phenotypes. Implementing alternative scheduling of MEK and 
EGFR inhibitors was proposed as a potential route for improving patient responses, though in 
vivo models will be important tools to evaluate the potential of this approach moving forward. Our 
findings have also provided further motivation to develop strategies and therapeutic compounds 
to specifically target SHP2 activity in carcinoma. Finally, we have identified several additional 
potential targets for inhibiting EMT that should be evaluated for their quantitative impact on the 
dynamics and strength of EMT induction.   
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CHAPTER 2: ERK1/2 Inhibition Prevents Epithelial-Mesenchymal 
Transition and Promotes Sensitivity to EGFR Inhibition in Lung 
Cancer Cells1 
2-1 ABSTRACT 
Understanding and overcoming the cellular mechanisms underlying de novo and 
acquired resistance to chemotherapy and targeted inhibitors remain challenges in treating many 
cancers, including non-small cell lung cancer (NSCLC).  A number of studies have linked the 
mesenchymal cellular phenotype and epithelial-mesenchymal transition (EMT) with resistance to 
multiple classes of cancer therapeutics, which begs the question of whether inhibiting or reversing 
EMT could be an attractive therapeutic goal.  Here, we demonstrate that ERK signaling plays a 
key role in determining mesenchymal cellular characteristics in NSCLC cells and that this 
connection can be leveraged to augment cellular response to inhibition of the epidermal growth 
factor receptor (EGFR).  In NSCLC cell lines, MEK inhibition pushed cells toward a more 
epithelial phenotype and prevented EMT induction by exogenous transforming growth factor beta.  
Moreover, in cell lines with de novo or acquired resistance to the EGFR inhibitor gefitinib, chronic 
MEK inhibition synergistically enhanced cellular sensitivity to gefitinib and slowed cell migration.  
These effects only occurred, however, when MEK was inhibited for enough time to observe 
changes in epithelial and mesenchymal marker expression.  Changes in these same phenotypes 
and associated changes in epithelial/mesenchymal markers also occurred as a result of KRAS 
mutant expression in a MEK-dependent manner.  These results suggest a potential clinical 
strategy for scheduling targeted inhibitors of MEK or ERK and EGFR in order to induce 
mesenchymal-epithelial transition as a way overcome naïve or acquired resistance to EGFR-
targeted therapy.  
                                                     
1 A version of Chapter 2 was previously published as: Buonato JM and Lazzara MJ, ERK1/2 
blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their 
sensitivity to EGFR inhibition, Cancer Research 74: 309-319, 2014. 
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2-2 INTRODUCTION 
Epidermal growth factor receptor (EGFR) over-expression and -activation are hallmarks 
of many cancers, including non-small cell lung cancer (NSCLC).  Consequently, a number of 
inhibitors and monoclonal antibodies targeting EGFR have been developed and approved for 
various cancers.  Unfortunately, these drugs are generally ineffective.  In NSCLC, response to 
EGFR inhibitors is limited mainly to the rare patients (~10%) whose tumors harbor somatic, 
kinase-activated mutants of EGFR [66, 67].  Even these patients almost invariably develop 
resistance to EGFR inhibitors, often through the EGFR “gatekeeper” mutation (T790M) [69, 70] or 
through up-regulation of c-MET or other receptors [71].  Combination therapies present a possible 
strategy to overcome resistance.  In NSCLC, recent investigations suggest promise for combining 
EGFR inhibitors with chemoradiation [99], the multi-kinase inhibitor sorafenib [100], or a c-MET 
inhibitor [101].  Scheduling multiple drugs such that initial therapy reprograms cells to respond to 
another drug is another possible strategy.  In one recent example, triple-negative breast cancer 
cells and NSCLC cells were dramatically sensitized to doxorubicin by pre-treatment with the 
EGFR inhibitor erlotinib [102].  
Epithelial-mesenchymal transition (EMT) is another pathway through which cancers of 
epithelial origin become chemoresistant.  EMT is a developmental process whereby epithelial 
cells lose cell-cell adhesions to become more motile and invasive.  Cells undergoing EMT lose 
expression of epithelial markers (e.g., E-cadherin) and gain expression of mesenchymal markers 
(e.g., vimentin and fibronectin) through differential expression and activation of transcription 
factors including Twist, ZEB1, and Snail [2, 103].  EMT is frequently hijacked in metastatic 
progression, and mesenchymal dedifferentiation has been associated with resistance to EGFR 
inhibitors, chemotherapy, and other targeted drugs in cancers of the lung [25-27], bladder [29], 
head and neck [30, 31], pancreas [32], and breast [33].  In NSCLC, in vitro acquired resistance to 
the EGFR inhibitor erlotinib can result from selection of a mesenchymal sub-population [35], and 
restoring E-cadherin expression in mesenchymal-like NSCLC cells potentiates sensitivity to 
EGFR inhibitors [104].  Additionally, growing evidence for AXL-mediated EGFR inhibitor 
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resistance has been tied to EMT [105].  Thus, developing treatments that elicit a mesenchymal-
epithelial transition (MET) could be a useful approach for expanding the efficacy of EGFR 
inhibitors. 
  Several studies have demonstrated a requirement for extracellular signal-regulated 
kinase-1/2 (ERK1/2) pathway activity in EMT induced by transforming growth factor beta (TGFβ) 
in non-transformed cells [14, 45, 52].  ERK2, but not ERK1, activity also induces EMT in non-
transformed mammary epithelial cells [93] and has been implicated as mediating oncogenic 
KRAS-induced invasion in pancreatic cancer cells [94].  Interestingly, ERK2 amplification was 
recently identified as a mechanism leading to acquired resistance to EGFR inhibitors in NSCLC 
[72]. 
Here, we sought to determine ERK’s role in governing EMT in NSCLC.  In a panel of 
NSCLC cell lines, MEK inhibitors prevented TGFβ-induced EMT and promoted epithelial cellular 
characteristics when administered alone. Conversely, augmented ERK activation, through 
KRAS12V expression or ERK2 amplification, promoted mesenchymal characteristics.  
Furthermore, chronic MEK inhibition for times long enough to observe changes in epithelial and 
mesenchymal marker expression augmented cellular sensitivity to the EGFR inhibitor gefitinib in 
cell lines with de novo or acquired resistance to EGFR inhibitors.  These changes were reversible 
and accompanied by shifts in expression of stem cell-like markers CD24 and CD44.  These 
results suggest the potential utility of drug scheduling strategies first targeting ERK to promote 
epithelial characteristics prior to targeting EGFR or other oncogenic signaling nodes.  
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2-3 MATERIALS AND METHODS 
Cell culture  
 H1666 cells were obtained from the American Type Culture Collection. H322, gefitinib-
resistant PC9 (clone GR4, referred to as GR henceforth), and WZ4002-resistant PC9 cells (clone 
WZR12, referred to as WZR henceforth) were provided by Dr. Pasi Jänne (Dana-Farber Cancer 
Institute).  Parental PC9 cells were provided by Dr. Douglas Lauffenburger (MIT).  Since PC9 
cells came from different labs, we confirmed similar expression of important proteins and 
response to gefitinib for parental stocks from both labs.  H358 cells were provided by Dr. Russ 
Carstens (University of Pennsylvania).  PC9 (all variants), H322, and H358 cells were maintained 
in RPMI 1640 supplemented with 10% FBS, 100 units/mL penicillin, 100 μg/mL streptomycin, and 
1 mM L-glutamine.  H1666 cells were maintained in ACL4 [74].  Cell culture reagents were from 
Life Technologies.  Cell lines were validated for anticipated responsiveness to gefitinib and were 
cultured for less than two months from low-passage frozen stocks. 
Chronic MEK inhibition in H1666, PC9GR, and PC9 WZR 
 H1666, PC9 GR, and PC9 WZR cells were maintained in 10 μM, 5 μM, and 20 μM 
U0126, respectively, with controls maintained in DMSO.  Responses to 1 hr or 2 day treatments 
with a range of U0126 concentrations were evaluated for each cell line to identify U0126 
concentrations yielding significantly inhibited ERK phosphorylation (Fig. 2-S1) but minimal 
background cell death.  For culture experiments, media was changed every two days or cells 
were passed as necessary.  When passing, cells were sub-cultured into inhibitor-free media to 
promote adhesion.  U0126 or DMSO was replaced the following day.  When appropriate, cells 
were lysed or gefitinib was added 24 hrs later.  Time points in figures with chronic MEK inhibition 
reflect the total time of U0126 exposure before lysing or gefitinib addition.  To probe the 
reversibility of U0126 effects, cells were split from U0126 cultures after 7 days and maintained in 
DMSO thereafter.  All time courses were performed from freshly thawed cells multiple times to 
demonstrate reproducibility.  Naïve cell death response to U0126 and gefitinib was quantified at 
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multiple points during time courses, including the beginning and end, to verify that baseline 
response was not changing.  
The MEK inhibitor CI-1040 (LC Labs) stock was prepared in DMSO.  All applicable 
experiments used 3 μM CI-1040.  Lysate preparation, wound healing measurements, and 
experiments testing gefitinib sensitivity from chronic MEK inhibition with CI-1040 were performed 
analogously to experiments described using U0126. 
Chronic MEK inhibition in H322, H358, and SKBR3 
 H322 cells were cultured in 40 μM U0126 and H358 and SKBR3 cells were cultured in 10 
μM U0126 or DMSO control, analogously to above.  After 5 days of U0126 culture, cells were 
lysed or treated with 5 μM gefitinib.  Cells treated for 48 hrs were collected and co-stained with 
TO-PRO3 and Annexin-V FITC conjugate (Southern Biotech) according to manufacturer 
instructions.  Cells were analyzed within 1 hr on a BD Biosciences FACSCalibur flow cytometer. 
Data for percent apoptotic cells reflects the sum of all cells staining positively for Annexin-V or 
TO-PRO3. 
Wound healing assay.  
 Confluent cell monolayers in 6-well plates were scratched with a pipet tip, and media was 
immediately changed.  Phase contrast images were taken with a Zeiss Axiovert 40 CFL 
microscope (10X objective) every 1-3 hrs for ≤11 hrs.  Scratch areas were quantified using 
ImageJ, and closure rates were calculated from linear fits of areas versus time and reported as 
percent of total image area closed per hr normalized to the conditions indicated in figures.  Where 
inhibitors were used, cells were plated at sub-confluence and treated at appropriate times with 
media containing inhibitor.  Media and inhibitor were changed every two days until wells reached 
confluence. 
Transwell migration assay 
 Untreated PC9 GR and WZR cells or H1666 cells treated with U0126 or DMSO for 4 
days were trypsinized and resuspended in media containing 0.1% FBS and U0126 or DMSO for 
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H1666.  20,000 untreated or DMSO-treated cells or 50,000 U0126-treated cells (adjusted for 
U0126-mediated changes in adhesion) were added to 8 μm Transwell membranes (Corning), 
which were placed in 24-well plates well containing complete media with DMSO or U0126.  After 
20 hrs, cells on the upper surfaces were removed with a cotton swab.  Cells on the lower 
surfaces were fixed in 4% paraformaldehyde for 30 min and washed with PBS, and nuclei were 
stained with Hoescht-33342.  Membranes were mounted and imaged (10X objective), and nuclei 
were counted using ImageJ.  Counts were normalized to the number of adhered cells from 
parallel wells for each condition. 
Flow cytometry 
 For cell death assays, cells were plated in 6-well dishes from their various culture 
conditions and treated with inhibitors.  Floating and adherent cells were collected 48 hrs later, 
resuspended in PBS containing TO-PRO3 (Life Technologies), and analyzed within 1 hr.  For 
CD24 and CD44 measurements, cells were collected as above, washed with 0.1% BSA in PBS 
(PBSA), blocked for 10 min in PBSA, and incubated for 1 hr with 3 μL each of FITC-conjugated 
anti-human CD44 antibody (BD Pharmingen, #555478) and Alexa-647 conjugated anti-human 
CD24 antibody (BioLegend, #311109) in 200 μL.  Labeled cells were washed again and 
resuspended in PBS.  Cytometry was performed on a BD Biosciences FACSCalibur cytometer, 
and data were analyzed using FlowJo.  
Western blotting 
 Cell lysates were prepared using a standard cell extraction buffer (Invitrogen) 
supplemented with 1 mM PMSF, additional protease inhibitors (Sigma), and phosphatase 
inhibitors (Sigma).  Proteins were resolved by SDS-PAGE and transferred to nitrocellulose 
membranes, which were blocked in Odyssey Blocking Buffer (LI-COR) and stripped with 0.2 M 
NaOH as needed.  Blots were scanned using a LI-COR Odyssey Infrared Imaging System. 
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Antibodies and other reagents 
 pERK T202/Y204 (#4377) and ERK (#4695) antibodies were from Cell Signaling 
Technology.  E-cadherin (sc-8426), vimentin (sc-373717), fibronectin (sc-8422), and GAPDH (sc-
32233) antibodies were from Santa Cruz Biotechnology.  Stocks of U0126 and gefitinib (LC Labs) 
were prepared in DMSO.  Recombinant human epidermal growth factor (EGF) and TGFβ were 
from Peprotech.  Infrared dye- and Alexa Fluor®-conjugated secondary antibodies were from 
Rockland Immunochemicals and Invitrogen, respectively. 
Immunofluorescence 
 Cells were plated on glass coverslips and maintained in 6-well dishes during ligand 
and/or inhibitor treatments.  Cells were then fixed in 4% paraformaldehyde in PBS for 20 min, 
blocked, stained, and imaged as described previously [106].  E-cadherin was stained using 2 
μg/mL antibody.  Alexa Fluor® 488-conjugated phalloidin at 6.6 nM (Invitrogen; provided by Dr. 
Deepak Nihilani, University of Pennsylvania) was added to the secondary antibody staining 
solution.  All samples within an experiment used identical image acquisition settings. 
KRAS12V expression 
 The pBabe-puro-KRAS-12V expression construct was acquired from Addgene (Dr. 
Channing Der, University of North Carolina).  Retrovirus was produced by calcium phosphate-
mediated transfection of amphotropic Phoenix cells (Dr. Gary Nolan, Stanford University).  Virus 
was harvested 24, 30, and 48 hrs post-transfection and used to infect target cells, which were 
selected in puromycin. 
EGF-mediated EGFR internalization assay 
 PC9 GR and WZR cells were treated for 24 hrs with 80 µM Dynasore (Calbiochem), a 
dynamin inhibitor, or DMSO (control).  EGF-mediated EGFR endocytosis rate constants (ke) were 
then measured using 10 ng/mL 125I-EGF with corrections for non-specific binding and spill over, 
as previously described [107, 108]. 
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2-4 RESULTS 
NSCLC cell lines undergo MEK-dependent TGFβ-induced EMT 
 H1666, H322, and H358 cells were cultured in complete media with TGFβ and EGF with 
or without U0126 for four days, with a media change after two days (Fig. 2-1).  In response to 
TGFβ and EGF, E-cadherin expression decreased and vimentin expression increased in all three 
cell lines, and fibronectin expression increased in H1666 and H358 cells (Fig. 2-1A).  U0126 co-
treatment inhibited changes in E-cadherin and vimentin, but did not prevent fibronectin induction.  
The same trends were found in H1666 cells using the alternative MEK inhibitor CI-1040 (Fig. 2-
S2).  The conditions used in Fig. 2-1A were explored in H1666 cells by immunofluorescence (Fig. 
2-1B).  Treatment with TGFβ and EGF promoted an elongated cellular morphology, the 
appearance of F-actin fibers, and decreased E-cadherin intensity.  U0126 addition prevented E-
cadherin loss and promoted E-cadherin localization at cell-cell junctions.  
 
Figure 2-1: MEK inhibition prevents TGFβ-induced EMT in NSCLC cell lines. 
(A) H1666, H322, and H358 cells were treated for four days with 10 ng/mL TGFβ + 50 ng/mL 
EGF, TGFβ + EGF and 20 μM U0126, or DMSO (control).  Whole cell lysates were analyzed by 
western blot with antibodies against indicated proteins.  Images are representative of at least 
three independent experiments. (B) H1666 cells on glass coverslips were treated as in (A), fixed, 
and stained for E-cadherin, F-actin, and DNA. Images are representative of three replicates from 
each of two independent experiments.  Scale bar = 20 μm. 
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Figure 2-2: MEK inhibition promotes epithelial characteristics in H1666 cells. 
(A) H1666 cells plated on glass coverslips were treated with 20 μM U0126 for 4 days, fixed, and 
stained for E-cadherin, F-actin, and DNA.  Images are representative of three replicates from 
each of two independent experiments.  Scale bar = 20 μm. (B) Wound closure rates were 
measured for H1666 cells treated with DMSO (control) or 20 μM U0126 at the time of scratch or 
for 1 or 4 days prior to scratch.  Rates normalized to the control condition for triplicate wells from 
two different platings (n = 6) are reported as averages ± s.e.m.  Representative phase contrast 
images are shown, with tracings added to identify open scratch areas.  Scale bar = 200 μm. (C) 
Lysates prepared in parallel to (B) were analyzed by western blot using antibodies against 
indicated proteins.  Signals normalized to respective DMSO controls are reported as averages ± 
s.e.m. (n = 3). (D) Transwell migration experiments were performed for H1666 cells pre-treated 
with DMSO or 20 μM U0126 for 4 days.  Counts normalized to DMSO control for duplicate wells 
from three separate experiments (n = 6) are reported as averages ± s.e.m. * and ** indicate p < 
0.05 and 0.005, respectively. 
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MEK inhibition promotes epithelial phenotypes in NSCLC cells 
 We next explored the ability of MEK inhibition alone to promote epithelial characteristics 
in H1666 cells.  As seen when combined with TGFβ and EGF, U0126 promoted E-cadherin 
localization at cell-cell junctions (Fig. 2-2A).  MEK inhibition also antagonized H1666 wound 
healing in a treatment time-dependent manner (Fig. 2-2B, 2-S3).  While U0126 inhibited ERK 
phosphorylation within 1 hr of addition (Fig. 2-S1), U0126 treatment for the duration of the scratch 
assay (10 hrs) did not significantly affect wound closure rate (“at scratch” condition versus DMSO 
in Fig. 2-2B).  Wound closure rate decreased significantly with 1 day of U0126 pre-treatment and 
was nearly zero with four days of pre-treatment.  Western blots of lysates created in parallel 
revealed that E-cadherin expression increased and vimentin expression decreased with 
increasing U0126 exposure time, consistent with the time-dependent changes in wound closure 
rate (Fig. 2-2C, Fig. 2-S3).  U0126-mediated changes in wound healing migration were further 
confirmed by assessing migration across Transwell inserts (Fig. 2-2D).  
Chronic MEK inhibition sensitizes NSCLC cells to EGFR inhibition on a time scale consistent with 
changes in epithelial and mesenchymal markers 
 Since epithelial characteristics have been connected to EGFR dependence in NSCLC 
[27, 104], we explored the ability of MEK inhibition to increase sensitivity to gefitinib (Fig. 2-3).  As 
described in Materials and Methods Section 2-3, H1666 cells were maintained in 10 μM U0126 or 
DMSO (control) for up to 3 weeks. Throughout the 3-week period, cells were evaluated for death 
response to gefitinib.  Without U0126 pre-treatment, 2 days of EGFR and MEK co-inhibition led to 
only 7% cell death in H1666, but this more than doubled with 3 days of U0126 pre-treatment (Fig. 
2-3A, 2-S4A).  This enhancement further increased with additional U0126 pre-treatment time, 
reaching a maximum at 11 days.  Increased cellular sensitivity to gefitinib was accompanied by 
increased E-cadherin expression (Fig. 2-3B, 2-S4B).  Beyond 11 days, the synergistic effect 
began to decrease, which was accompanied by increased fibronectin expression and decreased 
E-cadherin expression.  Similar effects were observed in H1666 cells using CI-1040 (Fig. 2-S4C).  
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H358 and H322 cells and the breast cancer cell line SKBR3 were also evaluated for 
response to gefitinib following chronic MEK inhibition (Fig. 2-S5).  H358 cells harbor a KRAS 
mutation and are ERK-addicted [109].  Not surprisingly therefore, H358 response to gefitinib was 
not augmented by U0126 pre-treatment.  However, H322 and SKBR3 cells were sensitized to 
EGFR inhibition with 5 days of U0126 exposure, suggesting fairly broad applicability of this 
strategy. 
We also probed the reversibility of the effects of chronic MEK inhibition in H1666 cells 
(Fig. 2-3C-E, 2-S6).  After 7 days, a fraction of cells was split from the U0126 culture and 
maintained in media containing DMSO (control).  This “U0126 removal” culture was subsequently 
plated in parallel with the cells maintained in U0126.  After 7 days of U0126 exposure, removal 
from U0126 for 4 days completely reversed changes in cellular sensitivity to gefitinib and 
epithelial and mesenchymal marker expression (Fig. 2-3C-D, 2-S6A).  
 Stem cell-like sub-populations with intrinsic therapeutic resistance are found within 
tumors [35, 110] and are typically identified as CD44high/CD24low [35] or E-cadherinlow [111]. 
CD44high/CD24low enrichment from heterogeneous cultures promotes mesenchymal behaviors 
including resistance to EGFR inhibitors [35].  Using flow cytometry, we measured the shift in the 
CD44high/CD24low sub-population with U0126 addition and subsequent removal (Fig. 2-3E, 2-
S6B).  U0126-treated cells had fewer CD44high/CD24low cells and more CD44low/CD24high cells 
than controls.  As with epithelial/mesenchymal marker expression, U0126 removal for four days 
reversed the effect on the CD44low/CD24high population.  
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Figure 2-3: Chronic MEK inhibition sensitizes NSCLC cells to EGFR inhibition. 
(A) H1666 cells were cultured in 10 μM U0126 or DMSO (control) for up to 3 weeks and were 
evaluated for cell death response to 10 μM gefitinib for various U0126 exposure times.  Cell 
death was measured by flow cytometry for TO-PRO3 permeability 48 hrs after gefitinib addition.  
Averaged data are shown ± s.e.m. (n = 3); significance is relative to any other condition from the 
same day. (B) Lysates prepared in parallel to (A), before gefitinib addition, were analyzed by 
western blot with antibodies against the indicated proteins.  Signals normalized to respective 
DMSO controls are reported as averages ± s.e.m. (n = 3). (C) The reversibility of U0126-
mediated effects was assessed as described in Materials and Methods Section 2-3.  For cells 
removed from (U0126 removal) or maintained in U0126, response to the same drug co-treatment 
was assessed by TO-PRO3 permeability at the indicated times.  Data are represented as 
averages ± s.e.m (n = 3). (D and E) Reversibility of U0126 effects was assessed by western blot 
(D), using antibodies against indicated proteins, and by flow cytometry for CD44 and CD24 
staining (E). Blot images are representative of three replicates. Flow cytometry data are 
represented as averages ± s.e.m. (n = 3).  Times indicated reflect the total time of U0126 
exposure prior to lysis, gefitinib addition, or staining; * and ** p < 0.05 and 0.005, respectively. 
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KRAS12V-mediated ERK activation promotes EMT 
 To further probe the connection between ERK activity and EMT, we expressed KRAS12V 
in H1666 cells.  This produced an anticipated increase in ERK phosphorylation and increased 
vimentin expression (Fig. 2-4A).  Gefitinib and U0126 promoted an epithelial shift in control cells, 
as determined by western blot and wound closure measurements (Fig. 2-4A, B).  KRAS12V 
promoted maintenance of ERK phosphorylation in response to gefitinib and largely prevented 
gefitinib-mediated changes in marker expression and wound closure (Fig. 2-4A, B).  Importantly, 
the effects of KRAS12V were MEK-dependent, as demonstrated by the effects of U0126 (Fig. 2-4). 
 
Figure 2-4: KRAS12V expression promotes mesenchymal characteristics in 
H1666 cells. 
(A) H1666 cells transduced with KRAS12V or an empty vector control (EV) treated for three days 
with DMSO, 2 μM gefitinib, or 20 μM U0126 were lysed and analyzed by western blot with 
antibodies against indicated proteins.  Signals normalized to DMSO-treated EV lysates are 
reported as averages ± s.e.m. (n = 3). (B) Wound closure rates were measured for EV- and 
KRAS12V-transduced cells treated as in panel (A).  Rates normalized to the EV DMSO control 
condition are reported as averages ± s.e.m. for triplicate wells from two different platings (n = 6).  
Representative phase contrast images are shown, with tracings added to identify open scratch 
areas.  Scale bar = 200 μm. * and ** indicate p < 0.05 and 0.005, respectively 
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MEK inhibition antagonizes mesenchymal phenotypes and acquired resistance to EGFR 
inhibition in an EGFR mutant-expressing cell line 
 We tested the effects of chronic MEK inhibition in a panel of cell lines derived from PC9 
cells, which express EGFRdelE746_A750 and are gefitinib sensitive.  In parental PC9 cells, MEK 
inhibition prevented TGFβ-mediated EMT and drove changes in epithelial/mesenchymal marker 
expression and wound healing consistent with the effects observed in H1666 cells (Fig. 2-5, 2-
S7).   
A previous study derived PC9 cells that acquired gefitinib resistance through EGFRT790M 
mutation [72].  Another cell line was then derived from these cells with secondary resistance to 
the irreversible EGFR inhibitor WZ4002, which potently inhibits EGFRT790M [72, 112].  WZ4002 
resistance arose through ERK2 amplification.  We used these gefitinib-resistant (GR) and 
WZ4002-resistant (WZR) clones to examine the effects of ERK2 activity, which has been tied to 
EMT in non-transformed cells [93].  WZR cells displayed a more mesenchymal marker 
expression pattern than parental or GR cells, with increased fibronectin and vimentin expression 
and decreased E-cadherin expression (Fig. 2-6A).  WZR cells were also more migratory than GR 
cells as measured by wound closure and Transwell migration (Fig. 2-6B, C).  
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Figure 2-5: ERK activity determines epithelial/mesenchymal characteristics 
in an NSCLC cell line with an EGFR-activating mutation. 
(A) Lysates of parental PC9 cells treated for four days with 10 ng/mL TGFβ + 50 ng/mL EGF, 
TGFβ + EGF and 20 μM U0126, or DMSO (control) were analyzed by western blot with 
antibodies against indicated proteins.  Images are representative of three independent 
experiments.  Scale bar = 20 μm. (B) PC9 cells on glass coverslips were treated as in (A), fixed, 
and stained for E-cadherin, F-actin, and DNA.  Images are representative of three replicates for 
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each of two independent experiments. (C) Wound closure rates were measured for PC9 cells 
treated with DMSO (control) or 20 μM U0126 at the time of scratch or for 1 or 4 days prior to 
scratch.  Rates  normalized to the control condition for triplicate wells from two different platings 
(n = 6) are reported as averages ± s.e.m.  Representative phase contrast images are shown, with 
tracings added to identify open scratch areas.  Scale bar = 200 μm. (D) Lysates prepared in 
parallel to (C) were analyzed by western blot using antibodies against indicated proteins.  Images 
are representative of three independent experiments.  Signals normalized to respective DMSO 
controls are reported as averages ± s.e.m. (n = 3); * and ** indicate p < 0.05 and 0.005, 
respectively, compared to control.  
 
The effects of chronic MEK inhibition were tested in GR and WZR cells, using a higher 
U0126 concentration for WZR because of the ERK2 amplification.  Death response to co-
treatment was enhanced by approximately two-fold with three days of U0126 pre-treatment in 
both cell lines (Fig. 2-7A, 2-S8A,B).  As in H1666 cells, sufficiently long U0126 exposure resulted 
in an eventual decrease in augmented response to EGFR inhibition.  Increased sensitivity to 
gefitinib correlated with reduced vimentin expression and slight increases in E-cadherin 
expression, and the eventual decrease in augmentation was accompanied by increased 
fibronectin expression in WZR cells (fibronectin was not detectable in GR cells) (Fig. 2-7B, 2-
S8C).  
 
30 
 
 
Figure 2-6: ERK2 amplification promotes mesenchymal characteristics in 
PC9 cells with acquired resistance to an irreversible EGFR inhibitor. 
(A) Lysates prepared from parental, gefitinib-resistant (GR), and WZ4002-resistant (WZR) PC9 
cells grown in complete media were analyzed by western blot using antibodies against indicated 
proteins.  Images are representative of three independent experiments.  Densitometry data are 
shown normalized to PC9 parental signals and are reported as averages ± s.e.m. (n = 3); ** 
indicates p < 0.01. (B) Wound closure rates were measured for GR and WZR cells.  Rates 
normalized to GR closure rate are reported as averages ± s.e.m. for triplicate wells from each of 
two different platings (n = 6); * indicates p < 0.05.  Representative phase contrast images are 
shown, with tracings added to identify open scratch areas.  Scale bar = 200 μm.  (C) Transwell 
migration measurements were made for GR and WZR cells.  Bars represent averages ± s.e.m. 
for duplicate wells from three separate experiments (n = 6) normalized to GR cells. 
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Figure 2-7: MEK inhibition sensitizes cells with acquired resistance to 
EGFR inhibitors. 
(A) Gefitinib-resistant (GR) and WZ4002-resistant (WZR) PC9 cells were cultured in 5 μM and 20 
μM U0126, respectively, or DMSO (control) for up to 9 days, as described in Materials and 
Methods Section 2-3, and were evaluated for cell death response to 5 μM gefitinib for various 
U0126 exposure times.  Cell death was measured by flow cytometry for TO-PRO3 permeability 
48 hrs after gefitinib addition.  Time points represent total time exposed to U0126 prior to gefitinib 
addition or lysis.  Data are represented as averages ± s.e.m. (n = 3); significance is shown 
relative to any other condition from the same day.  (B) GR and WZR cell lysates prepared in 
parallel to (A) were analyzed by western blot using antibodies against indicated proteins.  
Average signals normalized to respective DMSO controls are reported ± s.e.m (n = 3). * and ** 
indicate p < 0.05 and 0.005, respectively.  
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2-5 DISCUSSION 
We characterized the role of ERK in regulating EMT in NSCLC cells.  MEK inhibition 
prevented TGFβ-induced EMT in NSCLC cell lines expressing wild type EGFR and KRAS 
(H1666 and H322), wild type EGFR and mutant KRAS (H358), or mutant EGFR (PC9).  This 
suggests a general role for ERK in promoting mesenchymal characteristics across typical NSCLC 
cell types.  MEK inhibition also antagonized mesenchymal-associated characteristics including 
migration, resistance to EGFR inhibition, and CD44high/CD24low expression.  
The role of ERK in EMT has been explored in other cell types.  ERK is an established 
determinant of EMT in non-transformed cells [14, 113-115], with ERK2 specifically implicated as 
an EMT driver [93, 94, 116].  This is consistent with findings in breast cancer [117], where MEK 
inhibition reverses miR-21-mediated EMT, and with studies of phosphatases regulating ERK (i.e., 
MKP3, PTPN14, and SHP2) [95-97], which also suggest a connection between ERK activity and 
EMT.  
A number of factors regulate ERK activity in NSCLC cells.  For example, we previously 
demonstrated a connection between impaired mutant EGFR endocytosis and impaired ERK 
activity [74].  More recently, in collaboration with others, we identified a coupling between ERK2 
amplification and increased EGFR endocytosis in the WZ4002-resistant PC9 cells used here [72].  
Interestingly, inhibiting EGFR endocytosis in WZ4002-resistant cells reduced ERK 
phosphorylation and promoted an epithelial marker expression pattern (Fig. 2-S9), drawing a 
potential connection between EGFR endocytosis and EMT. 
In H1666 cells, KRAS12V-driven ERK activity promoted mesenchymal marker expression 
and resistance to gefitinib-mediated MET changes.  These findings are generally consistent with 
studies connecting oncogenic HRAS or KRAS mutants with EMT in mammary epithelia [93], 
pancreatic cancer [94, 109], and lung cancer [109].  The MEK dependence of our observations 
with KRAS12V may support exploration of MEK and ERK inhibitors in NSCLCs with KRAS 
mutation. 
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In addition to promoting epithelial marker expression, MEK inhibition promoted response 
to EGFR inhibition.  Some studies have suggested the efficacy of EGFR and MEK co-inhibition in 
gastric cancer [118] and pancreatic cancer cells [119], and current clinical trials are testing 
erlotinib combined with MEK inhibitors in NSCLC.  In light of this, it is worth noting that the effects 
we observed with MEK inhibition occurred on a time scale that was much longer than that for 
ERK inhibition and more consistent with changes in epithelial and mesenchymal marker 
expression.  This may suggest considering a clinical scheduling approach wherein a MEK 
inhibitor is initially used alone to promote an epithelial phenotype, followed by addition of an 
EGFR inhibitor.  An analogous staggered drug scheduling approach was effective in triple 
negative breast cancer cells which were sensitized to doxorubicin by erlotinib pre-treatment in 
vitro and in mouse tumor xenografts [102].  Applying this basic concept to future clinical trial 
design may allow for lower MEK inhibitor doses to curb toxicities [120] and promote response to 
EGFR inhibitors.  Given that the time windows for augmented response to gefitinib and the useful 
concentrations of U0126 were variable among cell lines, it will of course be important first to 
examine this strategy in pre-clinical animal models to assess general efficacy in an in vivo setting 
and optimize timing and dosing.   
We note as well that some recent data suggests that MET is required for efficient 
colonization of distant metastases [22, 23].  Thus, in evaluating different potential strategies for 
driving MET, the potential to drive proliferation of metastases will have to be weighed against 
potential ability to kill tumor cells.  ERK may be an especially attractive target in this regard.  In at 
least one study, ERK inhibition through microRNA-mediated reduction of SHP2 (a positive 
regulator of ERK signaling) reduced metastases in an in vivo breast cancer model [82], which 
was due to SHP2’s simultaneous regulation of proliferation, invasion, and transcription factor 
expression.  Thus, promoting MET through ERK inhibition, which should additionally inhibit 
cellular proliferation, may mitigate risks associated with proliferation of micrometastases.   
In all three cell lines we tested for effects of chronic MEK inhibition, enhanced gefitinib 
response eventually decreased.  Though initially unresponsive to U0126, U0126-cultured cells 
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displayed noticeable cell death at mid-range time points (partially reflected by cell death 
measurements for U0126-only samples in Figs. 2-3 and 2-7).  This could result in selection for 
U0126-resistant cells over time.  Since the fraction of CD44high/CD24low cells in U0126-treated 
cultures remained low at time points when resistance was observed (Fig. 2-3C,E), the potentially 
inherently resistant population was apparently not CD44high/CD24low.  Alternatively, resistance 
could arise from adaptation of the entire cell population, for example through increased 
fibronectin-mediated signaling, which has been linked to AKT activation and docetaxel resistance 
in ovarian and breast cancer cells [121].  Indeed, in all cases, the eventual drop in augmented 
response to gefitinib was accompanied by increased fibronectin expression.  Future work should 
consider effectors of fibronectin-mediated signaling as signaling nodes whose inhibition may 
augment EGFR inhibitor response. 
While our data suggest potential relevance of our findings to de novo and acquired EGFR 
inhibitor resistance, responsiveness to chronic MEK inhibition was not uniform among cell lines, 
which could result from any of the numerous differences in initial conditions among NSCLC cell 
lines.  For example, while H1666 cells express wild type EGFR and KRAS, they also express the 
low-activity G446V BRAF mutant [122], which could influence their death response to MEK 
inhibition.  In the future, therefore, investigating the cellular initial conditions that may determine 
responsiveness to this approach and identifying alternative signaling nodes whose inhibition may 
result in more stable maintenance of an epithelial cell type will also be important.   
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2-7 SUPPLEMENTAL MATERIAL 
 
Figure 2-S1 
Lysates were prepared from (A) H1666, (B) PC9 GR, or (C) PC9 WZR cells treated with a range 
of U0126 concentrations for 1 hr or 2 days and evaluated by western blot using antibodies 
against the indicated proteins.  Line plots on the right are quantifications of western blot signals. 
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Figure 2-S2 
H1666 cells were treated for four days with 10 ng/mL TGFβ + 50 ng/mL EGF, a combination of 
TGFβ + EGF and 3μM CI-1040, or DMSO (control).  Whole cell lysates were analyzed by western 
blot with antibodies against indicated proteins.  
 
 
 
Figure 2-S3 
Wound closure rates were calculated as described in Materials and Methods Section 2-3 for 
H1666 cells treated with DMSO (control) or 3 μM CI-1040 for 1 or 4 days prior to scratch.  Rates 
are reported as averages ± s.e.m. normalized to the control condition for triplicate wells from two 
independent platings (n = 6).  Lysates prepared in parallel with wound closure experiments were 
analyzed by western blot using antibodies against indicated proteins. 
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Figure 2-S4 
(A) H1666 cells were cultured in 10 μM U0126 or DMSO (control) for up to 3 weeks, as described 
in Materials and Methods Section 2-3, and were evaluated for cell death response to gefitinib for 
various U0126 treatment times.  At each time point, U0126 pre-treated cells were treated with or 
without 10 μM gefitinib, and cell death was measured by flow cytometry for TO-PRO3 
permeability 48 hrs later.  Representative flow cytometry dot plots for average data presented in 
Fig. 2-3A are shown for each condition from the 3 day time point with gating for TO-PRO3 
positive cells. (B) Cell lysates prepared in parallel to flow experiments, prior to gefitinib addition, 
were analyzed by western blot with antibodies against indicated proteins. Image is representative 
of three replicates, and densitometry analysis is shown in Fig. 2-3B. (C) H1666 cells were 
cultured in 3 μM CI-1040 or DMSO (control) for up to 23 days, as described in Materials and 
Methods Section 2-3, and were evaluated for cell death response to gefitinib for various CI-1040 
exposure times.  Pre-treated cells were then treated with or without 2 μM gefitinib, and cell death 
was measured by flow cytometry for TO-PRO3 permeability 48 hrs later.  Data are represented 
as averages ± s.e.m (n = 3); ** indicates p < 0.005, with significance relative to any other 
condition from the same day. 
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Figure 2-S5 
(A) H322 cells were cultured in 40 μM U0126 and (B) H358 and (C) SKBR3 cells were cultured in 
10 μM U0126 for a total of 5 days before addition of 5 μM gefitinib.  Cell death was measured by 
flow cytometry 48 hrs later using Annexin-V and TO-PRO3 co-staining, described in Materials 
and Methods Section 2-3.  Data are represented as averages ± s.e.m (n = 3); ** indicates p < 
0.005. 
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Figure 2-S6 
Experiments probing the reversibility of U0126-mediated effects were performed by splitting a 
fraction of cells from U0126 culture after 7 days and maintaining in DMSO (control) thereafter, as 
described in Materials and Methods Section 2-3. (A) For the times and treatment conditions 
indicated, cell lysates were analyzed by western blot using antibodies against indicated proteins.  
Data are represented as signals normalized to those from DMSO controls (i.e., cells maintained 
in DMSO throughout the experiment) and are reported as averages ± s.e.m. (n = 3).  A 
representative blot image is shown in Fig. 2-3D. (B) Reversibility was also evaluated by flow 
cytometry analysis for CD44 and CD24.  Representative flow cytometry dot plots for data in Fig. 
2-3E are shown for all three conditions of the 11 day time point. 
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Figure 2-S7 
(A) PC9 cells were treated for four days with 10 ng/mL TGFβ + 50 ng/mL EGF, a combination of 
TGFβ + EGF and 3 μM CI-1040, or DMSO (control).  Whole cell lysates were analyzed by 
western blot with antibodies against indicated proteins. (B) Wound closure rates were calculated 
as described in Materials and Methods Section 2-3 for PC9 cells treated with DMSO (control) or 
with 3 μM CI-1040 for 1 or 3 days prior to scratch.  Rates are reported as averages normalized to 
the control condition for duplicate wells. (C) Lysates prepared in parallel with wound closure 
experiments were analyzed by western blot using antibodies against indicated proteins. 
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Figure 2-S8 
 
 (A and B) PC9 GR and WZR cells were cultured in 5 μM and 20 μM U0126, respectively, or 
DMSO (control) for up to 9 days, as described in Materials and Methods, and were evaluated for 
cell death response to gefitinib for various U0126 exposure times.  At each time point, U0126 pre-
treated cells were treated with or without 5 μM gefitinib, and cell death was measured by flow 
cytometry for TO-PRO3 permeability 48 hrs after gefitinib addition.  Representative flow 
cytometry dot plots for averaged data in Fig. 2-7A are shown for GR cells (A) and WZR cells (B) 
from each condition from the 3 day time point with gating for TO-PRO3 positive cells. (C) Cell 
lysates prepared in parallel with flow experiments, prior to gefitinib addition, were analyzed by 
western blot with antibodies against the indicated proteins.  The image is representative of three 
replicates, and densitometry analysis is shown in Fig. 2-7B. 
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Figure 2-S9 
(A) EGF-mediated EGFR internalization rate constants (ke) for PC9 GR and WZR cells treated 
with 80 μM Dynasore or DMSO (control) were measured using 10 ng/mL 125I-EGF. Data are 
represented as averages ± s.e.m. for two separate experiments performed in triplicate (n = 6); * 
indicates p < 0.05. (B) PC9 GR and WZR cells in 6-well plates were treated with 80 μM Dynasore 
or DMSO (control) for 4 days, and lysates were analyzed by western blot with antibodies against 
the indicated proteins.  Triplicate samples are shown for each condition. 
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CHAPTER 3: EGF Augments TGFβ-Induced Epithelial-
Mesenchymal Transition by Promoting SHP2 Binding to GAB12 
 
3-1 ABSTRACT 
 In many epithelial cells, epidermal growth factor (EGF) augments the epithelial-
mesenchymal transition (EMT) that occurs when cells are treated with transforming growth factor 
beta (TGFβ).  Here, we demonstrate that this augmentation requires activation of SH2 domain-
containing phosphatase-2 (SHP2), a proto-oncogene. In lung and pancreatic cancer cell lines, 
reductions in E-cadherin expression, increases in vimentin expression, and increases in cell 
scatter rates were larger when cells were treated with TGFβ and EGF versus TGFβ or EGF 
alone. SHP2 knockdown promoted epithelial characteristics basally and antagonized EMT in 
response to TGFβ alone or in combination with EGF. While EGF promoted SHP2 binding to 
tyrosine phosphorylated GAB1, which promotes SHP2 activity, TGFβ did not induce SHP2 
association with phosphotyrosine-containing proteins. Knockdown of endogenous SHP2 and 
reconstitution with an SHP2 mutant with impaired phosphotyrosine binding ability eliminated the 
EGF-mediated EMT augmentation that was otherwise restored with wild type SHP2 
reconstitution. These results demonstrate roles for basal and ligand-induced SHP2 activity in 
EMT and further motivate efforts to identify specific ways to inhibit SHP2, given the role of EMT in 
cancer dissemination and chemoresistance.  
                                                     
2 A version of Chapter 3 is under revision at a peer-reviewed journal and includes co-author Ingrid 
Lan 
45 
 
3-2 INTRODUCTION 
Epithelial-mesenchymal transition (EMT) is a cellular program in which epithelial cells 
lose polarity and strong cell-cell adhesions and partially dedifferentiate to become more motile 
and invasive [2]. EMT is accompanied by shifts in transcription factor expression, cytoskeletal 
arrangement, RNA splicing, and cell signaling [2-4]. While EMT is required for normal 
development and wound healing, aberrant EMT has also been linked to metastasis [21, 123] and 
tumor resistance to therapy [124]. In lung and pancreatic cancer cells, sensitivity to therapeutic 
agents can be increased by promoting an epithelial phenotype [104, 125, 126]. These findings 
have motivated studies to decipher the signaling and regulatory mechanisms underlying EMT 
[127-129].  
EMT is efficiently driven in vitro and in vivo by transforming growth factor-β (TGFβ) [4], 
which initiates a network of cellular signaling pathways including SMADs, extracellular signal-
regulated kinase-1/2 (ERK1/2), p38, and c-Jun N-terminal kinase [46, 47]. Activity of ERK1/2 
(hereafter referred to as ERK) has been identified as particularly important for TGFβ-driven EMT 
[14, 45, 126]. Epidermal growth factor (EGF), which initiates its own signaling network including 
ERK, is often combined with TGFβ to enhance EMT outcomes in vitro [12-14, 57], and the 
augmented EMT that results has been attributed to ERK activation [14, 57].  In some cell settings, 
TGFβ cross-activates the EGF receptor (EGFR), which augments ERK pathway activation [55, 
56, 98].  
Downstream of EGFR and other receptor tyrosine kinases (RTKs), complete ERK 
activation depends upon the activity of SH2 domain-containing phosphatase-2 (SHP2), a 
cytosolic protein tyrosine phosphatase.  In the basal state, an auto-inhibited SHP2 conformation 
is stabilized wherein the N-terminal SH2 domain binds and occludes the catalytic domain [77, 
130]. Binding of SHP2 SH2 domains to phosphotyrosines on various RTKs or on adaptor proteins 
such as GRB2 associated binding protein-1 (GAB1) [76, 78] relieves this intramolecular inhibitory 
mechanism and allows SHP2 phosphatase domain access to substrates [79, 131, 132]. Point 
mutations of the βB5 arginine residues in the FLVRES motifs of either or both of the SH2 
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domains reduce the ability of phosphotyrosine peptides to induce SHP2 phosphatase activity, 
with greater effects for the more N-terminal SH2 domain arginine, Arg32 [79, 133]. Furthermore, 
SHP2 isoforms with either or both of these SH2 domain point mutants (R32K/R138K) display 
impaired ability to induce downstream signaling [134, 135] and lead to developmental defects in 
mice [135, 136], again with greater dependence on Arg32 functionality. SHP2 is a proto-oncogene, 
with SHP2 mutations or overexpression linked to a number of malignancies [80]. In breast cancer 
models, endogenous wild type SHP2 promotes tumor progression and metastasis in mice [82] 
and promotes mesenchymal marker expression and phenotypes in cultured breast cancer cell 
lines [97]. SHP2 has also been identified as a promoter of TGFβ-mediated EMT in A549 lung 
carcinoma cells [137], but whether differential SHP2 activation and regulation of ERK activity play 
a role in the ability of EGF to enhance TGFβ-mediated EMT is unknown. 
We used lung and pancreatic cancer cell lines to explore the role of SHP2 in driving EMT 
in response to TGFβ. While TGFβ alone produced EMT effects in both cell lines, combining EGF 
with TGFβ enhanced EMT as determined by increased cell scatter and by larger decreases in E-
cadherin expression and larger increases in vimentin expression observed by immunoblot and 
immunofluorescence. In contrast to TGFβ, EGF (alone or in combination with TGFβ) induced 
SHP2 activity by promoting SHP2 association with phosphorylated GAB1. Knockdown of 
endogenous SHP2 promoted baseline epithelial cell characteristics and inhibited EMT-associated 
changes in response to TGFβ with or without EGF. Reconstitution with SHP2WT restored EMT in 
response to TGFβ and the ability of EGF to enhance the effects of TGFβ, but reconstitution with 
SHP2R32,138K, a mutant with impaired ability to bind phosphorylated GAB1, did not improve EMT 
induction from either growth factor treatment compared to empty vector controls. These results 
suggest that basal SHP2 activity is needed for the incomplete EMT observed in response to 
TGFβ, but that the activation of SHP2 induced by its association with phosphotyrosine-containing 
proteins such as GAB1 is needed for the more complete EMT observed when ligands such as 
EGF are combined with TGFβ.  
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3-3 MATERIALS AND METHODS 
Cell culture and reagents  
H322 cells (Dr. Pasi Jänne, Dana-Farber Cancer Institute), H358 cells (Dr. Russ 
Carstens, University of Pennsylvania), PC9 cells (Dr. Douglas Lauffenburger, MIT), and AsPC1 
and HPAF-II cells (Dr. Carl June, University of Pennsylvania) were maintained in RPMI 
supplemented with 10% FBS, 1 mM L-glutamine, 100 units/mL penicillin, and 100 μg/mL 
streptomycin. CAPAN-2 cells (Dr. Carl June) were maintained in DMEM supplemented as RPMI 
above. Cell culture reagents were from Life Technologies (Carlsbad, CA).  Recombinant human 
EGF and TGFβ were purchased from Peprotech (Rocky Hill, NJ).  
Antibodies  
pERK T202/Y204 (4377), ERK (4695), pSMAD2/3 S465/467/S423/425 (8828), and 
pGAB1 Y627 (3233) antibodies were from Cell Signaling Technology (Danvers, MA). E-cadherin 
(sc-8426), vimentin (sc-373717), SHP2 (sc-7384), GAB1 (sc-9049) and GAPDH (sc-32233) 
antibodies were from Santa Cruz Biotechnology (Dallas, TX).  Phosphotyrosine antibody (4G10) 
was from Millipore (Billerica, MA). Infrared dye- and Alexa Fluor®-conjugated secondary 
antibodies were from Rockland Immunochemicals (Gilbertsville, PA) and Life Technologies, 
respectively. 
Western blotting  
Whole cell lysates were prepared in a standard cell extraction buffer (Life Technologies) 
supplemented with protease inhibitors and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO). 
Lysates were cleared by centrifugation at 16,100 g for 10 min, and total protein concentrations 
were determined by micro-bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, Waltham, 
MA). Proteins were resolved on 4-12% gradient polyacrylamide gels (Life Technologies) under 
denaturing and reducing conditions and transferred to 0.2 μm nitrocellulose membranes (Bio-Rad 
Laboratories, Hercules, CA). Membranes were imaged using a LI-COR Odyssey Imaging 
System. As needed, membranes were stripped with 0.2 M NaOH. 
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Immunoprecipitation  
Cells were lysed in an immunoprecipitation lysis buffer (Cell Signaling Technologies) 
supplemented with protease and phosphatase inhibitors. Lysates were prepared and assayed for 
total protein as described above, and 500 μg of protein was incubated with protein G agarose 
beads conjugated to SHP2 or normal mouse IgG control antibodies at 4°C overnight. Beads were 
washed three times with cold lysis buffer, re-suspended in LDS sample buffer (Life Technologies) 
and boiled before western blotting.   
Immunofluorescence staining and image analysis  
Cells were plated on glass coverslips and maintained in 6-well plates. Following the 
indicated time of treatment with growth factors, cells were washed and fixed for 20 min in 4% 
paraformaldehyde and permeabilized with 0.25% Triton X-100 in PBS for 5 min. Washed 
coverslips were incubated with an anti-E-cadherin or anti-vimentin antibody in a humidified 
chamber for 3 hr at 37ºC. Washed coverslips were incubated with Alexa Fluor-conjugated anti-
mouse secondary antibodies and Hoechst-33342 DNA stain (Sigma-Aldrich) for 1 hr at 37ºC. 
Coverslips were mounted on microscope slides using Prolong Gold Antifade mounting media 
(Life Technologies) and dried overnight. Fixed slides were imaged on a Zeiss Axiovert 40 CFL 
microscope using an A-Plan 20X objective (vimentin) or 100X oil objective (E-cadherin) and a 
SPOT Insight CCD camera. Identical acquisition settings were used across all images from a 
single experiment. 
E-cadherin junctional localization was quantified using ImageJ and a method similar to 
that described in Loerke et al. 2012 [138].  Each cell-cell junction was traced with a 15-pixel (1.1 
μm) wide freehand line (corresponding to the average thickness of E-cadherin stained junctions 
in the untreated condition), for which the area (Aj), integrated density (IDj), and area-averaged 
mean intensity (Mj) were measured. Mj was taken to be the average junctional signal. The three 
measurements, Atotal, IDtotal, Mtotal, were then taken for an increased thickness of 100 pixels (7.5 
μm) encompassing junctional and peri-junctional E-cadherin staining.  In order to find the mean 
cytoplasmic density (Mc), Aj and IDj were first subtracted from Atotal and IDtotal, respectively, to obtain 
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the cytoplasm-only quantities Ac and IDc. Mc was then calculated by dividing IDc by Ac. In order to 
quantify the extent of junctional localization of E-cadherin, the ratio Mj/Mc was calculated for each 
junction.  All full junctions contained within an image were analyzed. 
Quantification of percent of cells positive for vimentin was also performed using ImageJ. 
Nuclei were counted in each image from Hoechst staining to obtain the total number of cells.  In 
the corresponding vimentin image, cell outlines were drawn using a freehand tool from which 
mean intensities of vimentin staining were recorded. Cells with mean intensities higher than the 
intensity of background non-specific staining were considered to be vimentin-positive, and the 
total number of vimentin-positive cells was divided by the number of nuclei to obtain the 
percentage of vimentin-positive cells in each image. 
Cell scatter experiments and quantification  
Cells were plated in complete medium at low density (500 cells per well in 12-well plates). 
When individual cells had expanded into well-defined colonies 4-5 days later, the scatter 
experiment was initiated by the addition of complete medium containing EGF (50 ng/mL), TGFβ 
(10 ng/mL), or a combination of the two ligands. Individual cell clusters were monitored and 
phase contrast images were captured with a Zeiss Axiovert 40 CFL microscope (10X objective) 
over 24 hr. Image segmentation was performed using the MATLAB image processing toolbox 
(MathWorks, Natick, MA) to identify all objects (cell clusters) within each image and record their 
area and perimeter. As described previously [139], a circularity index was calculated as 
4π(area/perimeter2) (=1 for a circle) for each cluster. 
Plasmids and viral infections 
DNA oligonucleotides encoding short hairpins targeting human SHP2 (Integrated DNA 
Technologies, San Jose, CA) were cloned into the pSicoR vector (Tyler Jacks, MIT; [140]). The 
shRNA-1 targeted nucleotides 1780-1798 of SHP2 mRNA (5’-GGACGTTCATTGTGATTGA-3’), 
shRNA-2 targeted nucleotides 5890-5908 (5’-GTATTGTACCAGAGTATTA-3’), and shRNA-3 
targeted nucleotides 4931-4949 (5’-GCTGGTGGGTATTAAATAT-3’). Control vectors were 
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created using shRNA sequences that do not target a known human mRNA. For stable shRNA 
expression, lentivirus was produced by calcium phosphate-mediated transfection of 293FT cells 
(Life Technologies) with pSicoR plasmids along with the packaging plasmids pCMV-VSV-G, 
pMDL-gp-RRE, and pRSV-Rev (Dr. Marilyn Farquhar, University of California San Diego). Virus-
containing media was collected 48 and 72 hrs post-transfection and filtered using 0.45 µm 
syringe filters prior to infecting target cells, which were subsequently selected and maintained in 2 
μg/mL puromycin. 
SHP2 cDNA encoding SHP2WT or SHP2R32,138K (Ben Neel, Ontario Cancer Institute) was 
inserted between the BamHI and EcoRI sites of the pBabe.Hygro vector. Retrovirus was 
produced by calcium phosphate-mediated transfection of amphotropic Phoenix cells (Dr. Gary 
Nolan, Stanford University) with vector. Virus-containing media was harvested 24 and 48 hrs 
post-transfection and used to infect target cells, which were selected and maintained in 200 
μg/mL hygromycin. All expression and shRNA constructs were validated by sequencing. 
Wound closure assay  
A scratch was formed on confluent cell monolayers in 6-well plates using a pipet tip, and 
media was changed immediately thereafter. Phase contrast images were taken with a Zeiss 
Axiovert 40 CFL microscope (10X objective) every 1-3 hrs for up to 11 hrs. Open scratch areas 
were quantified using ImageJ, and closure rates were calculated from linear fits of scratch areas 
versus time and reported as percent of total image area closed per hr. For experiments with 
different pre-treatment conditions, cells were plated at appropriately modified densities such that 
all wells within an experiment reached confluence on the same day. 
Statistical analysis  
Statistical significance was determined using one- or two-way ANOVA in Kaleidagraph 
4.0 (Synergy Software, Reading, PA). One-way ANOVA p-values were determined using 
Student-Newman-Keuls test for multiple corrections in Kaleidagraph 4.0. Two-way ANOVA p-
values were determined using the Bonferroni correction for multiple comparisons using the 
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GraphPad online QuickCalcs calculator for ANOVA p-values (GraphPad Software Inc., La Jolla, 
CA). 
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3-4 RESULTS 
EGF augments TGFβ-induced EMT  
To evaluate the EMT-inducing effects of TGFβ and EGF, H322 and H358 lung carcinoma 
cells and HPAF-II and CAPAN-2 pancreatic cancer cells were treated with EGF (50 ng/mL), 
TGFβ (10 ng/mL) or both ligands for 5 days (Fig. 3-1, 3-S1A,B). These cell lines were chosen 
because they display baseline epithelial characteristics [141-143] and represent common 
genotypes for their respective diseases – wild type EGFR, RAS and RAF for H322 and mutant 
KRAS for H358, HPAF-II, and CAPAN-2 [68, 143]. SMAD4 participates in signaling directly 
downstream of the TGFβ receptors and the SMAD4 gene is mutated or deleted in approximately 
50% of pancreatic cancers. However, there are conflicting reports regarding whether SMAD4 
mutation promotes or antagonizes EMT [25, 26] and thus HPAF-II and CAPAN-2 cell lines were 
chosen for their wild-type SMAD4 status to avoid interfering effects. TGFβ treatment reduced 
expression of the epithelial marker E-cadherin, increased expression of the mesenchymal marker 
vimentin, and altered cell morphology from cobblestone to more spindle-like in all cell lines (Fig. 
3-1A,B). Although EGF produced a modest reduction in E-cadherin expression by itself, its 
combination with TGFβ led to significantly enhanced shifts in E-cadherin and vimentin expression 
and associated morphological changes compared to EGF or TGFβ alone in both H322 and 
HPAF-II.  
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Figure 3-1: EGF enhances TGFβ-mediated shifts in epithelial and mesenchymal marker 
expression. 
 
(A) H322, H358, HPAF-II, and CAPAN-2 cells were treated for 5 days with EGF (50 ng/mL), 
TGFβ (10 ng/mL), or both and lysates were analyzed by western blotting using antibodies against 
the indicated proteins. Densitometry data normalized to results from untreated samples are 
represented as mean ± s.e.m. (n = 3); * p < 0.05 for all pairwise comparisons unless indicated not 
significant (dotted line); for vimentin expression in CAPAN-2, only significant comparison is 
untreated vs. TGFβ+EGF. (B) H322 and HPAF-II cells were treated as in A and subsequently 
imaged by phase contrast microscopy. (C and D) H322 and HPAF-II cells were treated as in 
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panel A and stained for (C) E-cadherin and DNA or (D) vimentin and DNA. (E) Image 
quantification for replicate images from C and D were performed. E-cadherin localization 
quantification comparing the relative intensity at cell-cell junctions versus peri-junctional regions 
was calculated as described in Materials and Methods Section 3-3 for all junctions within an 
image. The mean ratio per image was averaged for four images from each of two independent 
experiments (n = 8).  The percent of vimentin-positive cells was calculated as described in 
Materials and Methods Section 3-3 for four images from each of two independent experiments (n 
= 8).  Data are represented as mean ± s.e.m; * p < 0.05 for all pairwise comparisons except 
where indicated as not significant (dotted line). 
 
Quantitative analysis of immunofluorescence staining for E-cadherin and vimentin in 
H322 and HPAF-II (Fig. 3-1C-E) confirmed the trends described in Fig. 3-1A and provided 
additional information at the individual cell level.  Quantifying the ratio of E-cadherin staining at 
individual cell-cell junctions relative to junction-proximal regions demonstrated that the overall 
decrease in E-cadherin expression observed by western blot was accompanied by a 
delocalization of E-cadherin from cell-cell junctions in response to TGFβ with or without EGF.  A 
similar E-cadherin localization analysis was used to support findings related to reduced cell 
adhesion [138, 139].  Analysis of vimentin staining revealed that the higher total levels of vimentin 
expression measured by western blot reflected an increased percentage of vimentin-positive cells 
within the population.  These effects were most profound when EGF was combined with TGFβ. 
Of note, EGF addition results in robust activation of the ERK pathway, which is required for EMT 
in H322 and HPAF-II cells (Fig. 3-S1C, and [126]) and which TGFβ is unable to do on its own in 
these cells (Fig. 3-1A). Since EGF alone was unable to drive EMT despite high ERK 
phosphorylation, this ERK activation may be necessary but insufficient for EMT induction. 
EMT-associated changes in migration require TGFβ and EGF co-treatment  
Accompanying the shifts in adhesion and cytoskeletal protein expression, cells 
undergoing EMT often become more migratory and invasive [2]. We assessed the differential 
effects of TGFβ and/or EGF on cell scatter from clusters and on collective migration of cells 
grown in a monolayer for H322 and HPAF-II cells which displayed the greatest differential growth 
factor responses (Fig. 3-2). Weakening cell-cell junctions within preformed epithelial cell clusters 
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can lead to disrupted cluster circularity and scatter of cells away from these clusters [138]. These 
changes can be monitored by calculating a cluster circularity index (CI), calculated as 
4π(area/perimeter2), which has a value of 1 for a circle and a value of 0 for a line [139]. H322 and 
HPAF-II cell clusters containing ~10-20 cells were grown from individual cells and subsequently 
monitored for scatter and morphological changes over 24 hr in response to EGF, TGFβ, or both 
(Fig. 3-2A,B). Both H322 and HPAF-II cells displayed reduced CI over this time period, with the 
only statistically significant decreases observed for cells treated with both TGFβ and EGF.   
In wound closure migration assays, H322 cells pre-treated for three days with EGF or 
TGFβ alone did not display enhanced migration (Fig. 3-2C). However, combining EGF and TGFβ 
for the three day treatment led to a 2.7-fold increase in the migration rate of H322 cells. This was 
accompanied by the appearance of individual cells migrating away from the cell sheet 
(arrowheads in the corresponding phase contrast image). In contrast, HPAF-II cells did not 
display enhanced migration in a monolayer for any of the ligand treatments (Fig. 3-2D).  This may 
have occurred because of the reduced ability to observe EMT induction at the high cell density 
required for this monolayer assay in HPAF-II but not H322 (Fig. 3-S2). Notably, for changes in 
cell scatter in both H322 and HPAF-II and wound closure in H322, TGFβ did not produce a 
significant effect on its own, and the effect of combining EGF with TGFβ exceeded an additive 
effect of the single growth factor treatments. Thus, we observed that the addition of EGF to TGFβ 
promoted more complete shifts in marker expression and measurable changes in migration while 
also enhancing signaling through ERK (Figs. 3-1, 3-2).  
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Figure 3-2: EGF enhances cellular migration in response to TGFβ. 
(A) H322 and (B)  HPAF-II cell clusters grown in 12-well plates from single cells were treated with  
EGF (50 ng/mL), TGFβ (10 ng/mL), or both and monitored for 24 hr for cell scatter. Silhouettes 
from MATLAB analysis of representative cell cluster images are shown. Circularity indices versus 
time for clusters from twelve frames per condition in each of three independent experiments were 
quantified as described in Materials and Methods Section 3-3 and are reported as averages ± 
s.e.m. (n > 45); * p < 0.05 for all comparisons with TGFβ + EGF. Wound closure rates were 
measured for (C) H322 cells treated for 3 days and (D) HPAF-II cells treated for 4 days with EGF 
(50 ng/mL), TGFβ (10 ng/mL), or both prior to scratch. Rates for triplicate wells from two different 
platings (n = 6) are reported as averages ± s.e.m; * p < 0.05 for all comparisons with TGFβ + 
EGF. Representative phase contrast images are shown, with tracings added to identify open 
scratch areas. White arrowheads indicate individual cells that migrated away from the cell 
monolayers into the open wound area.   
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Figure 3-3: SHP2 depletion promotes epithelial characteristics. 
SHP2-targeting shRNA (SHP2 shRNA-1) or a control shRNA was stably expressed in H322, 
H358, PC9, HPAF-II, CAPAN-2, and AsPC1 cells. (A) Cells expressing control or SHP2 shRNA-1 
grown in complete medium were lysed and analyzed by western blotting using antibodies against 
the indicated proteins. Densitometry data normalized to control shRNA samples are represented 
as mean ± s.e.m. (n = 3); * p < 0.05. (B) Representative phase contrast images of the same cells 
grown in complete medium are shown. (C) Wound closure rates were measured for the indicated 
cell lines expressing control or SHP2 shRNA-1 grown to confluence in complete medium for 
triplicate wells from two independent experiments (n = 6) and are reported as averages ± s.e.m.; 
* p < 0.05; no data (n.d.) for AsPC1 due to inability to form monolayer. 
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SHP2 knockdown enhances baseline epithelial characteristics  
Given the established importance of ERK activation in EMT induction, we assessed how 
SHP2, a positive regulator of ERK activity, contributes to EMT phenotypes, looking first at 
baseline cellular characteristics. SHP2 was depleted by stable shRNA expression in H322, H358, 
HPAF-II, and CAPAN-2 cells as well as one additional lung and pancreatic cancer cell line, PC9 
and AsPC1, which display higher mesenchymal character at baseline (Fig. 3-3). Across these six 
cell lines SHP2 knockdown generally promoted E-cadherin expression and reduced vimentin 
expression (Fig. 3-3A). Importantly, SHP2 knockdown also reduced baseline ERK 
phosphorylation. Cells with SHP2 knockdown had increased cobblestone morphology compared 
to control shRNA cells, an effect that was especially apparent in PC9 and AsPC1, which typically 
display very spindle-like morphology with very few cell-cell contacts (Fig. 3-3B). These 
morphological and protein expression shifts toward epithelial characteristics were accompanied 
by corresponding decreases in migration of SHP2 knockdown cells compared to control (Fig. 3-
3C). Thus, SHP2 knockdown promoted a mesenchymal-epithelial transition (MET) of cells grown 
in unstimulated conditions. 
EMT induced by TGFβ with or without EGF is impaired by SHP2 knockdown  
We next evaluated how SHP2 knockdown impacted cellular response to TGFβ with or 
without EGF. SHP2 depletion inhibited induction of vimentin expression and reduction of E-
cadherin expression in response to growth factor treatment in H322, H358, HPAF-II, and CAPAN-
2 cell lines (Fig. 3-4A,B and 3-S3). This corresponded to impaired ERK phosphorylation in cells 
with SHP2 knockdown, which was most apparent in EGF treatment conditions. These western 
blot measurements were supported by immunofluorescence staining in H322 and HPAF-II (Fig. 3-
4C,D). Cells with SHP2 depletion displayed some loss of total E-cadherin levels in response to 
TGFβ with or without EGF, but E-cadherin remained strongly maintained at cell-cell junctions.  
The appearance of a vimentin-positive cell population was significantly inhibited by SHP2 
knockdown in both cell lines. Importantly, SHP2 depletion inhibited EMT induction in response to 
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TGFβ with or without EGF addition, indicating that the role of SHP2 in this setting extends beyond 
regulating only response to EGFR activation. 
 
Figure 3-4: SHP2 is required for TGFβ-mediated EMT effects and EGF-mediated EMT 
augmentation. 
(A) H322 and (B) HPAF-II cells expressing a control or SHP2-targeting shRNA (SHP2 shRNA-1) 
were treated with EGF (50 ng/mL), TGFβ (10 ng/mL), or both for 5 days and subsequently 
analyzed by western blotting with antibodies against the indicated proteins. Images are 
representative of three independent experiments. (C) H322 and (D) HPAF-II cells plated on glass 
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coverslips were treated as in panels A and B, fixed, and stained for E-cadherin or vimentin and 
DNA. Quantification of the relative E-cadherin intensity at cell-cell junctions versus peri-junctional 
regions was calculated as described in Materials and Methods Section 3-3 for all junctions within 
an image. The mean ratio per image was averaged for four images from each of two independent 
experiments (n = 8). The percent of vimentin-positive cells was calculated as described in 
Materials and Methods Section 3-3 for four images from each of two independent experiments (n 
= 8). Data are represented as mean ± s.e.m; * p < 0.05 compared to control sample with same 
treatment, ǂ p < 0.05 compared to untreated sample from same cells. 
 
EGF and TGFβ differentially drive SHP2 association with phosphotyrosine-containing proteins  
The results of Figure 3-4 suggested an importance of SHP2 activity for EMT induction in 
response to TGFβ alone or the combination of TGFβ and EGF, which leads to high ERK 
activation and produces the greatest EMT. To assess the extent of induced SHP2 activity under 
conditions of varying EMT potential, we probed for SHP2 associations with phosphotyrosine 
containing proteins in response to EGF, TGFβ, or a combination of the two through SHP2 
immunoprecipitation experiments (Fig. 3-5A). Since SHP2 binds to phosphotyrosine-containing 
proteins through its SH2 domains, which stabilizes an active SHP2 conformation, increased 
SHP2 phosphotyrosine binding generally correlates with increased SHP2 activity [133]. In 
response to EGF, a phosphotyrosine-containing protein of approximately 110 kDa co-
immunoprecipitated with SHP2.  This protein was confirmed to be GAB1 phosphorylated at 
Tyr627.  SHP2 association with GAB1 was detected in samples from both H322 and HPAF-II cells 
treated with EGF and the strength of this association in response to EGF was insensitive to TGFβ 
addition. Interestingly, TGFβ itself did not drive any SHP2-phosphotyrosine associations.  The 30 
min treatment time for this experiment corresponded to observed phosphorylation of downstream 
signaling intermediates in response to EGF or TGFβ (Fig. 3-5B), suggesting that TGFβ had 
initiated signaling that did not involve SHP2 activation. Direct comparison of immunoprecipitates 
from H322, HPAF-II, and H358 demonstrated that the less significant effect of EGF on enhancing 
TGFβ-mediated EMT in H358 was associated with the lowest levels of EGF-induced GAB1-SHP2 
association compared to the other cell lines (Fig. 3-S4). 
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Figure 3-5: EGF, but not TGFβ, promotes SHP2 association with phosphotyrosine-
containing proteins. 
(A) SHP2 or IgG control immunoprecipitates from serum starved H322 and HPAF-II cells treated 
for 30 min with EGF (50 ng/mL), TGFβ (10 ng/mL), or both were analyzed by western blotting 
using antibodies against the indicated proteins. Arrow indicates phosphorylated GAB1 detected 
with total phospho-tyrosine (pY) antibody. Densitometry data normalized to maximum value are 
represented as mean ± s.e.m. (n = 3); * p < 0.05 compared to untreated sample from same cells. 
(B) Whole cell lysates (WCL) were analyzed by western blotting using antibodies against the 
indicated proteins. Images are representative of three independent experiments. Densitometry 
data normalized to results from untreated samples are represented as mean ± s.e.m. (n = 3); * p 
< 0.05 compared to untreated sample from same cells. 
 
SHP2 SH2-domain engagement by phosphotyrosines is essential for EGF-mediated 
augmentation of EMT  
The observations that EMT depended on SHP2, which was activated by EGF but not 
TGFβ, and that EGF augmented TGFβ-driven EMT outcomes suggested that EGF-induced SHP2 
activation may be responsible for its ability to augment EMT. Since TGFβ alone drove SHP2-
dependent EMT without inducing SHP2-phosphotyrosine binding, this also suggested that basal 
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SHP2 activity was sufficient for some degree of EMT. To test this model for the contribution of 
SHP2 binding to phosphotyrosine-containing proteins in EMT, we reconstituted cells with 
knockdown of endogenous SHP2 with either wild type SHP2 or the double SH2-domain mutant 
SHP2R32,138K.  For these experiments, knockdown of endogenous SHP2 was accomplished using 
two shRNA sequences targeting the 3’ untranslated region (UTR) of SHP2 (SHP2 shRNA-2&3) in 
HPAF-II cells to allow for RNAi-resistant reconstitution using SHP2 constructs not containing the 
UTRs (Fig. 3-S3, 3-6).  The R-K mutations antagonize the ability of SHP2 SH2 domains to bind 
phosphotyrosines downstream of SHP2-activating stimuli [134, 135]. In HPAF-II cells, SHP2WT 
reconstitution rescued the ability of TGFβ, with or without EGF, to induce E-cadherin loss and 
vimentin increase (Fig. 3-6A). Cells with SHP2R32,138K reconstitution, however, responded more 
closely to cells with knockdown, displaying E-cadherin maintenance and impaired vimentin 
induction in response to TGFβ and EGF. Though ERK phosphorylation rebounded in shRNA-2&3 
cells with empty-vector control relative to shRNA-2&3 only, cells with SHP2R32,138K reconstitution 
displayed significant impairment of ERK phosphorylation, which was associated with impaired 
EMT induction (Fig. 3-6A, 3-S3). Immunofluorescence confirmed that SHP2R32,138K reconstitution 
impaired shifts in E-cadherin and vimentin expression in response to TGFβ with and without EGF 
compared to cells with SHP2WT reconstitution (Fig. 3-6B).  Immunoprecipitation experiments 
confirmed that SHP2R32,138K did not associate with tyrosine phosphorylated proteins in response 
to EGF treatment (Fig. 3-6C).  Thus, the ability of SHP2 to promote EMT in response to 
exogenous ligands depends upon SHP2 engagement of phosphotyrosine residues on cognate 
adaptor proteins such as GAB1, and the complete EMT observed when EGF and TGFβ were 
combined was due to SHP2 activation driven by EGF specifically. 
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Figure 3-6: SHP2 SH2 domain binding to phosphotyrosines is required for 
SHP2-mediated EMT effects. 
HPAF-II cells expressing control shRNA or two shRNAs targeting the 3’ untranslated region of the 
human SHP2 transcript (SHP2 shRNA-2&3) were transduced with an empty pBabe vector (EV) or 
pBabe vector encoding SHP2WT (WT) or SHP2R32,138K (R-K). (A) Cells treated for 5 days with 
TGFβ (10 ng/mL) with or without EGF (50 ng/mL) were lysed and analyzed by western blotting 
using antibodies against the indicated proteins. Western blot images are representative of four 
independent experiments. Densitometry data are represented as mean ± s.e.m. (n = 4); * p < 
0.05 compared to control + EV sample with same treatment, ǂ p < 0.05 compared to untreated 
sample of same cells. All significant comparisons are shown. (B) The same cells plated on 
coverslips were treated as in panel A and stained for E-cadherin or vimentin and DNA. E-
cadherin staining quantification comparing the relative intensity at cell-cell junctions versus peri-
junctional regions was calculated as described in Materials and Methods Section 3-3 for all 
junctions within an image. The mean ratio per image was averaged for four images from each of 
two independent experiments (n = 8). The percent of vimentin-positive cells was calculated as 
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described in Materials and Methods Section 3-3 for four images from each of two independent 
experiments (n = 8). Data are represented as mean ± s.e.m; * p < 0.05 compared to SHP2WT 
sample with same treatment, ǂ p < 0.05 compared to untreated sample of same cells. All 
significant comparisons are shown. (C) SHP2 or IgG control immunoprecipitates from serum 
starved cells treated for 5 min with EGF (50 ng/mL) were analyzed by western blotting using 
antibodies against the indicated proteins. Images are representative of three independent 
experiments. 
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3-5 DISCUSSION 
 Our results identify for the first time a mechanism wherein SHP2 SH2 domain 
engagement of a phosphotyrosine-containing protein contributes to EMT and thus uncovers a 
new aspect of the well-documented ability of EGF to augment the EMT that occurs in response to 
TGFβ, as summarized in Figure 3-7. In our proposed model, TGFβ binding to its receptors 
activates some pathways that promote a partial EMT but does not elevate SHP2 activity above its 
low basal level. The low basal activity of SHP2 nonetheless plays a role in EMT driven by TGFβ 
alone. When EGF is combined with TGFβ, GAB1 becomes tyrosine phosphorylated and SHP2 
SH2 domain engagement by phosphorylated GAB1 increases SHP2 activity, promoting stronger 
EMT induction. EGF-mediated activation of SHP2 is not sufficient for strong EMT induction 
without the additional signaling processes driven by TGFβ.  
 
Figure 3-7: Schematic summary of the role of SHP2 in promoting EMT. 
EGF alone efficiently drives SHP2 and ERK activation, but without concomitant TGFβ-mediated 
signaling, minimal EMT is driven. In the presence of TGFβ alone, cells undergo an incomplete 
EMT due to activation of pathways including p38 and SMADs, while ERK and SHP2 activities 
remain at low basal levels. When EGF is combined with TGFβ, EGFR activation leads to GAB1 
phosphorylation and binding to SHP2, which promotes SHP2 activity. SHP2 activation augments 
ERK activity and drives stronger EMT-related shifts in marker expression, cell morphology, and 
migratory phenotypes. 
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Previous work has established that EGFR activation enhances TGFβ-mediated EMT [55-
57]. We analyzed that effect in detail here in terms of expression and localization of the 
prototypical epithelial and mesenchymal markers E-cadherin and vimentin, respectively, and 
through cellular migration measurements. In all cases, EGF addition to TGFβ augmented the 
EMT-associated effects observed, and in some cases no effect was observed with TGFβ alone. 
Other studies have linked the presence of exogenous or autocrine-released growth factors 
including HGF [11], oncostatin-M [11], PDGF [144], and IL-6 [35] to enhanced TGFβ-mediated 
effects. Signaling downstream of many of these ligands involves SHP2, but it is unclear if SHP2 
participates in the augmented EMT that accompanies the combination of these ligands with 
TGFβ. 
Another effect uncovered in this study was the cell line-dependent ability of high cell 
density to inhibit EMT induction. Specifically, EMT induction in the pancreatic carcinoma cell line 
HPAF-II was completely inhibited at high plating densities, whereas the lung carcinoma cell line 
H322 showed no such dependence. Previous work in the human keratinocyte cell line HaCaT 
showed that high cell density significantly impaired TGFβ-induced formation of nuclear SMAD3-
SMAD4 complexes [145]. Recent investigation by Nallet-Staub and colleagues also captured the 
density dependence of SMAD nuclear localization in HaCaT cells, but intriguingly not all cell lines 
displayed this density effect [146]. The effect of cell density on EMT induction may be particularly 
important in vivo where cellular environments correspond to ‘high density’, though 
microenvironmental cues not present in vitro may enable cells to escape the inhibitory effect of 
high cell density for EMT induction. Within the SMAD pathway, it will also be informative to 
evaluate the effect of SMAD4 deletion and mutation, which is present in approximately 50% of 
pancreatic carcinomas [147], on the TGFβ and EGF-mediated effects reported here. HPAF-II and 
CAPAN-2 are both SMAD4 wild-type, whereas AsPC1 has a SMAD4 mutation. Though all three 
cell lines demonstrated SHP2-dependent mesenchymal traits, concrete determination of the role 
of SMAD4 in EMT will require further studies in an isogenic cell background 
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Based on our previous work and evidence from other studies demonstrating the 
importance of ERK activation in EMT [93, 126], SHP2-mediated augmentation of ERK activity is 
likely to be a critical factor in SHP2-mediated effects on EMT. Though ERK pathway regulation by 
SHP2 is important downstream of EGFR, SHP2 contributes to many other signaling processes, 
some of which may have relevance to EMT induction. For example, SHP2 has been shown to 
dephosphorylate focal adhesion kinase (FAK) at the leading edge of a cell to promote focal 
adhesion turnover [148]. Through regulating FAK and other components of focal adhesions SHP2 
promotes cellular migration, polarity, and mechanical sensing [148, 149], phenotypes with clear 
connections to EMT. Other work demonstrated that inhibiting or stably depleting FAK inhibits 
TGFβ-driven signaling, EMT induction, and tumorigenesis in mice [150]. We recently described a 
mechanism by which EGFR activation leads to formation of SHP2-GAB1 complexes that can 
remain associated distal from the receptor [151]. In the mechanism we identified, Src family 
kinases (SFKs) served as effectors activated by EGFR that maintained GAB1 phosphorylation, 
and therefore GAB1-SHP2 complexes, distal from EGFR through multiple rounds of GAB1-SHP2 
dissociation and tyrosine dephosphorylation. Others have identified SFKs as necessary 
intermediates for EGFR-dependent TGFβ-mediated transformation [55, 56], a finding which could 
be related to the ability of SFKs to promote SHP2 activation via GAB1 phosphorylation and 
GAB1-SHP2 complex formation. 
Of course, a role for SHP2 driving EMT is consistent with its identification as a proto-
oncogene and the concept of SHP2 as a driver of malignancy and therapeutic resistance. SHP2-
activating mutations occur in cancers including juvenile myelomonocytic leukemia, acute 
myelogenous leukemia, and lung and colon carcinomas, as well as Noonan syndrome, a 
developmental disorder leading to increased risk of certain malignancies [81, 152]. In mouse 
tumor xenograft studies of breast and brain cancer cells, SHP2 promotes tumorigenesis [82, 83]. 
SHP2 activity also contributes to cellular resistance to EGFR inhibition in non-small cell lung 
carcinoma cells [75]. These and other findings provide continued motivation for the ongoing 
search for specific inhibitors of SHP2. New strategies developing SHP2 inhibitors that target 
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allosteric binding sites unique to SHP2 have shown promise toward achieving SHP2 specificity 
[153, 154]. Therapies developed using such strategies would have promise in many diseases 
based on the evidence above. In particular, our findings suggest SHP2 may be a potential target 
for reversing the mesenchymal dedifferentiation process in malignant tumor cells through chronic 
inhibition prior to administration of another targeted cancer therapeutic, analogous to a strategy 
we described previously wherein chronic ERK inhibition led to enhanced EGFR inhibitor response 
in NSCLC cells [126].   
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3-7 SUPPLEMENTAL MATERIAL 
 
Figure 3-S1 
(A) HPAF-II and H358 cells were treated for 5 days with EGF (50 ng/mL), TGFβ (10 ng/mL), or a 
combination of the two ligands and lysates were analyzed by western blot using antibodies 
against the indicated proteins. (B) HPAF-II cells were treated as in A and stained for ZO-1 and 
DNA. (C) H322 and HPAF-II cells were treated for 5 days with EGF (50 ng/mL), TGFβ (10 
ng/mL), or a combination of the two ligands and 3 μM CI-1040 (a MEK inhibitor) or DMSO as a 
control. Lysates were analyzed by western blotting with antibodies against the indicated proteins. 
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Figure 3-S2. 
H322 and HPAF-II cells were plated at low (50,000 cells/well) and high (≥300,000 cells/well) 
densities in 6-well plates, and treated 24 hr later with EGF (50 ng/mL), TGFβ (10 ng/mL), or a 
combination of the two ligands. The low and high densities reflect the plating conditions used for 
western blotting experiments and wound closure assays, respectively. Cells were lysed after 3 
days of treatment with ligands and analyzed by western blotting using antibodies against the 
indicated proteins.  
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Figure 3-S3. 
(A) H322 and HPAF-II cells expressing control shRNA or SHP2-targeting shRNA (SHP2 shRNA-
1) were treated with EGF (50 ng/mL), TGFβ (10 ng/mL), or both for 5 days and subsequently 
analyzed by western blotting. Densitometry data normalized to untreated control cells are 
represented as mean ± s.e.m. (n = 3); * p < 0.05 compared to control sample with same 
treatment. (B) HPAF-II cells expressing a control shRNA or two independent shRNAs targeting 
the 3’ untranslated region of the human SHP2 transcript (SHP2 shRNA-2&3) were treated as in 
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panel A.  Lysates were analyzed by western blotting with antibodies against the indicated 
proteins. Images are representative of three independent experiments. (C) H358 (D) and CAPAN-
2 cells expressing control shRNA or SHP2-targeting shRNA (SHP2 shRNA-1) were treated with 
EGF (50 ng/mL), TGFβ (10 ng/mL), or both for 5 days and subsequently analyzed by western 
blotting. Densitometry data normalized to untreated control cells are represented as mean ± 
s.e.m. (n = 3). 
 
 
 
 
Figure 3-S4: SHP2 knockdown with UTR-targeting hairpins inhibits EMT 
induction. 
SHP2 or IgG control immunoprecipitates from serum starved H322, HPAF-II, and H358 cells 
treated for 30 min with EGF (50 ng/mL) were analyzed by western blotting using antibodies 
against the indicated proteins. Densitometry data normalized to maximum value are represented 
as mean ± s.e.m. (n = 3); * p < 0.05. 
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CHAPTER 4: A Partial Least Squares Regression Analysis 
Identifies Cell Signaling Events Regulating Epithelial-
Mesenchymal Transition3 
 
4-1 ABSTRACT 
 Epithelial-mesenchymal transition (EMT) is a cellular process hijacked in many cancers 
to drive metastasis and increased resistance to therapy, motivating efforts to understand the 
cellular processes controlling EMT induction. In particular, the roles of specific signaling pathways 
controlling EMT induction have been described in some cases, but it is clear that EMT results 
from integration of multivariate signaling through many pathways. To provide a more complete 
understanding of EMT induction with an appreciation for this network integration, we performed a 
systematic analysis of the cell signaling processes that regulate EMT in pancreatic cancer cells. 
Our approach relies upon the development of a partial least squares regression (PLSR) statistical 
model to predict the relationships between multivariate signaling events and EMT-associated 
phenotypes, using a cell culture model of EMT induction in response to transforming growth 
factor beta, epidermal growth factor, and hepatocyte growth factor alone or in various 
combinations. In our model, quantitative protein phosphorylation measurements were combined 
with phenotypic measurements of EMT marker expression and measurements of cell migration. 
The results of our validated statistical model will be used to rationally identify signaling nodes 
whose inhibition will antagonize or reverse EMT. Such signaling nodes would be candidate 
therapeutic targets whose inhibition may slow tumor metastasis or promote tumor cell sensitivity 
to therapy.  
  
                                                     
3 Chapter 4 was completed as part of a collaboration with co-authors Erica L. Carpenter and 
Stephanie S. Yee  
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4-2 INTRODUCTION 
Pancreatic cancer is the fourth-leading cause of cancer deaths in the United States, with 
an estimated 5-year survival rate of only 4% [155]. This poor prognosis is due in part to a 
combination of low rates of surgically resectable tumors at diagnosis and overall poor response to 
chemotherapeutic agents [155]. Despite significant advances in molecular and pathological 
characterization of pancreatic tumors and development of molecularly-targeted therapies, there 
has been little translation of these advancements to predicting patient outcomes [156]. Identifying 
strategies to revert tumor malignancy and enhance therapeutic response are needed to improve 
pancreatic cancer prognosis. Here we describe the generation of a data-driven statistical model 
to identify key regulators of epithelial-mesenchymal transition (EMT), a cellular process that 
contributes to malignant progression and therapeutic resistance in many cancers. 
EMT is a cellular program engaged during normal development and wound healing in 
which epithelial cells, such as those lining pancreatic ducts, lose apical-basal polarity and strong 
cell-cell adhesions to partially dedifferentiate becoming more motile and invasive [1-3]. EMT can 
be monitored through loss of epithelial markers, such as E-cadherin, and increased expression of 
mesenchymal markers such as vimentin. While EMT is required for normal development and 
wound healing [3], aberrant EMT has also been linked to metastasis [123] and has been 
observed to occur from pre-cancerous pancreatic lesions to promote metastasis during 
cancerous progression [21], suggesting clinical relevance for EMT at the earliest stages of 
pancreatic cancer. EMT has emerged as a common predictor of poor prognosis in pancreatic 
cancer and other carcinomas [24]. Additionally, EMT is associated with therapeutic resistance in 
pancreatic cancer cells [32, 125], as well as other cancer types [25, 29, 30, 33]. Promoting an 
epithelial cellular phenotype can confer enhanced therapeutic response [104, 126]. 
EMT is efficiently driven in vitro and in vivo by transforming growth factor-β (TGFβ) [4], a 
ligand which initiates signaling through a network of pathways including SMADs, extracellular 
signal-regulated kinase-1/2 (ERK1/2), p38, and c-Jun N-terminal kinase (JNK) [46, 47]. Multiple 
studies have indicated that activation of ERK1/2 [14, 45, 126], p38 [157], or nuclear factor kappa-
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light-chain-enhancer of activated B cells (NFκB) [158] signaling are necessary for EMT induction 
in different cell types, but little work has assessed the impact of multivariate pathway integration. 
In addition to TGFβ, other growth factors such as epidermal growth factor (EGF) [53] and 
hepatocyte growth factor (HGF, the ligand for c-MET receptor) [11, 159] can induce EMT on their 
own or be combined with TGFβ to enhance EMT induction [11-14, 57]. These growth factors are 
known to promote signaling through their own defined networks that share certain common 
elements among them (e.g., ERK pathway activation by each EGF [160], HGF [161], and TGFβ 
[47]). The dynamics, strength, and balance of signaling events within each network, however, are 
distinct to each growth factor, and such differences can influence phenotype determination [162].  
High throughput analysis of signaling dynamics in response to EGF, HGF, and TGFβ 
could reveal unique and overlapping elements to each network, but synthesizing this information 
to determine the key factors determining cellular outcome cannot be achieved by inspection. 
Instead, a systematic and unbiased approach is needed to quantitatively evaluate which signaling 
measurements are most predictive of resulting cellular phenotype. Partial least squares 
regression (PLSR) is a statistical modeling technique popularized in the field of chemometrics 
[163, 164] that has been adapted in multiple areas of study to integrate large multivariate data 
sets to identify key variables determining system outputs. In particular, systems biology 
approaches to understand how cell signaling impacts phenotype determination have employed 
PLSR modelling [102, 165, 166]. For example, previous work has identified network ‘signatures’ 
predictive of migration and proliferation in response to growth factor treatments [167] or 
expression of the EGFR-family member HER2 [166]. These approaches, however, have not yet 
been utilized to relate the extent of EMT induction in response to various stimuli to the activation 
of key signaling components. 
Here we characterize the quantitative changes in EMT-associated phenotypic measures 
in response to EGF, HGF, TGFβ, and the combinations TGFβ+EGF and TGFβ+HGF in the 
pancreatic cancer cell line HPAF-II. HGF produced the greatest EMT of any single ligand and its 
combination with TGFβ produced the greatest EMT overall. EMT was measured by quantitative 
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western blotting for E-cadherin and vimentin, image analysis for protein localization, and cellular 
migration assays. A phosphoprotein antibody microarray was used in a screen to identify proteins 
involved in EMT response. Hits from this screen were combined with signaling intermediates with 
known roles in growth factor-dependent EMT to form a panel of 45 proteins for quantitative 
analysis by Luminex and western blotting. Protein phosphorylation across this panel was 
measured at five time points in response to the growth factor treatments and a PLSR model was 
built using these profiles to predict EMT responses. PLSR analysis revealed protein 
phosphorylation events that are most associated with EMT induction and provided potential 
targets for inhibiting mesenchymal dedifferentiation.   
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4-3 MATERIALS AND METHODS 
Cell culture and reagents  
 HPAF-II cells (Dr. Carl June, University of Pennsylvania) were maintained in RPMI 
supplemented with 10% FBS, 1 mM L-glutamine, 100 units/mL penicillin, and 100 μg/mL 
streptomycin. Cell culture reagents were from Life Technologies (Carlsbad, CA).  Recombinant 
human EGF, HGF, and TGFβ were purchased from Peprotech (Rocky Hill, NJ). In all 
experiments, growth factor concentrations were 50 ng/mL for EGF and HGF and 10 ng/mL for 
TGFβ. During treatment, media containing growth factors was replenished every 48 hr. 
Antibodies  
 pERK T202/Y204 (4377), ERK (4695), pSTAT3 Y705 (9145), pALK Y1604 (3341), p-p38 
T180/Y182 (4511), and pSMAD2 S465/467/pSMAD3 S423/425 (8828) antibodies were from Cell 
Signaling Technology (Danvers, MA). E-cadherin (sc-8426), vimentin (sc-373717), and GAPDH 
(sc-32233) antibodies were from Santa Cruz Biotechnology (Dallas, TX).  pSRC Y418 (44660G) 
was from Life Technologies. p-p27/Kip1 T157 (AF1555) was from R&D Systems (Minneapolis, 
MN). Phosphotyrosine antibody (4G10) was from Millipore (Billerica, MA). Infrared dye- and Alexa 
Fluor®-conjugated secondary antibodies were from Rockland Immunochemicals (Gilbertsville, 
PA) and Life Technologies, respectively. 
Western blotting  
 Whole cell lysates were prepared in a standard cell extraction buffer (Life Technologies) 
supplemented with protease inhibitors and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO). 
Lysates were cleared by centrifugation at 17,000 g for 10 min, and total protein concentrations 
were determined by micro-bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, Waltham, 
MA). Proteins were resolved on 4-12% gradient polyacrylamide gels (Life Technologies) under 
denaturing and reducing conditions and transferred to 0.2 μm nitrocellulose membranes (Bio-Rad 
Laboratories, Hercules, CA). Membranes were imaged using a LI-COR Odyssey Imaging 
System. As needed, membranes were stripped with 0.2 M NaOH. 
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Antibody microarray experiments 
 Cell lysates were prepared and cleared as for western blotting from cells treated with or 
without TGFβ + EGF for 30 min following overnight serum starvation. Phospho Explorer Antibody 
Array (Full Moon Biosystems, Sunnyvale, CA) sample processing, array conjugation, and raw 
data analysis were performed at Full Moon Biosystems. Quantification of duplicate array dots per 
condition was performed and fold-changes in phosphorylated-to-total peptide signal ratios were 
calculated as treated/untreated. 
Multiplexed Luminex assay measurements   
 Multiplexed Luminex kits NF-κB Signaling (48-630MAG), Early Apoptosis (48-669MAG), 
RTK Mitogenesis Phosphoprotein (48-672MAG), Akt/mTOR phosphoprotein (48-611MAG), and 
MAPK/SAPK Signaling (48-660MAG) were purchased from Millipore to measure a total of 39 
phospho proteins, listed in Table 4-1. Whole cell lysates were prepared in kit-supplied lysis buffer 
supplemented with protease inhibitors from cells treated with indicated growth factor 
combinations in complete medium. Lysates were first clarified by centrifugation at 21,000 g for 10 
min, and further purified by passing through supplied filters from Millipore. Luminex assay was 
performed at the University of Pennsylvania Human Immunology Core, using standard 
techniques. Mean fluorescence intensity (MFI) values from the Luminex assay were background 
corrected by subtracting MFI signal from assay buffer-only samples from all other values. Initial 
calibration assays were performed for each kit using serial dilution of untreated and TGFβ + EGF 
stimulated cell lysates to verify detection of induced signals as well as signal linearity. Protein 
loading for each kit was chosen based on calibration assay results. For final data collection 
biological triplicates were analyzed for all treatment conditions. Any analytes with non-linear 
signals were not included in final data set. 
Excess lysate from the Luminex assay preparation was analyzed by western blotting for 
phosphorylated proteins for which no Luminex bead was available or Luminex signal was not 
linear, listed in Table 4-2. Since all treatment conditions could not fit on a single western blot, 
untreated samples were included on each gel for direct comparison. 
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Immunofluorescence staining and image analysis  
 Cells were plated on glass coverslips in 6-well plates and maintained in full serum media 
supplemented with the indicated growth factors 24 hr after plating. Following the indicated time of 
treatment, cells were washed and fixed for 20 min in 4% paraformaldehyde and permeabilized 
with 0.25% Triton X-100 in PBS for 5 min. Washed coverslips were incubated with an anti-E-
cadherin or anti-vimentin antibody in a humidified chamber for 3 hr at 37ºC. Washed coverslips 
were incubated with Alexa Fluor-conjugated anti-mouse secondary antibodies and Hoechst-
33342 DNA stain (Sigma-Aldrich) for 1 hr at 37ºC. Coverslips were mounted on microscope 
slides using Prolong Gold Antifade mounting media (Life Technologies) and dried overnight. 
Fixed slides were imaged on a Zeiss Axiovert 40 CFL microscope using an A-Plan 20X objective 
(vimentin) or 100X oil objective (E-cadherin) and a SPOT Insight CCD camera. Identical 
acquisition settings were used across all images from a single experiment. 
E-cadherin junctional localization was quantified using ImageJ and a method similar to 
that described in Loerke et al. 2012 [138].  Each cell-cell junction was traced with a 15-pixel (1.1 
μm) wide freehand line (corresponding to the average thickness of E-cadherin stained junctions 
in the untreated condition), for which the area (Aj), integrated density (IDj), and area-averaged 
mean intensity (Mj) were measured. Mj was taken to be the average junctional signal. The three 
measurements, Atotal, IDtotal, Mtotal, were then taken for an increased thickness of 100 pixels (7.5 
μm) encompassing junctional and peri-junctional E-cadherin staining.  In order to find the mean 
cytoplasmic density (Mc), Aj and IDj were first subtracted from Atotal and IDtotal, respectively, to 
obtain the cytoplasm-only quantities Ac and IDc. Mc was then calculated by dividing IDc by Ac. In 
order to quantify the extent of junctional localization of E-cadherin, the ratio Mj/Mc was calculated 
for each junction.  All full junctions contained within an image were analyzed. 
Quantification of the percent of cells positive for vimentin was also performed using 
ImageJ. Nuclei were counted in each image from Hoechst staining to obtain the total number of 
cells.  In the corresponding vimentin image, cell outlines were drawn using a freehand tool from 
which mean intensities of vimentin staining were recorded. Cells with mean intensities higher than 
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the intensity of background non-specific staining were considered to be vimentin-positive, and the 
total number of vimentin-positive cells was divided by the number of nuclei to obtain the 
percentage of vimentin-positive cells in each image. 
Cell scatter experiments and quantification  
 Cells were plated in complete medium at low density (500 cells per well in 12-well plates). 
When individual cells had expanded into well-defined colonies 3-4 days later, the scatter 
experiment was initiated by the addition of complete medium containing EGF, HGF, TGFβ, or a 
combination of the ligands. Individual cell clusters were monitored, and phase contrast images 
were captured with a Zeiss Axiovert 40 CFL microscope (10X objective) over 3 days. Image 
segmentation was performed using the MATLAB image processing toolbox (MathWorks, Natick, 
MA) to identify all objects (cell clusters) within each image and record their area and perimeter. 
As described previously [139], a circularity index was calculated as 4π(area/perimeter2) (=1 for a 
circle) for each cluster. 
Partial least squares regression model development 
 PLSR model generation was performed using SIMCA-P software (Umetrics, Umeå, 
Sweden) as described previously [166], based on mathematical models detailed in Geladi & 
Kowalski, 1986 and Wold et al., 2001 [163, 164]. For the initial PLSR model, the 6x160 data 
matrix, X, was composed of Luminex and western blot phosphoprotein measurements. The M = 6 
rows corresponded to the following cellular conditions: untreated, EGF, HGF, TGFβ, TGFβ+EGF, 
and TGFβ+HGF. The N = 160 columns corresponded to protein phosphorylation measurements 
for 32 proteins x 5 time points (15 min, 30 min, 1 hr, 4 hr, and 48 hr) for each condition. The 6x5 
output matrix, Y, was generated from EMT measurement data for the same conditions, with the K 
= 5 columns being measurements for total E-cadherin, total vimentin, E-cadherin junctional 
localization, fraction of vimentin-positive cells, and circularity index after a 3 day treatment. All 
data columns were mean centered and scaled to unit variance prior to PLSR analysis. Using 
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SIMCA-P the non-linear iterative partial least squares (NIPALS) algorithm was implemented to 
solve the linear regression: 
             Y = XB + G      (1) 
Where B is a matrix of regression coefficients and G represents the residual. To achieve this, X is 
decomposed into scores vectors, t, that span sample space and loadings vectors, p, that span X-
variable space such that the residual E is small in the outer product representation: 
             X = TP’ + E      (2) 
Y is equivalently decomposed into Y-scores vectors, u, and Y-weights vectors, c, that span Y with 
residual F: 
             Y = UC’ + F      (3) 
 In PLSR, the X-scores t, which are small in number, represent new latent variables 
termed principal components (PCs) that maximally capture covariance between the X and Y data 
matrices. The t’s are linear combinations of the original X-variables with weights w*:   
              T = XW*       (4) 
The X-scores must also be good models of Y such that the residual G is small: 
           Y = TC’ + G      (5) 
Combining equations (4) and (5) and relating back to equation (1) gives: 
             B = W*C’       (6) 
 In the NIPALS algorithm, the X-matrix is deflated after each component and the ath PC is 
solved using the X- residual from the previous component (note: E0 = X): 
       Ea = Ea-1 – tapa’      (7) 
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         ta = Ea-1wa      (8) 
The scores and weights vectors for the ath PC, ta and wa, are found such that they maximally 
capture X-Y covariance remaining after a-1 PCs, and are therefore determined from the residual 
matrix. Thus the w’s correspond to weights for the residual matrices, while w*’s relate to the 
original X-matrix. For relating back to the full model, w*’s are found using the following relation:   
         W* = W (P’W)-1      (9) 
Each weight vector wa is the normalized eigenvector associated with the greatest eigenvalue of 
the covariance matrix Xa’YaYa’Xa. Given that each PC is solved after subtracting the contribution 
from the previous PC, together the wa’s represent an orthonormal set defining directions in the X 
data space to maximally capture Y-relevant information.  
 The PLSR model was tested for goodness of prediction, Q2, using a leave-one-out cross-
validation approach and information captured, R2Y and R2X, after each successive component 
using standard calculations.  
Statistical analysis 
 Statistical significance was determined using one-way ANOVA and p-values were 
determined using Student-Newman-Keuls test for multiple corrections in Kaleidagraph 4.0 
(Synergy Software, Reading, PA).  
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Table 4-1 Panel of proteins measured by Luminex 
  Protein Phosphorylation 
1 AKT S473 
2 ATF2 T71 
3 BAD S112 
4 BCL-2* S70 
5 Caspase 8* active 
6 Caspase 9 active 
7 c-Jun S73 
8 c-MET panY 
9 c-MYC   
10 EGFR panY 
11 ERBB3 panY 
12 ERBB4* panY 
13 ERK1/2 T185/Y187 
14 FADD S194 
15 GSK3α S21 
16 GSK3β S9 
17 HER2 panY 
18 HSP27* S78 
19 IGF-IR* Y1135/1136 
20 IGF-IR* panY 
21 IKKα/β* S177/181 
22 IR* Y1162/1163 
23 IR* panY 
24 IRS1 S363 
25 IκB S32 
26 JNK T183/Y185 
27 MEK S222 
28 MSK S212 
29 mTOR S2448 
30 NFκB S536 
31 p38* T180/Y182 
32 p53* S15 
33 p53 S46 
34 p70S6K T412 
35 PTEN* S380 
36 RPS6 S235/236 
37 STAT1* Y707 
38 TNFRI   
39 TSC2 S939 
* analytes that did not produce linear Luminex signal and were removed from 
PLSR model construction; text color corresponds to kit: cell cycle+apoptosis, 
AKT/mTOR, MAPK, NFκB, receptors 
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Table 4-2 Panel of proteins measured by western blot 
  Protein Phosphorylation 
1 ALK Y1604 
2 p27 T157 
3 p38 T180/Y182 
4 SMAD2/3 S465/467 S423/425 
5 SRC Y418 
6 STAT3 Y705 
Where appropriate, text color corresponds to Luminex 
kit functions; proteins with other pathway functionality 
are colored grey: cell cycle+apoptosis, MAPK, 
receptors, other   
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4-4 RESULTS 
Characterization of EMT-associated shifts in protein expression in response to EGF, HGF, and 
TGFβ 
 The HPAF-II pancreatic cancer cell line was used to analyze the ability of different culture 
conditions to induce EMT (Fig. 4-1). This cell line displays differentiated epithelial characteristics, 
harbors mutations in KRAS, p16, and p53, and is SMAD4 wild type [143]. We have previously 
described the ability of different combinations of EGF and TGFβ to induce varying extents of EMT 
induction in HPAF-II (Chapter 3). In addition to EGF and TGFβ, we analyzed cellular response to 
HGF in this study, which is known to induce mesenchymal cellular characteristics on its own in 
certain cellular contexts [54]. Cells were monitored for EMT induction when maintained in 
complete medium supplemented with EGF (50 ng/mL), HGF (50 ng/mL), TGFβ (10 ng/mL), 
TGFβ+EGF, or TGFβ+HGF. After 5 days of treatment, cells had undergone EMT as indicated by 
acquisition of spindle-like morphology with fewer cell-cell junctions, decreased E-cadherin 
expression, and increased vimentin expression, with the degree of these changes dependent on 
treatment condition (Fig. 4-1A-D). Across conditions, HGF produced the greatest EMT as a single 
ligand, and the combination of TGFβ+HGF produced the greatest EMT overall. Western blot 
quantification for total protein abundance and quantitative immunofluorescence analysis of 
individual cell expression of E-cadherin and vimentin produced largely similar comparisons 
between conditions, but the profiles had some distinct differences (Fig. 4-1B-D). For example, 
western blotting results reflected greater differences in vimentin expression between HGF and 
TGFβ treatments as well as greater differences in E-cadherin among HGF, TGFβ, TGFβ+EGF, 
and TGFβ+HGF. These comparisons demonstrate consistency and complementarity between the 
two methods for analyzing changes in prototypical epithelial and mesenchymal markers. 
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Figure 4-1: EGF, HGF, and TGFβ induce differential changes in epithelial and 
mesenchymal marker expression and localization. 
HPAF-II cells were treated for five days with EGF (50 ng/mL), HGF (50 ng/mL), TGFβ (10 ng/mL), 
TGFβ+EGF, or TGFβ+HGF and subsequently imaged by phase contrast microscopy, prepared 
for immunofluorescence staining for E-cadherin and DNA or vimentin and DNA, or lysed for 
western blotting. (A) Representative phase contrast and immunofluorescence images are shown. 
(B) Lysates were analyzed by western blotting with antibodies against the indicated proteins. 
Densitometry values for each condition were normalized to the mean signal across conditions for 
88 
 
each of four independent experiments (n = 4). (C) E-cadherin localization quantification 
comparing the relative intensity at cell-cell junctions versus peri-junctional regions was calculated 
as described in Materials and Methods Section 4-3 for all junctions within an image. The mean 
ratio per image was averaged for four images from each of two independent experiments (n = 8).  
(D) The percent of vimentin-positive cells was calculated as described in Materials and Methods 
Section 4-3 for four images from each of two independent experiments (n = 8).  Data throughout 
are represented as mean ± s.e.m; * p < 0.01 for all pairwise comparisons unless indicated not 
significant (n.s.). 
 
Measuring cell scatter in response to EMT-inducing growth factors 
 Accompanying changes in protein expression and morphology, cells undergoing EMT 
become more motile and invasive [2, 168]. We assessed the ability of the growth factor conditions 
explored in Figure 4-1 to induce migration by using a cell scatter assay. As has been employed 
previously, monitoring the circularity index (CI = 4π(area/perimeter2)) of epithelial cell clusters in 
response to stimuli provides a quantitative measure of cellular scatter and migration and is 
related to the weakening of cell-cell junctions [139]. Quantifying circularity indices of clusters over 
3 days of treatment revealed similar qualitative trends in the EMT-promoting capacity among the 
treatment conditions as seen for protein expression (Fig. 4-2). TGFβ+HGF again displayed the 
greatest effect, and HGF had the largest effect of the single growth factor treatments. 
Interestingly, TGFβ+EGF-mediated effects seemed dampened compared to the measurements 
based on protein expression in Figure 4-1, performing no better than HGF alone. 
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Figure 4-2: EMT inducing growth factors promote cell scatter. 
HPAF-II cell clusters grown in 12-well plates from single cells were treated with EGF (50 ng/mL), 
HGF (50 ng/mL), TGFβ (10 ng/mL), TGFβ+EGF, or TGFβ+HGF and monitored for 3 days for cell 
scatter. Silhouettes from MATLAB analysis of representative cell cluster images are shown. 
Circularity indices versus time for clusters from twelve frames per condition in each of three 
independent experiments were quantified as described in Materials and Methods Section 4-3 and 
are reported as averages ± s.e.m. (n > 45); * p < 0.05 for all comparisons with TGFβ+HGF. 
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Antibody microarray reveals EMT-relevant phosphorylated protein targets for further investigation 
 Cellular integration of signaling through many networks in response to stimuli enables 
phenotype determination, including the ability for different growth factor treatments to elicit distinct 
extents of EMT induction. To identify the particular signaling nodes that differentiate among EMT 
states observed with different ligand treatments, we sought to quantitatively survey a large panel 
of signaling proteins to relate to the measured differences in EMT induction. Before focusing on 
quantitative evaluation of specific proteins, however, we interrogated a broad array of 
phosphorylation events in an unbiased screen using an antibody microarray with >1,300 distinct 
antibodies. We evaluated protein phosphorylation using antibody microarray in cells treated with 
TGFβ+EGF. After surveying a large number of time points by western blot (Fig. 4-3), a treatment 
time of 30 min was selected because it enabled measurement of both early and delayed 
phosphorylation events as detected by total phosphotyrosin (pY) western blotting.  
 
Figure 4-3: Evaluating total phosphotyrosine content from TGFβ+EGF time course. 
HPAF-II cells in 6-well plates were maintained in complete medium and treated with TGFβ (10 
ng/mL) and EGF (50 ng/mL) for the indicated times before lysis. Lysates were analyzed by 
western blotting with antibodies against the indicated proteins. Portions of the total 
phosphotyrosine (pY) scan are shown at higher contrast to visualize lower intensity bands. 
Images are representative of three independent experiments. 
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 Table 4-3 - Proteins with greatest 
induction of phosphorylation from microarray 
Phosphorylated Protein Fold Change 
NFkB-p65 Ser536 2.49 
p27Kip1 Thr187  2.33 
p53 Thr18  2.00 
Cytokeratin 8 Ser431 1.86 
CSFR Tyr561 1.83 
ETK Tyr566 1.82 
CASP2 Ser157 1.81 
CD3Z Tyr142 1.79 
HSP27 Ser15  1.78 
CASP1 Ser376 1.78 
NFkB-p100/p52 Ser869 1.77 
ALK Tyr1507 1.76 
NFkB-p100/p52 Ser865  1.76 
Synapsin Ser62 1.76 
CDK1/CDC2 Thr14 1.76 
VAV1 Tyr174  1.76 
CD5 Tyr453 1.75 
Epo-R Tyr368 1.75 
c-Jun Ser243  1.73 
IKK-gamma Ser31 1.70 
Tuberin/TSC2 Ser939 1.69 
Calsenilin/KCNIP3 Ser63 1.69 
Myc Ser62 1.67 
Elk1 Thr417  1.67 
Tuberin/TSC2 Thr1462 1.66 
 
Table 4-4 - Proteins with greatest decrease in 
phosphorylation from microarray 
Phosphorylated Protein Fold Change 
MAPKAPK2 Thr334 0.20 
HDAC1 Ser421 0.24 
4E-BP1 Ser65 0.37 
MEK1 Thr291  0.47 
Caspase-3 Ser150 0.53 
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 Antibody microarray analysis, which tends to produce false negatives with low incidence 
of false positives, revealed a number of protein phosphorylation events that were increased 
(Table 4-3) or decreased (Table 4-4) in response to a 30 min treatment with TGFβ+EGF. Of note, 
four proteins of the top 25 hits for phosphorylation increase were in the NFκB pathway, including 
the first-ranked protein NFκB p65 phosphorylated at Ser536. Other notable proteins indicated were 
p27/Kip (a cell cycle regulator), ALK, p53, TSC2 (upstream of mTOR), 4E-BP1 (downstream of 
mTOR), MYC, and MAPKAPK2 (directly phosphorylated by p38). The connections to the 
AKT/mTOR, p38, and NFκB pathways, which have all been implicated in EMT induction, 
suggested inclusion of these pathways moving forward. Additionally, a necessary role for p27/Kip 
in EMT was recently described through promoting STAT3 activation in mammary epithelial cells 
[169], which argued for its inclusion as well. 
 
Partial least squares regression model predicts signaling events most relevant for EMT 
phenotype acquisition 
 Using insight from the antibody microarray results and the literature, we measured 
phosphorylation of 45 proteins, listed in full in Tables 4-1 & 4-2, in response to all five growth 
factor treatments at five time points (15 min, 30 min, 1 hr, 4 hr, and 48 hr) by Luminex and 
western blotting. As described in Materials and Methods Section 4-3, 13 Luminex analytes were 
discarded from final PLSR model construction due to lack of linear signal. The phosphorylation 
profiles for the 32 remaining proteins included in our final data set are shown in Figure 4-4.  
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Figure 4-4: Individual protein phosphorylation profiles reveal differences in 
growth factor-mediated signaling. 
HPAF-II cells plated in 6-wells were maintained in complete media, prior to addition of the 
indicated combinations of EGF (50 ng/mL), HGF (50 ng/mL), and TGFβ (10 ng/mL). Cells were 
lysed and lysates were analyzed by Luminex and western blotting according to Materials and 
Methods Section 4-3. Averaged triplicate Luminex and western blot-based measurements of 
protein phosphorylation are shown. * indicates protein measured by western blot, all others by 
Luminex. Full list of phosphorylation sites measured is given in Tables 4-1 and 4-2. 
  
 A PLSR model was generated using the data in Figure 4-4 as the X-data with 160 X-
variables and the phenotype measurements from Figures 4-1 and 4-2 for the Y data (Fig. 4-5). 
Inspection of the scores and weights plots revealed that the first principal component was 
positively correlated with epithelial characteristics with untreated cells and E-cadherin measures 
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having the highest scores and weights in PC1, respectively (Figure 4-5A,B). Conversely, the 
TGFβ+HGF treatment condition and vimentin measures had the most negative scores and 
weights values for PC1. Thus, PC1 provides a primary EMT axis, and X-variables weighted most 
negatively in PC1 are likely candidates for important roles in EMT induction. In the weights plot 
PC2 provided further separation between epithelial and mesenchymal phenotypes, again with 
positive values associated with epithelial characteristics, suggesting that there is additional 
information within PC2 regarding which variables contribute to EMT differences. The scores plot 
furthermore suggests that PC2 provides information distinguishing between single growth factor 
treatment conditions. Despite meaningful interpretation of the first few principal components, 
further analysis revealed that the overall model quality was not high (Fig. 4-5C). Though a two-
component model captured the majority of Y information, the cross-validation of model prediction, 
given by Q2, indicated a fairly low predictive ability of the model. These limitations may arise in 
PLSR models that are over-specified or when the PLSR model is built using X-data that is not Y-
relevant.  
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Figure 4-5: A PLSR model reveals an EMT signaling axis. 
A PLSR model was built using phenotype and phosphorylated protein measurements from 
Figures 4-1, 4-2, and 4-4 as described in Materials and Methods Section 4-3. (A) Weights and (B) 
scores plots were generated for the first two principal components. In A dots are colored based 
on protein kit/function as shown in legend. (C) Cumulative measures of information captured, R2X 
and R2Y, and cross-validated prediction, Q2, are shown for up to a 5-component model.  
 
Reducing the X dataset improves PLSR model prediction and reveals key EMT signaling nodes 
 The results from Figure 4-5C suggested that there may have been Y-irrelevant 
information incorporated into the original X data set. Additionally, the considerable overlap of X-
variables in the weights plot (Fig. 4-5A) indicated that many variables were providing redundant 
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information. To address these issues, we systematically evaluated the quality of information 
provided by each X-variable. First, we sought to eliminate redundant information provided by 
proteins within the same kit or pathway using a principal components analysis (PCA) for each 
time point (Fig. 4-S1). When two or more analytes from the same kit measured at the same time 
point were very proximal in a two-component PCA loadings plot, one representative analyte was 
chosen for model inclusion while the other(s) were removed. This analysis was performed for 
each time point. Next, the averaged data were inspected to reveal which time points showed no 
meaningful differences in protein level or activation. In this case, data processing prior to PLSR 
input would falsely separate these measurements from each other and thus provide misleading 
information for model inclusion. For example, in Figure 4-4 JNK phosphorylation returned to 
baseline values for all conditions by the 48 hr time point, indicating this should not be included as 
an x-variable for model construction. 
 This systematic approach led to a reduced X data set of 74 of the original 160 variables. 
A resulting PLSR model demonstrated quite similar separation of epithelial and mesenchymal Y-
variables and conditions as the initial model (Fig. 4-5, 4-6A,B) with greatly improved model quality 
(Fig. 4-6C). In agreement with the known multivariate nature of EMT signaling, the distribution of 
variables in the weights plot indicates high correlation of EMT induction with all major signaling 
pathways measured for the overall model. Proteins within MAPK, AKT/mTOR, NFκB, STAT, and 
SMAD signaling pathways were all clustered near mesenchymal traits, and a number of variables 
within cell cycle and apoptosis pathways were distributed near epithelial traits. To rank the value 
of specific protein phosphorylation measurements for the overall two-component model, we 
analyzed the variable importance in the projection (VIP) scores for this reduced PLSR model (Fig. 
4-7, Table 4-S1). A VIP score > 1 indicates a variable to be informative for the model, which was 
true of 38 variables in this model. This analysis again highlighted the multivariate nature of EMT 
signaling, with measurements of 26 separate proteins which spanned all pathways represented 
among the 38 variables with VIP score > 1. 
97 
 
 
Figure 4-6: Systematic reduction of X variables improves model quality. 
A PLSR model was built as in Figure 4-5 using a reduced X data set as described. (A) Weights 
and (B) scores plots were generated for the first two principal components. In A dots are colored 
based on protein kit/function as shown in legend. Text next to dots indicates protein and time 
point in hr. (C) Cumulative measures of information captured, R2X and R2Y, and cross-validated 
prediction, Q2, are shown for up to a 5-component model.  
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Figure 4-7: VIP score analysis confirms multivariate EMT regulation. 
The VIP scores were calculated for the 74-variable PLSR model shown in Figure 4-6. 
Measurements are ranked by VIP score and colored according to pathway. 
 
A minimal PLSR model identifies key EMT signaling nodes for further validation 
 Despite the obvious complexity of EMT signaling indicated by our analysis to this point, 
we wished to identify a subset of key variables predictive of EMT induction. A sequential VIP 
analysis was used to develop a minimal PLSR model using only 10 X-variables. First, the top-
ranked measurement for each of the 26 proteins represented in the VIP scores in Table 4-S1 
were used to generate a PLSR model. This model (not shown) had 10 variables with VIP score > 
1, which were subsequently used to generate the minimal PLSR model (Fig. 4-8). The resulting 
model had altered distribution of variables and conditions in the two-component weights and 
scores plots compared to Figures 4-5 and 4-6 (Fig. 4-8A,B), despite some notable similarities. In 
this model, PC1 again provided the most meaningful separation between epithelial and 
mesenchymal states, whereas PC2 separated the different signaling pathways. Importantly, 
despite the vast reduction in input data for the model, the overall model quality was high (Fig. 4-
8C). The minimal model included several proteins with negative weights, which suggests their 
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association with the mesenchymal state. The implicated signaling pathways would therefore 
represent promising targets for inhibiting or reversing mesenchymal phenotypes for future study. 
 
 
Figure 4-8: A minimal PLSR model captures important EMT signaling. 
A PLSR model was built using a reduced X data set as described. (A) Weights and (B) scores 
plots were generated for the first two principal components. In A dots are colored based on 
protein kit/function as shown in legend. Text next to dots indicates protein and time point. (C) 
Cumulative measures of information captured, R2X and R2Y, and cross-validated prediction, Q2, 
are shown for up to a 5-component model.  
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4-5 DISCUSSION 
 This study produced the first quantitative model directly connecting multivariate signaling 
events to the ability of different treatments to produce varying extents of EMT in pancreatic 
cancer cells. We quantified the ability of EGF, HGF, TGFβ, TGFβ+EGF, and TGFβ+HGF to 
induce differential changes in migration measured by cell scatter and expression and localization 
of E-cadherin and vimentin. TGFβ+HGF consistently displayed the greatest EMT-inducing 
capacity of all conditions across all phenotypes. We then undertook an unbiased screen of 
protein phosphorylation events under EMT-inducing conditions to identify key signaling events in 
EMT induction. Phosphorylation profiles for a panel of 32 proteins at 5 time points were 
quantitatively measured in response to all five growth factor treatment conditions. These protein 
phosphorylation measurements were combined with the quantified phenotype analysis in a PLSR 
model to identify signaling proteins whose activity covaried most with EMT status. Systematic 
reduction of phosphorylation measurements included in the model based on pruning of redundant 
or low confidence variables and VIP analysis led to identification of 10 key signaling 
measurements. These measurements produced a two-component PLSR model that captured 
>90% of the information in the EMT phenotype data. 
 The ten proteins from the minimal PLSR model provide promising potential targets for 
inhibiting or reversing mesenchymal phenotypes. In particular, the eight proteins with strongly 
negative weight into PC1 – c-Jun, p38, MEK, MSK1, NFκB, STAT3, SRC, and SMAD2/3 - are 
implicated as positive predictors of EMT induction. MEK, MSK1, c-Jun, and p38 are all MAPK 
signaling components, and their importance for EMT induction may not be surprising given 
previous reports particularly for MEK/ERK and p38 [47, 49, 57, 126]. c-Jun phosphorylation at 
Ser73 after 4 hr of treatment was also among the most highly correlated with EMT induction in our 
model. The activity of JNK and c-Jun phosphorylation are less frequently implicated in EMT 
induction than ERK and p38, but a recent report identified c-Jun activation as crucial for 
mesenchymal differentiation from pluripotent stem cells [170]. These findings along with the 
present study, therefore, suggest JNK as a promising potential target for suppressing 
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mesenchymal cellular traits for future biochemical studies. An interesting aspect to this analysis 
could involve determining the reason for the delayed time scale of c-Jun activation and why this 
was unique to the combination of TGFβ and HGF (Fig. 4-4). SMAD2&3 are necessary effectors in 
TGFβ-mediated signaling, so the association of SMAD2/3 activity with TGFβ-mediated EMT 
induction is expected. Interestingly, though mTOR phosphorylation at 30 min had a high VIP 
score in the 74-variable model and many components of AKT/mTOR signaling were highly 
associated with EMT (Figs. 4-6 & 4-7), all of the measurements within the AKT/mTOR pathway 
were eventually dispensable for the minimal model generation. Further in vitro studies could 
reveal whether or not AKT/mTOR signaling is indeed dispensable for EMT induction as 
suggested by this analysis. 
 Among the proteins measured in this study, SRC/SFK phosphorylation at Tyr418 was also 
among the most strongly correlated with EMT induction. Interestingly, SRC activity has been 
previously implicated as a driver of EMT induction with reported roles phosphorylating the type II 
TGFβ receptor [49] and EGFR [55] following TGFβ treatment. Additionally, following TGFβ 
treatment SFK can be activated by EGFR to suppress apoptotic signaling and promote full AKT 
activation [56]. These findings are in line with the implied role of SFK from our PLSR analysis and 
motivate further experimental analysis of the importance of SFK activity for EMT induction in 
response to different growth factor treatments. These investigations could employ siRNA or SFK 
inhibitors, which would each provide meaningful information. Small molecule inhibitors, such as 
PP2, have the ability to inhibit multiple SFK proteins simultaneously [171], which provides 
information of the general importance of SFK activity, but using PP2 would not enable evaluation 
of rank importance of specific SFK proteins. Alternatively, siRNA could be used to deplete 
specific SFK proteins such as c-SRC, FYN, LYN, and YES individually to determine which are 
particularly responsible for SFK-dependent EMT.  
 A notable finding from this study was the ability to improve model performance by 
reducing the input data incorporated in the model from 160 phosphoprotein measurements to 10 
measurements. The ability to capture the majority of dependent variable variation using a 
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reduced PLSR model with ten or fewer independent variables has been reported previously [102, 
166], and is in fact a strength of PLSR analysis. By identifying a small number of key parameters 
that predict cellular phenotypes, PLSR models such as the one reported here can be leveraged in 
the future for predicting responses to new treatments or in new contexts such as additional 
pancreatic cancer cell lines by making a minimal number of measurements. Further refinement 
and validation of the reduced PLSR model could provide a succinct list of key protein 
phosphorylation measurements that could be used to predict phenotypic responses in tumors or 
lead to the identification of nodes for inhibiting EMT induction.  
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4-7 SUPPLEMENTAL MATERIAL 
 
Figure 4-S1: PCA analysis enables systematic exclusion of redundant X-variables. 
The loadings plot for a PCA model based only on measurements from the 30 min treatment 
conditions is shown. Analytes shown in red were excluded from subsequent PLSR analysis in 
Figure 4-6 due to their proximity to other analytes within the same kit/pathway. This systematic 
analysis was performed for each of the five time points (15 min, 30 min, 1 hr, 4 hr, and 48 hr) to 
identify variables for PLSR model exclusion. 
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Table 4-S1: Protein measurements with VIP > 1.0 from 74-variable PLSR model 
Rank # Protein/phosphorylation/time point 
1 p27 T157 - 4 hr 
2 MSK1 S212 - 4 hr 
3 cMYC - 48 hr 
4 mTOR S2448 - 4 hr 
5 STAT3 Y705 - 15 min 
6 p27 T 157 - 48 hr 
7 SMAD2 S465/467 / SMAD3 S423/425 - 15 min 
8 SMAD2 S465/467 / SMAD3 S423/425 - 4 hr 
9 c-Jun S73 - 4 hr 
10 Caspase-9 active - 48 hr 
11 MEK1 S222 - 48 hr 
12 NFkB S536 - 4 hr 
13 SRC Y418 - 15 min 
14 ErbB2 panY - 15 min 
15 NFkB S536 - 15 min 
16 SMAD2 S465/467 / SMAD3 S423/425 - 30 min 
17 IkBa S32 - 48 hr 
18 p38 - 1 hr 
19 SRC Y418- 1 hr 
20 IkBa S32 - 30 min 
21 GSK3b S9 - 4 hr 
22 TSC2 S939 - 4 hr 
23 p53 S46 - 48 hr 
24 cMYC - 4 hr 
25 p27 T157 - 1 hr 
26 GSK3a S21 - 30 min 
27 JNK T183/Y185 - 60 min 
28 c-Jun S73 - 60 min 
29 ERK T185/Y187 - 4 hr 
30 AKT S473 - 15 min 
31 RPS6 S235 - 4 hr 
32 GSK3b S9 - 30 min 
33 BAD S112 - 60 min 
34 IRS1 S636 - 30 min 
35 SRC Y418 - 30 min 
36 ERK T185 Y 187 - 30 min 
37 BAD S112 - 4 hr 
38 NFkB S536 - 30 min 
Proteins are color-coded according to kit/function: cell cycle+apoptosis, AKT/mTOR, MAPK, 
NFκB, receptors, other 
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CHAPTER 5: Conclusions and Future Work 
 
5-1 SUMMARY 
 The work described in this thesis has enhanced the understanding of how EMT is 
regulated by specific cell signaling pathways and has identified potential routes for enhancing 
clinical outcomes in cancer. Of particular note was the development of a drug scheduling strategy 
aimed at enhancing EGFR inhibitor response after initial treatment with a MEK inhibitor in lung 
cancer cells (Chapter 2). In this study, MEK inhibition prevented EMT induction in response to 
TGFβ and EGF and promoted mesenchymal-epithelial transition (MET) in the absence of growth 
factors. The acquisition of epithelial traits from chronic MEK inhibition enhanced cell death in 
response to EGFR inhibition in cell lines characterized by both de novo or acquired resistance to 
EGFR inhibition. Though several recent studies have suggested the potential of MEK and EGFR 
coinhibition as a therapeutic strategy, this work suggests an alternative approach for combining 
these inhibitors sequentially to improve response. This work also demonstrated MEK-dependent 
acquisition of mesenchymal traits from ectopic expression of mutant KRAS, which is found in a 
significant portion of patients across cancer types.  
 The findings of Chapter 2 raised interest as to which ERK pathway components were 
responsible for transducing EMT-driving signals. In Chapter 3 we described a necessary role for 
the cytosolic phosphatase SHP2 in EMT and provided evidence that SHP2 activation states tune 
the extent of EMT observed in response to different ligands. Specifically, TGFβ treatment 
produced a partial EMT that corresponded to low SHP2 activity, which was nevertheless required 
for the observed EMT shifts. EGF co-administration with TGFβ led to induced SHP2 activity 
which greatly augmented the ability of TGFβ to promote mesenchymal dedifferentiation.  
 Experimental and computational approaches were then undertaken to survey additional 
signaling pathways that may also control EMT induction in Chapter 4. First, we observed that 
HGF and TGFβ+HGF treatments provide further diversity in the spectrum of EMT induction 
compared to treatments with EGF, TGFβ, or TGFβ+EGF. TGFβ+HGF produced the greatest 
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EMT of these conditions and HGF was the most efficient EMT inducer as a single agent. These 
findings were combined with quantitative protein phosphorylation measurements in response to 
each condition to generate a partial least squares regression computational model of which 
protein phosphorylation events are most predictive of the extent of EMT induction. These results 
provide a framework for developing novel strategies to inhibit mesenchymal phenotypes through 
combining targeted inhibitors. Implementing these strategies and the approach developed in 
Chapter 2 in preclinical and clinical models may demonstrate promising new therapeutic methods 
to improve cancer patient prognosis. The remainder of this chapter will elaborate on 
considerations for such preclinical and clinical models as well as other implications and future 
directions of this work. 
 
5-2 EFFECTS OF CHRONIC MEK INHIBITION AND FURTHER INVESTIGATION   
 The results of Chapter 2 suggested a novel strategy for enhancing therapeutic response 
to EGFR inhibitors in NSCLC. Specifically, the elevated gefitinib response observed after an MET 
from several days of MEK inhibition suggests that the sequential delivery of therapies wherein a 
MEK inhibitor is administered alone initially to promote an epithelial phenotype in cancer cells 
followed by addition of an EGFR inhibitor could enhance response to the EGFR inhibitor. Some 
studies have suggested the efficacy of EGFR and MEK inhibitor co-administration in gastric 
cancer [118], colorectal cancer [172], and pancreatic cancer cells [119], and current clinical trials 
are evaluating the combination of erlotinib with MEK inhibitors in NSCLC [84]. It seems, however, 
that response in these studies could potentially be increased by delaying initial administration of 
the EGFR inhibitor, since MEK inhibitor pretreatment enhanced or at least maintained EGFR 
inhibitor response in all cell lines tested in this work. Employing such a strategy could provide a 
clinical application for specific MEK inhibitors that could not be FDA-approved as single agents, 
such as CI-1040 [84], or an additional clinical indication for trametinib, the first FDA-approved 
MEK inhibitor, which is currently approved for metastatic melanoma patients with BRAF mutation 
[91, 92]. 
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 Before translating these strategies into the clinic, the efficacy of the proposed drug 
scheduling must be evaluated in more cell lines and in animal models. It is likely that similar 
effects of MEK inhibition could be observed in other cancer types in addition to NSCLC, since 
ERK activation drives EMT phenotypes in cells from oral cancers [173], melanoma [174], and 
pancreatic cancer [94]. These and other tumor types with mesenchymal-associated therapy 
resistance could be initially tested in in vitro experiments as in Chapter 2 before further analysis in 
animal models.  
 For in vivo work, the dose and schedule of inhibitors will likely require optimization since 
the time of maximal gefitinib response varied between cell lines and was not always associated 
with most epithelial marker expression. Qualitatively, response to MEK inhibition may also be 
improved overall in vivo, as suggested by recent results where EGFR-containing signaling 
complexes were much more abundant in some cells in subcutaneous xenografts compared to the 
same cells in vitro [175]. If these findings apply across cell lines, ERK activity may be generally 
enhanced in vivo which could broadly enhance phenotypic effects of MEK inhibition in vivo. 
These studies could initially rely upon subcutaneous xenograft experiments using a panel of cell 
lines or alternatively, patient-derived xenografts (PDXs), in which primary tumor cells from a 
patient are directly transplanted into the flank of a mouse. PDX samples recapitulate tumor 
heterogeneity seen in primary tissue and patient-to-patient variability [176, 177], and PDX studies 
have been used in lung [175], colorectal [172], breast [178], head and neck [179], renal cell [180], 
and ovarian [181] cancers to test therapeutic molecules and identify novel predictors of patient 
response. PDX cells are passaged between mice, which in future studies would enable matched 
comparison of different scheduling and combinations of MEK and EGFR inhibitors as an 
extension of the work in this thesis. Development of this therapeutic approach may prove an 
effective means of extracting value and clinical potential from therapeutic molecules that are 
clinically safe and biochemically effective but have not yet translated to clinical success. 
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5-3 SIGNALING TARGETS FOR EMT REVERSAL AND COMBINATION THERAPIES 
 The pervasive nature of the malignant consequences from EMT induction in cancer has 
motivated studies to identify pharmacological targets to suppress mesenchymal traits [182]. 
Interestingly, this aim is in line with long-standing efforts toward ‘differentiation therapy’ for many 
malignancies [183, 184], which seeks to improve cancer therapeutic response in poorly 
differentiated tumors. To identify EMT targets, several studies have performed screens using 
libraries of available compounds or siRNAs to selectively target mesenchymal cells [129, 185], 
reduce migration [186], or promote E-cadherin expression [128, 187]. Though these techniques 
employ high-throughput screening to survey a very large number of targets for EMT suppression, 
they rarely incorporate integrated analysis of multiple EMT-relevant phenotypes, which may prove 
a limitation in finding broadly effective targets. More definitive identification of critical EMT 
regulators will require following up on these studies with more in-depth analysis of specific 
intermediates or with screens that incorporate several phenotypes. 
 The results in Chapter 2 and 3 provided a thorough analysis of ERK as an important 
signaling regulator that can be perturbed to control EMT phenotypes. However, several pieces of 
evidence indicated that other pathways play complimentary or overlapping roles to control EMT 
induction. For example, though MEK inhibition and SHP2 knockdown consistently and 
significantly inhibited mesenchymal dedifferentiation, these effects were sometimes incomplete 
and/or transient. In these cases, other pathways must, therefore, compensate for ERK when it is 
inhibited or play redundant roles in promoting EMT. In Chapter 4 we used a PLSR model to 
identify candidate EMT-relevant signaling intermediates by measuring phosphorylation of proteins 
from many signaling pathways against multiple phenotypic measures of EMT induction in 
response to growth factors. Future studies based on proteins indicated in the PLSR model will 
evaluate whether specifically targeting each protein or multiple proteins in combination can inhibit 
EMT induction, reverse mesenchymal traits, and potentially enhance therapeutic response. 
 One promising target for future investigation is the cytosolic kinase, SRC and other SRC-
family kinases (SFKs). Previous work has demonstrated that TGFβ-mediated phenotypic shifts 
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depend upon SRC kinase activity [49, 56] through direct phosphorylation of TGFβ receptor II [49] 
and EGFR [55] after TGFβ treatment. In these studies, SRC kinase activity promoted signaling 
through p38 [49], ERK [55], and AKT [56] suggesting that SRC could potentially regulate 
signaling flux through multiple pathways controlling EMT induction. Additionally, EGFR-driven 
SFK activity promotes prolonged SHP2 activity [151], which may relate to the necessary role for 
SHP2 activity in EMT induction we described in Chapter 3. Importantly, many findings 
surrounding the role of SRC have relied on the pan-SFK inhibitor PP2 which has substantial 
affinity for other kinases including p38 [171], necessitating use of more specifically targeted tools 
for future investigation. The breadth of findings regarding the importance of SFK activity merits 
further analysis of the role of specific SFKs in EMT induction. Measuring response to TGFβ with 
or without EGF or HGF in cells with depletion of specific SFK proteins could reveal more 
conclusively the role for SFK proteins in EMT induction. 
 
5-4 SHP2 AS A THERAPEUTIC TARGET  
 Given that SHP2 depletion prevented EMT induction in response to TGFβ with and 
without EGF in Chapter 3, targeting SHP2 activity may provide another potential strategy for 
promoting an epithelial phenotype in cancer cells. This fits within and contributes to the growing 
motivation to target SHP2 activity in cancer. SHP2-activating mutations occur in multiple cancers 
including juvenile myelomonocytic leukemia, acute myelogenous leukemia, and lung and colon 
carcinomas, as well as Noonan syndrome, a developmental disorder leading to increased risk of 
certain malignancies [81, 152]. SHP2 depletion, through suppressing ERK pathway activity, has 
been shown previously to confer gefitinib sensitivity in NSCLC cells [75], and SHP2 promotes 
tumorigenesis in xenograft studies of breast and brain cancer cells [82, 83]. The known roles of 
SHP2 and other PTPs in cancer and other diseases have motivated significant research efforts to 
develop specifically-targeted small molecule PTP inhibitors, which has been attainable for many 
kinases [188]. These efforts for PTPs have been quite challenging, however, due to the highly 
polar nature of and homology between PTP active sites, which introduce difficulties in 
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bioavailability and specificity, respectively [189, 190]. New strategies targeting allosteric binding 
sites unique to SHP2 [153, 154] and another phosphatase PTP1B [191] have shown promise 
toward improving specificity of PTP inhibitors. Since SHP2 drives malignancy in multiple cancers, 
further development of these newly-identified small molecule inhibitors would have great potential 
for preclinical and clinical investigations. 
 
5-5 MEASURING SHP2 ASSOCIATIONS WITH HIGHER SENSITIVITY AND SPATIAL 
RESOLUTION 
 Though we identified that EGF’s ability to enhance TGFβ-mediated EMT depended upon 
SHP2 SH2 engagement by phosphotyrosines, additional questions remain regarding the specific 
molecular alterations underlying the ability of SHP2 to influence EMT. SHP2 was required for 
EMT induced by TGFβ alone, despite no detectable TGFβ-induced associations between SHP2 
and phosphotyrosine-containing proteins. This may occur simply because basal SHP2 
phosphatase activity in the absence of SH2 domain engagement is sufficient for TGFβ-mediated 
effects. Additionally, TGFβ mediates signaling through many pathways which could potentially 
involve SHP2 binding to proteins that are not detectable using phosphotyrosine western blotting. 
One recently-identified mechanism for SHP2 positively impacting TGFβ-mediated effects was 
through decreased SHP2 binding with Hook1, a negative regulator of SHP2 activity [192]. TGFβ-
mediated unbinding of Hook1 from SHP2 provides a potential model for SHP2 activity being 
induced at a low level during TGFβ treatment without engagement by phosphotyrosine. SHP2 
has additional signaling roles not assessed in this thesis. For example, SHP2 can regulate EMT-
associated phenotypes through interactions with components of focal adhesions including focal 
adhesion kinase [148, 149] and the adherens junction protein α-catenin [193], which could also 
be explored in the context of TGFβ treatment. Since these interactions were not detected through 
SHP2 immunoprecipitation western blotting higher sensitivity methods using proteomic mass 
spectrometry techniques for interaction mapping [194] could elucidate whether SHP2 binds to 
these proteins that may have lower abundance or to proteins that are not tyrosine 
112 
 
phosphorylated. Specific SHP2 interactions required for TGFβ-mediated effects could provide 
protein targets which have more potent small molecule inhibitors than SHP2 for inhibiting EMT 
induction. Such inhibitors could be combined with a MEK inhibitor, for example, to suppress 
multiple pathways influencing EMT induction. 
 In addition to enhancing our understanding of which proteins are engaged by SHP2 
under different cellular conditions, the question of where this engagement occurs also merits a 
more thorough investigation. We identified SHP2-GAB1 interaction as critical for mediating EMT 
inducing signals in Chapter 3, motivating further characterization of factors influencing 
maintenance of this complex. In a recent study, we found that SFK activity maintains SHP2-GAB1 
complexes distal from EGFR, which nucleates complex formation [151]. This complex persistence 
could allow SHP2 to dephosphorylate substrates distal from the receptor (e.g., the focal adhesion 
protein paxillin, [195]) by maintaining SHP2 activation as it diffuses away from the receptor. 
Computational modelling has enhanced the quantitative understanding of which kinetic 
parameters influence the ability of SHP2-GAB1 complexes to persist in the cell interior 
(unpublished results from Furcht et al.), though the spatially resolved persistence of complexes 
has not yet been measured in live cells. The abundance of SHP2 throughout the cell leads to high 
background in attempts to visualize co-localization of SHP2 and GAB1 in standard 
immunofluorescence staining and thus more sophisticated microscopy techniques are required to 
characterize SHP2-GAB1 spatial distribution.  
 Two methods for imaging protein co-localization in cells are fluorescence resonance 
energy transfer (FRET) microscopy and proximity ligation assay (PLA), which would each have 
advantages and disadvantages for the direct visualization of SHP2-GAB1 complexes. FRET 
utilizes the ability to detect energy transfer between two fluorophores when they are within 1-10 
nm of each other (summarized in [196]). Using SHP2 and GAB1 genetically tagged with 
fluorescent proteins, FRET could thus enable high resolution temporal measurement of SHP2-
GAB1 co-localization. Challenges in implementing FRET include proper selection and 
stoichiometric ratios of fluorophores and optimizing fluorophore placement on proteins such that 
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their inherent biochemical activities are retained while bringing the fluorophores close enough for 
FRET to occur [197]. Without resolved structures of full length SHP2 and GAB1 proteins bound 
together, optimal placement of fluorescent tags on the proteins is difficult to predict. FRET has 
historically relied on ectopic expression for genetic tagging of proteins, but recent advances in the 
CRISPR system for gene knock-in could allow for fluorescent tagging at the endogenous SHP2 
and GAB1 loci for FRET experiments. Alternatively, PLA is an antibody-based method that uses 
in situ PCR to detect co-localization of two targets in fixed cells, which detects endogenous 
protein without concerns of fluorophore compatibility [198]. PLA has typically been used to detect 
the presence or extent of protein binding rather than intracellular distribution of complexes [175]. 
Therefore to study SHP2-GAB1 complex persistence using PLA, method verification with proper 
controls to distinguish between localization of SHP2-GAB1 complexes on endocytic vesicles 
versus in the cytosol would be necessary. Since PLA is performed on fixed samples, analysis is 
restricted to distinct time points rather than live-cell imaging in FRET, reducing the ease with 
which time-resolved detection of complex persistence could be achieved. 
 
5-6 TGFβ SIGNALING  
 As reviewed in Chapter 1, TGFβ binding to its receptors and subsequent TGFβ receptor-
mediated signaling is complex and can be highly context dependent [4]. For example, in Chapter 
3 TGFβ did not induce ERK phosphorylation (at the time points we investigated) in H322 and 
HPAF-II cells, despite direct links between TGFβ signaling and ERK activation in other cell 
settings [47]. Given the importance of ERK for EMT induction, it would be informative to 
investigate what cellular components determine the connectivity between TGFβ and ERK. For 
example, relative abundance of TGFβ type I and II receptors, SMAD2/3, or other signaling 
intermediates likely impact how TGFβ-mediated signals are transmitted through cellular networks. 
Since TGFβ type II receptor has low tyrosine kinase activity relative to serine/threonine kinase 
activity [48], higher abundance of TGFβ type II receptors could facilitate higher tyrosine 
phosphorylation of the receptor complexes, which favors recruitment of adapters in the MAPK 
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signaling cascades such as SHC [50, 51]. Therefore, it would be informative to determine relative 
abundance of TGFβ type I and II receptors and their phosphorylation at key residues following 
TGFβ treatment in H322 and HPAF-II cells compared to a cell line that displays TGFβ-induced 
ERK phosphorylation. Differences between these cell lines could suggest potential biochemical 
mechanisms determining pathway connectivity. 
 Chapter 3 revealed the importance of cell context on the density dependence of TGFβ-
mediated EMT induction. Specifically, the pancreatic cancer cell line HPAF-II was highly sensitive 
to cell density for EMT induction, with no detectable EMT induced at high plating densities. The 
lung cancer cell line H322 showed no such dependence. Previous work in the human 
keratinocyte cell line HaCaT showed that TGFβ-induced formation of nuclear SMAD3-SMAD4 
complexes detected by PLA was highly dependent on cell density, with significantly fewer 
complexes in cells plated at high density [145]. Recent investigation by Nallet-Staub and 
colleagues also captured the density dependence of SMAD nuclear localization in HaCaT cells as 
well as a melanoma cell line, but also showed that a mammary epithelial cell line did not display 
this density effect [146]. This cell context dependence provides further motivation to adapt these 
experimental techniques in H322 and HPAF-II as well as other cancer cell lines. PLA-based 
measurements of TGFβ-induced SMAD signaling could potentially reveal differences between 
H322 and HPAF-II, and the flexibility of PLA would enable detection of other EMT-relevant 
signaling complexes (e.g., TGFβ receptor type II-SRC and SHP2-GAB1 binding). 
 A downstream component in TGFβ signaling common to all SMAD signaling pathways is 
the co-regulator SMAD4, which facilitates translocation of SMAD2/3 complexes into the cell 
nucleus [4]. In addition to having a very high incidence of KRAS mutation (95%), pancreatic 
cancer is also characterized by mutation or deletion of SMAD4 in roughly 50% of patient tumors 
[147]. Though SMAD4 is known to positively regulate TGFβ-mediated SMAD signaling, whether 
SMAD4 is required for TGFβ-mediated EMT remains unclear. Some investigations found that 
SMAD4 is involved in TGFβ tumor suppressive roles and not EMT response [199, 200], while 
other investigations determined that TGFβ-mediated EMT is distinctly dependent on SMAD4 
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activity [201]. HPAF-II, the pancreatic cancer cell line used in this thesis, harbors expected 
mutation of KRAS but is wild type for SMAD4. It would be informative to test whether SMAD4 
status affects the EMT induction patterns reported in this thesis. Correlative examination of 
SMAD4 wild type versus mutant cell lines could reveal patterns in EMT dependence, but an 
isogenic cell line model to study SMAD4 variants would provide a more robust framework for 
elucidating the EMT relevance of SMAD4. The CRISPR-Cas9 system is a recently adapted tool 
for modifying chromosomal DNA [202] that could be utilized to introduce mutations at the SMAD4 
locus or create a chromosomal deletion. 
 
5-7 USING PLSR TO PREDICT CLINICALLY RELEVANT PHENOTYPES 
 In Chapter 4, a PLSR model was developed to elucidate signaling processes underlying 
differential EMT induction in response to different growth factor conditions, which led to 
identification of targets to inhibit or suppress EMT for future investigation. The ability to adapt 
PLSR to any data set with corresponding independent and dependent variable data matrices for a 
given set of experimental conditions makes it a widely applicable computational tool. Moving 
forward, there will be many opportunities to develop additional PLSR models to study clinically 
relevant processes based on this thesis. For example, a PLSR model could be developed for 
prediction of response to the MEK inhibition strategy developed in Chapter 2. Though multiple cell 
lines with differing genotypes were sensitized to EGFR inhibition by MEK inhibitor pretreatment, 
other cell lines tested were not responsive to this strategy. A PLSR model built upon 
phosphorylation profiles in cells at rest and in response to MEK inhibition and corresponding cell 
death or proliferation measurements in response to EGFR inhibition could be used to predict 
response in additional panels of cell lines or future clinical samples. Such a model could also 
identify possible modes of adaptive resistance or escape from this strategy. 
 Another outstanding question in the EMT literature is determining what factors influence 
stable versus reversible mesenchymal dedifferentiation. In vitro, the extent and reversibility of 
TGFβ-mediated EMT is dependent on the concentration of TGFβ and length of treatment [203]. 
116 
 
Metastatic colonization appears to rely on this reversibility of mesenchymal traits through MET 
induction [22, 23]. Since many carcinoma-derived cell lines (often with therapeutic resistance) 
display distinct permanent mesenchymal phenotypes [27, 141, 143], stable EMT induction also 
has clear relevance to understanding patient outcomes. Whether similar regulatory mechanisms 
are responsible for dynamic EMT induction and stable mesenchymal maintenance is unknown. 
PLSR analysis of EMT phenotypes using protein abundance and phosphorylation profiles in a 
large panel of cell lines across the spectrum of baseline epithelial and mesenchymal traits and 
cells undergoing growth factor-mediated EMT could reveal mechanisms underlying the distinction 
between permanent and transient EMT. Such a model could also incorporate measurements of 
response to EGFR inhibitors or chemotherapeutics to determine how the dynamics of EMT 
influence widely observed therapeutic resistance. 
 
 
  
117 
 
BIBLIOGRAPHY 
 
1. Yang, J. and R.A. Weinberg, Epithelial-mesenchymal transition: at the crossroads of 
development and tumor metastasis. Dev Cell, 2008. 14(6): p. 818-29. 
2. Kalluri, R. and R.A. Weinberg, The basics of epithelial-mesenchymal transition. J Clin 
Invest, 2009. 119(6): p. 1420-8. 
3. Thiery, J.P., Epithelial-mesenchymal transitions in development and pathologies. Curr 
Opin Cell Biol, 2003. 15(6): p. 740-6. 
4. Massague, J., TGFbeta in Cancer. Cell, 2008. 134(2): p. 215-30. 
5. Yilmaz, M. and G. Christofori, EMT, the cytoskeleton, and cancer cell invasion. Cancer 
Metastasis Rev, 2009. 28(1-2): p. 15-33. 
6. Schmidt, J.M., et al., Stem-cell-like properties and epithelial plasticity arise as stable traits 
after transient Twist1 activation. Cell Rep, 2015. 10(2): p. 131-9. 
7. Tam, W.L., et al., Protein kinase C alpha is a central signaling node and therapeutic 
target for breast cancer stem cells. Cancer Cell, 2013. 24(3): p. 347-64. 
8. Warzecha, C.C., et al., An ESRP-regulated splicing programme is abrogated during the 
epithelial-mesenchymal transition. EMBO J, 2010. 29(19): p. 3286-300. 
9. De Craene, B. and G. Berx, Regulatory networks defining EMT during cancer initiation 
and progression. Nat Rev Cancer, 2013. 13(2): p. 97-110. 
10. Wakefield, L.M. and A.B. Roberts, TGF-beta signaling: positive and negative effects on 
tumorigenesis. Curr Opin Genet Dev, 2002. 12(1): p. 22-9. 
11. Argast, G.M., et al., Cooperative signaling between oncostatin M, hepatocyte growth 
factor and transforming growth factor-beta enhances epithelial to mesenchymal transition 
in lung and pancreatic tumor models. Cells Tissues Organs, 2011. 193(1-2): p. 114-32. 
12. Saha, D., et al., Synergistic induction of cyclooxygenase-2 by transforming growth factor-
beta1 and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia, 1999. 
1(6): p. 508-17. 
13. Docherty, N.G., et al., TGF-beta1-induced EMT can occur independently of its 
proapoptotic effects and is aided by EGF receptor activation. Am J Physiol Renal Physiol, 
2006. 290(5): p. F1202-12. 
14. Grande, M., et al., Transforming growth factor-beta and epidermal growth factor 
synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-
dependent mechanism in primary cultured pig thyrocytes. J Cell Sci, 2002. 115(Pt 22): p. 
4227-36. 
15. Bissell, M.J. and D. Radisky, Putting tumours in context. Nat Rev Cancer, 2001. 1(1): p. 
46-54. 
16. O'Brien, L.E., M.M. Zegers, and K.E. Mostov, Opinion: Building epithelial architecture: 
insights from three-dimensional culture models. Nat Rev Mol Cell Biol, 2002. 3(7): p. 531-
7. 
17. Reginato, M.J., et al., Bim regulation of lumen formation in cultured mammary epithelial 
acini is targeted by oncogenes. Mol Cell Biol, 2005. 25(11): p. 4591-601. 
18. Mehlen, P. and A. Puisieux, Metastasis: a question of life or death. Nat Rev Cancer, 
2006. 6(6): p. 449-58. 
118 
 
19. Weigelt, B., J.L. Peterse, and L.J. van 't Veer, Breast cancer metastasis: markers and 
models. Nat Rev Cancer, 2005. 5(8): p. 591-602. 
20. Tarin, D., E.W. Thompson, and D.F. Newgreen, The fallacy of epithelial mesenchymal 
transition in neoplasia. Cancer Res, 2005. 65(14): p. 5996-6000; discussion 6000-1. 
21. Rhim, A.D., et al., EMT and dissemination precede pancreatic tumor formation. Cell, 
2012. 148(1-2): p. 349-61. 
22. Celia-Terrassa, T., et al., Epithelial-mesenchymal transition can suppress major attributes 
of human epithelial tumor-initiating cells. J Clin Invest, 2012. 122(5): p. 1849-68. 
23. Tsai, J.H., et al., Spatiotemporal regulation of epithelial-mesenchymal transition is 
essential for squamous cell carcinoma metastasis. Cancer Cell, 2012. 22(6): p. 725-36. 
24. Singh, A. and J. Settleman, EMT, cancer stem cells and drug resistance: an emerging 
axis of evil in the war on cancer. Oncogene, 2010. 29(34): p. 4741-51. 
25. Garofalo, M., et al., EGFR and MET receptor tyrosine kinase-altered microRNA 
expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med, 
2011. 18(1): p. 74-82. 
26. Thomson, S., et al., Kinase switching in mesenchymal-like non-small cell lung cancer 
lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp 
Metastasis, 2008. 25(8): p. 843-54. 
27. Yauch, R.L., et al., Epithelial versus mesenchymal phenotype determines in vitro 
sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer 
Res, 2005. 11(24 Pt 1): p. 8686-98. 
28. Wilson, C., et al., AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. 
Cancer Res, 2014. 74(20): p. 5878-90. 
29. Shrader, M., et al., Molecular correlates of gefitinib responsiveness in human bladder 
cancer cells. Mol Cancer Ther, 2007. 6(1): p. 277-85. 
30. Frederick, B.A., et al., Epithelial to mesenchymal transition predicts gefitinib resistance in 
cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. 
Mol Cancer Ther, 2007. 6(6): p. 1683-91. 
31. Maseki, S., et al., Acquisition of EMT phenotype in the gefitinib-resistant cells of a head 
and neck squamous cell carcinoma cell line through Akt/GSK-3beta/snail signalling 
pathway. Br J Cancer, 2012. 106(6): p. 1196-204. 
32. Yin, T., et al., Expression of snail in pancreatic cancer promotes metastasis and 
chemoresistance. J Surg Res, 2007. 141(2): p. 196-203. 
33. Li, X., et al., Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J 
Natl Cancer Inst, 2008. 100(9): p. 672-9. 
34. Suda, K., et al., Epithelial to mesenchymal transition in an epidermal growth factor 
receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac 
Oncol, 2011. 6(7): p. 1152-61. 
35. Yao, Z., et al., TGF-beta IL-6 axis mediates selective and adaptive mechanisms of 
resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A, 2010. 
107(35): p. 15535-40. 
36. Kemper, K., et al., Phenotype switching: tumor cell plasticity as a resistance mechanism 
and target for therapy. Cancer Res, 2014. 74(21): p. 5937-41. 
119 
 
37. Bonnet, D. and J.E. Dick, Human acute myeloid leukemia is organized as a hierarchy that 
originates from a primitive hematopoietic cell. Nat Med, 1997. 3(7): p. 730-7. 
38. Al-Hajj, M., et al., Prospective identification of tumorigenic breast cancer cells. Proc Natl 
Acad Sci U S A, 2003. 100(7): p. 3983-8. 
39. O'Brien, C.A., et al., A human colon cancer cell capable of initiating tumour growth in 
immunodeficient mice. Nature, 2007. 445(7123): p. 106-10. 
40. Mani, S.A., et al., The epithelial-mesenchymal transition generates cells with properties of 
stem cells. Cell, 2008. 133(4): p. 704-15. 
41. Antoniou, A., et al., Cancer stem cells, a fuzzy evolving concept: a cell population or a 
cell property? Cell Cycle, 2013. 12(24): p. 3743-8. 
42. Floor, S., et al., Cancer cells in epithelial-to-mesenchymal transition and tumor-
propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene, 
2011. 30(46): p. 4609-21. 
43. Lemmon, M.A. and J. Schlessinger, Cell signaling by receptor tyrosine kinases. Cell, 
2010. 141(7): p. 1117-34. 
44. Schlessinger, J. and M.A. Lemmon, SH2 and PTB domains in tyrosine kinase signaling. 
Sci STKE, 2003. 2003(191): p. RE12. 
45. Zavadil, J., et al., Genetic programs of epithelial cell plasticity directed by transforming 
growth factor-beta. Proc Natl Acad Sci U S A, 2001. 98(12): p. 6686-91. 
46. Gonzalez, D.M. and D. Medici, Signaling mechanisms of the epithelial-mesenchymal 
transition. Sci Signal, 2014. 7(344): p. re8. 
47. Zhang, Y.E., Non-Smad pathways in TGF-beta signaling. Cell Res, 2009. 19(1): p. 128-
39. 
48. Lawler, S., et al., The type II transforming growth factor-beta receptor autophosphorylates 
not only on serine and threonine but also on tyrosine residues. J Biol Chem, 1997. 
272(23): p. 14850-9. 
49. Galliher, A.J. and W.P. Schiemann, Src phosphorylates Tyr284 in TGF-beta type II 
receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell 
proliferation and invasion. Cancer Res, 2007. 67(8): p. 3752-8. 
50. Galliher-Beckley, A.J. and W.P. Schiemann, Grb2 binding to Tyr284 in TbetaR-II is 
essential for mammary tumor growth and metastasis stimulated by TGF-beta. 
Carcinogenesis, 2008. 29(2): p. 244-51. 
51. Lee, M.K., et al., TGF-beta activates Erk MAP kinase signalling through direct 
phosphorylation of ShcA. EMBO J, 2007. 26(17): p. 3957-67. 
52. Xie, L., et al., Activation of the Erk pathway is required for TGF-beta1-induced EMT in 
vitro. Neoplasia, 2004. 6(5): p. 603-10. 
53. Lo, H.W., et al., Epidermal growth factor receptor cooperates with signal transducer and 
activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via 
up-regulation of TWIST gene expression. Cancer Res, 2007. 67(19): p. 9066-76. 
54. Savagner, P., K.M. Yamada, and J.P. Thiery, The zinc-finger protein slug causes 
desmosome dissociation, an initial and necessary step for growth factor-induced 
epithelial-mesenchymal transition. J Cell Biol, 1997. 137(6): p. 1403-19. 
120 
 
55. Joo, C.K., et al., Ligand release-independent transactivation of epidermal growth factor 
receptor by transforming growth factor-beta involves multiple signaling pathways. 
Oncogene, 2008. 27(5): p. 614-28. 
56. Murillo, M.M., et al., Involvement of EGF receptor and c-Src in the survival signals 
induced by TGF-beta1 in hepatocytes. Oncogene, 2005. 24(28): p. 4580-7. 
57. Uttamsingh, S., et al., Synergistic effect between EGF and TGF-beta1 in inducing 
oncogenic properties of intestinal epithelial cells. Oncogene, 2008. 27(18): p. 2626-34. 
58. Salt, M.B., S. Bandyopadhyay, and F. McCormick, Epithelial-to-mesenchymal transition 
rewires the molecular path to PI3K-dependent proliferation. Cancer Discov, 2014. 4(2): p. 
186-99. 
59. Jahn, S.C., et al., An in vivo model of epithelial to mesenchymal transition reveals a 
mitogenic switch. Cancer Lett, 2012. 326(2): p. 183-90. 
60. Shilo, B.Z., Regulating the dynamics of EGF receptor signaling in space and time. 
Development, 2005. 132(18): p. 4017-27. 
61. Wieduwilt, M.J. and M.M. Moasser, The epidermal growth factor receptor family: biology 
driving targeted therapeutics. Cell Mol Life Sci, 2008. 65(10): p. 1566-84. 
62. Mukohara, T., et al., Expression of epidermal growth factor receptor (EGFR) and 
downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). 
Lung Cancer, 2003. 41(2): p. 123-30. 
63. Aldape, K.D., et al., Immunohistochemical detection of EGFRvIII in high malignancy 
grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol, 
2004. 63(7): p. 700-7. 
64. Frederick, L., et al., Diversity and frequency of epidermal growth factor receptor 
mutations in human glioblastomas. Cancer Res, 2000. 60(5): p. 1383-7. 
65. Chong, C.R. and P.A. Janne, The quest to overcome resistance to EGFR-targeted 
therapies in cancer. Nat Med, 2013. 19(11): p. 1389-400. 
66. Lynch, T.J., et al., Activating mutations in the epidermal growth factor receptor underlying 
responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004. 350(21): p. 
2129-39. 
67. Sordella, R., et al., Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-
apoptotic pathways. Science, 2004. 305(5687): p. 1163-7. 
68. Helfrich, B.A., et al., Antitumor activity of the epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines 
correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin 
Cancer Res, 2006. 12(23): p. 7117-25. 
69. Kobayashi, S., et al., EGFR mutation and resistance of non-small-cell lung cancer to 
gefitinib. N Engl J Med, 2005. 352(8): p. 786-92. 
70. Pao, W., et al., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is 
associated with a second mutation in the EGFR kinase domain. PLoS Med, 2005. 2(3): p. 
e73. 
71. Engelman, J.A., et al., MET amplification leads to gefitinib resistance in lung cancer by 
activating ERBB3 signaling. Science, 2007. 316(5827): p. 1039-43. 
72. Ercan, D., et al., Reactivation of ERK Signaling Causes Resistance to EGFR Kinase 
Inhibitors. Cancer Discov, 2012. 2(10): p. 934-947. 
121 
 
73. Takeyama, Y., et al., Knockdown of ZEB1, a master epithelial-to-mesenchymal transition 
(EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer 
Lett, 2010. 296(2): p. 216-24. 
74. Lazzara, M.J., et al., Impaired SHP2-mediated extracellular signal-regulated kinase 
activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth 
factor receptor-activating mutations. Cancer Res, 2010. 70(9): p. 3843-50. 
75. Furcht, C.M., et al., Diminished functional role and altered localization of SHP2 in non-
small cell lung cancer cells with EGFR-activating mutations. Oncogene, 2013. 32(18): p. 
2346-55, 2355 e1-10. 
76. Gu, H. and B.G. Neel, The "Gab" in signal transduction. Trends Cell Biol, 2003. 13(3): p. 
122-30. 
77. Barford, D. and B.G. Neel, Revealing mechanisms for SH2 domain mediated regulation 
of the protein tyrosine phosphatase SHP-2. Structure, 1998. 6(3): p. 249-54. 
78. Neel, B.G., H. Gu, and L. Pao, The 'Shp'ing news: SH2 domain-containing tyrosine 
phosphatases in cell signaling. Trends Biochem Sci, 2003. 28(6): p. 284-93. 
79. Pluskey, S., et al., Potent stimulation of SH-PTP2 phosphatase activity by simultaneous 
occupancy of both SH2 domains. J Biol Chem, 1995. 270(7): p. 2897-900. 
80. Chan, G., D. Kalaitzidis, and B.G. Neel, The tyrosine phosphatase Shp2 (PTPN11) in 
cancer. Cancer Metastasis Rev, 2008. 27(2): p. 179-92. 
81. Mohi, M.G. and B.G. Neel, The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev, 
2007. 17(1): p. 23-30. 
82. Aceto, N., et al., Tyrosine phosphatase SHP2 promotes breast cancer progression and 
maintains tumor-initiating cells via activation of key transcription factors and a positive 
feedback signaling loop. Nat Med, 2012. 18(4): p. 529-37. 
83. Furcht, C.M., et al., Multivariate signaling regulation by SHP2 differentially controls 
proliferation and therapeutic response in glioma cells. J Cell Sci, 2014. 127(Pt 16): p. 
3555-67. 
84. Neuzillet, C., et al., MEK in cancer and cancer therapy. Pharmacol Ther, 2014. 141(2): p. 
160-71. 
85. Roberts, P.J. and C.J. Der, Targeting the Raf-MEK-ERK mitogen-activated protein kinase 
cascade for the treatment of cancer. Oncogene, 2007. 26(22): p. 3291-310. 
86. Cox, A.D., et al., Drugging the undruggable RAS: Mission possible? Nat Rev Drug 
Discov, 2014. 13(11): p. 828-51. 
87. Der, C.J., T.G. Krontiris, and G.M. Cooper, Transforming genes of human bladder and 
lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten 
sarcoma viruses. Proc Natl Acad Sci U S A, 1982. 79(11): p. 3637-40. 
88. Parada, L.F., et al., Human EJ bladder carcinoma oncogene is homologue of Harvey 
sarcoma virus ras gene. Nature, 1982. 297(5866): p. 474-8. 
89. Cox, A.D. and C.J. Der, The raf inhibitor paradox: unexpected consequences of targeted 
drugs. Cancer Cell, 2010. 17(3): p. 221-3. 
90. Heidorn, S.J., et al., Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor 
progression through CRAF. Cell, 2010. 140(2): p. 209-21. 
91. Flaherty, K.T., et al., Improved survival with MEK inhibition in BRAF-mutated melanoma. 
N Engl J Med, 2012. 367(2): p. 107-14. 
122 
 
92. Robert, C., et al., Improved overall survival in melanoma with combined dabrafenib and 
trametinib. N Engl J Med, 2015. 372(1): p. 30-9. 
93. Shin, S., et al., ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via 
DEF motif-dependent signaling events. Mol Cell, 2010. 38(1): p. 114-27. 
94. Botta, G.P., et al., Constitutive K-RasG12D activation of ERK2 specifically regulates 3D 
invasion of human pancreatic cancer cells via MMP-1. Mol Cancer Res, 2011. 10(2): p. 
183-96. 
95. Liu, X., et al., PTPN14 interacts with and negatively regulates the oncogenic function of 
YAP. Oncogene, 2012. 
96. Wong, V.C., et al., Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs 
cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int J 
Cancer, 2011. 130(1): p. 83-95. 
97. Zhou, X.D. and Y.M. Agazie, Inhibition of SHP2 leads to mesenchymal to epithelial 
transition in breast cancer cells. Cell Death Differ, 2008. 15(6): p. 988-96. 
98. Wendt, M.K., J.A. Smith, and W.P. Schiemann, Transforming growth factor-beta-induced 
epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast 
cancer progression. Oncogene, 2010. 29(49): p. 6485-98. 
99. Blumenschein, G.R., Jr., et al., Phase II study of cetuximab in combination with 
chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J 
Clin Oncol, 2011. 29(17): p. 2312-8. 
100. Spigel, D.R., et al., Randomized, double-blind, placebo-controlled, phase II trial of 
sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell 
lung cancer. J Clin Oncol, 2011. 29(18): p. 2582-9. 
101. Xu, L., et al., Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the 
Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET. 
Cancer Res, 2012. 72(13): p. 3302-3311. 
102. Lee, M.J., et al., Sequential application of anticancer drugs enhances cell death by 
rewiring apoptotic signaling networks. Cell, 2012. 149(4): p. 780-94. 
103. Zavadil, J. and E.P. Bottinger, TGF-beta and epithelial-to-mesenchymal transitions. 
Oncogene, 2005. 24(37): p. 5764-74. 
104. Witta, S.E., et al., Restoring E-cadherin expression increases sensitivity to epidermal 
growth factor receptor inhibitors in lung cancer cell lines. Cancer Res, 2006. 66(2): p. 
944-50. 
105. Zhang, Z., et al., Activation of the AXL kinase causes resistance to EGFR-targeted 
therapy in lung cancer. Nat Genet, 2012. 44(8): p. 852-60. 
106. Furcht, C.M., et al., Diminished functional role and altered localization of SHP2 in non-
small cell lung cancer cells with EGFR-activating mutations. Oncogene, 2012. 
107. Lund, K.A., et al., Quantitative analysis of the endocytic system involved in hormone-
induced receptor internalization. J Biol Chem, 1990. 265(26): p. 15713-23. 
108. Wiley, H.S. and D.D. Cunningham, The endocytotic rate constant. A cellular parameter 
for quantitating receptor-mediated endocytosis. J Biol Chem, 1982. 257(8): p. 4222-9. 
109. Singh, A., et al., A gene expression signature associated with "K-Ras addiction" reveals 
regulators of EMT and tumor cell survival. Cancer Cell, 2009. 15(6): p. 489-500. 
123 
 
110. Basu, D., et al., Evidence for mesenchymal-like sub-populations within squamous cell 
carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene, 2010. 
29(29): p. 4170-82. 
111. Basu, D., et al., Detecting and targeting mesenchymal-like subpopulations within 
squamous cell carcinomas. Cell Cycle, 2011. 10(12): p. 2008-16. 
112. Zhou, W., et al., Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. 
Nature, 2009. 462(7276): p. 1070-4. 
113. Janda, E., et al., Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and 
metastasis: dissection of Ras signaling pathways. J Cell Biol, 2002. 156(2): p. 299-313. 
114. Lehmann, K., et al., Raf induces TGFbeta production while blocking its apoptotic but not 
invasive responses: a mechanism leading to increased malignancy in epithelial cells. 
Genes Dev, 2000. 14(20): p. 2610-22. 
115. Peinado, H., M. Quintanilla, and A. Cano, Transforming growth factor beta-1 induces 
snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal 
transitions. J Biol Chem, 2003. 278(23): p. 21113-23. 
116. von Thun, A., et al., ERK2 drives tumour cell migration in three-dimensional 
microenvironments by suppressing expression of Rab17 and liprin-beta2. J Cell Sci, 
2012. 125(Pt 6): p. 1465-77. 
117. Han, M., et al., Antagonism of miR-21 Reverses Epithelial-Mesenchymal Transition and 
Cancer Stem Cell Phenotype through AKT/ERK1/2 Inactivation by Targeting PTEN. 
PLoS One, 2012. 7(6): p. e39520. 
118. Yoon, Y.K., et al., Combination of EGFR and MEK1/2 inhibitor shows synergistic effects 
by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. 
Mol Cancer Ther, 2009. 8(9): p. 2526-36. 
119. Diep, C.H., et al., Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-
type human pancreatic cancer cells. Clin Cancer Res, 2011. 17(9): p. 2744-56. 
120. Wang, D., et al., Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys 
Acta, 2007. 1773(8): p. 1248-55. 
121. Xing, H., et al., Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel 
by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett, 
2008. 261(1): p. 108-19. 
122. Pratilas, C.A., et al., Genetic predictors of MEK dependence in non-small cell lung 
cancer. Cancer Res, 2008. 68(22): p. 9375-83. 
123. Chaffer, C.L. and R.A. Weinberg, A perspective on cancer cell metastasis. Science, 
2011. 331(6024): p. 1559-64. 
124. Tan, T.Z., et al., Epithelial-mesenchymal transition spectrum quantification and its 
efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med, 
2014. 6(10): p. 1279-93. 
125. Arumugam, T., et al., Epithelial to mesenchymal transition contributes to drug resistance 
in pancreatic cancer. Cancer Res, 2009. 69(14): p. 5820-8. 
126. Buonato, J.M. and M.J. Lazzara, ERK1/2 blockade prevents epithelial-mesenchymal 
transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer 
Res, 2014. 74(1): p. 309-19. 
127. Davis, F.M., et al., Targeting EMT in cancer: opportunities for pharmacological 
intervention. Trends Pharmacol Sci, 2014. 35(9): p. 479-488. 
124 
 
128. Dragoi, A.M., et al., Novel strategies to enforce an epithelial phenotype in mesenchymal 
cells. Cancer Res, 2014. 74(14): p. 3659-72. 
129. Wilson, C., et al., Overcoming EMT-associated resistance to anti-cancer drugs via 
Src/FAK pathway inhibition. Oncotarget, 2014. 5(17): p. 7328-41. 
130. Hof, P., et al., Crystal structure of the tyrosine phosphatase SHP-2. Cell, 1998. 92(4): p. 
441-50. 
131. Eck, M.J., et al., Spatial constraints on the recognition of phosphoproteins by the tandem 
SH2 domains of the phosphatase SH-PTP2. Nature, 1996. 379(6562): p. 277-80. 
132. Lechleider, R.J., et al., Activation of the SH2-containing phosphotyrosine phosphatase 
SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived 
growth factor receptor. J Biol Chem, 1993. 268(29): p. 21478-81. 
133. Sugimoto, S., et al., Activation of the SH2-containing protein tyrosine phosphatase, SH-
PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. 
J Biol Chem, 1994. 269(18): p. 13614-22. 
134. Kapoor, G.S., et al., Distinct domains in the SHP-2 phosphatase differentially regulate 
epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma 
cells. Mol Cell Biol, 2004. 24(2): p. 823-36. 
135. O'Reilly, A.M. and B.G. Neel, Structural determinants of SHP-2 function and specificity in 
Xenopus mesoderm induction. Mol Cell Biol, 1998. 18(1): p. 161-77. 
136. Stewart, R.A., et al., Phosphatase-dependent and -independent functions of Shp2 in 
neural crest cells underlie LEOPARD syndrome pathogenesis. Dev Cell, 2010. 18(5): p. 
750-62. 
137. Li, S., et al., SHP2 Positively Regulates TGFbeta1-induced Epithelial-mesenchymal 
Transition Modulated by Its Novel Interacting Protein Hook1. J Biol Chem, 2014. 
138. Loerke, D., et al., Quantitative imaging of epithelial cell scattering identifies specific 
inhibitors of cell motility and cell-cell dissociation. Sci Signal, 2012. 5(231): p. rs5. 
139. Caslavsky, J., Z. Klimova, and T. Vomastek, ERK and RSK regulate distinct steps of a 
cellular program that induces transition from multicellular epithelium to single cell 
phenotype. Cell Signal, 2013. 25(12): p. 2743-51. 
140. Ventura, A., et al., Cre-lox-regulated conditional RNA interference from transgenes. Proc 
Natl Acad Sci U S A, 2004. 101(28): p. 10380-5. 
141. Thomson, S., et al., Epithelial to mesenchymal transition is a determinant of sensitivity of 
non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor 
receptor inhibition. Cancer Res, 2005. 65(20): p. 9455-62. 
142. Rajasekaran, S.A., et al., HPAF-II, a cell culture model to study pancreatic epithelial cell 
structure and function. Pancreas, 2004. 29(3): p. e77-83. 
143. Deer, E.L., et al., Phenotype and genotype of pancreatic cancer cell lines. Pancreas, 
2010. 39(4): p. 425-35. 
144. Gotzmann, J., et al., A crucial function of PDGF in TGF-beta-mediated cancer 
progression of hepatocytes. Oncogene, 2006. 25(22): p. 3170-85. 
145. Zieba, A., et al., Intercellular variation in signaling through the TGF-beta pathway and its 
relation to cell density and cell cycle phase. Mol Cell Proteomics, 2012. 11(7): p. M111 
013482. 
125 
 
146. Nallet-Staub, F., et al., Cell Density Sensing Alters TGF-beta Signaling in a Cell-Type-
Specific Manner, Independent from Hippo Pathway Activation. Dev Cell, 2015. 32(5): p. 
640-51. 
147. Schutte, M., et al., DPC4 gene in various tumor types. Cancer Res, 1996. 56(11): p. 
2527-30. 
148. Hartman, Z.R., M.D. Schaller, and Y.M. Agazie, The tyrosine phosphatase SHP2 
regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and 
cell migration. Mol Cancer Res, 2013. 11(6): p. 651-64. 
149. Lee, H.H., et al., Shp2 plays a crucial role in cell structural orientation and force polarity in 
response to matrix rigidity. Proc Natl Acad Sci U S A, 2013. 110(8): p. 2840-5. 
150. Wendt, M.K. and W.P. Schiemann, Therapeutic targeting of the focal adhesion complex 
prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res, 2009. 11(5): 
p. R68. 
151. Furcht, C.M., J.M. Buonato, and M.J. Lazzara, EGFR-activated Src Family Kinases 
Maintain GAB1-SHP2 Complexes Distal from EGFR. Science Signaling, 2015. 
Accepted. 
152. Bentires-Alj, M., et al., Activating mutations of the noonan syndrome-associated 
SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. 
Cancer Res, 2004. 64(24): p. 8816-20. 
153. Yu, B., et al., Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-
associated malignancies. Mol Cancer Ther, 2013. 12(9): p. 1738-48. 
154. Chio, C.M., C.S. Lim, and A.C. Bishop, Targeting a cryptic allosteric site for selective 
inhibition of the oncogenic protein tyrosine phosphatase shp2. Biochemistry, 2015. 54(2): 
p. 497-504. 
155. Vincent, A., et al., Pancreatic cancer. Lancet, 2011. 378(9791): p. 607-20. 
156. Costello, E., W. Greenhalf, and J.P. Neoptolemos, New biomarkers and targets in 
pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol, 
2012. 9(8): p. 435-44. 
157. Bakin, A.V., et al., p38 mitogen-activated protein kinase is required for TGFbeta-
mediated fibroblastic transdifferentiation and cell migration. J Cell Sci, 2002. 115(Pt 15): 
p. 3193-206. 
158. Maier, H.J., et al., NF-kappaB promotes epithelial-mesenchymal transition, migration and 
invasion of pancreatic carcinoma cells. Cancer Lett, 2010. 295(2): p. 214-28. 
159. Nagai, T., et al., Sorafenib inhibits the hepatocyte growth factor-mediated epithelial 
mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther, 2011. 10(1): p. 
169-77. 
160. Albeck, J.G., G.B. Mills, and J.S. Brugge, Frequency-modulated pulses of ERK activity 
transmit quantitative proliferation signals. Mol Cell, 2013. 49(2): p. 249-61. 
161. Birchmeier, C., et al., Met, metastasis, motility and more. Nat Rev Mol Cell Biol, 2003. 
4(12): p. 915-25. 
162. Purvis, J.E. and G. Lahav, Encoding and decoding cellular information through signaling 
dynamics. Cell, 2013. 152(5): p. 945-56. 
163. Geladi, P. and B.R. Kowalski, Partial Least-Squares Regression - a Tutorial. Analytica 
Chimica Acta, 1986. 185: p. 1-17. 
126 
 
164. Wold, S., M. Sjostrom, and L. Eriksson, PLS-regression: a basic tool of chemometrics. 
Chemometrics and Intelligent Laboratory Systems, 2001. 58(2): p. 109-130. 
165. Janes, K.A. and M.B. Yaffe, Data-driven modelling of signal-transduction networks. Nat 
Rev Mol Cell Biol, 2006. 7(11): p. 820-8. 
166. Kumar, N., et al., Modeling HER2 effects on cell behavior from mass spectrometry 
phosphotyrosine data. PLoS Comput Biol, 2007. 3(1): p. e4. 
167. Kim, H.D., et al., Signaling network state predicts twist-mediated effects on breast cell 
migration across diverse growth factor contexts. Mol Cell Proteomics, 2011. 10(11): p. 
M111 008433. 
168. Wong, I.Y., et al., Collective and individual migration following the epithelial-
mesenchymal transition. Nat Mater, 2014. 13(11): p. 1063-71. 
169. Zhao, D., et al., Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor 
metastasis via STAT3-mediated Twist1 upregulation. Oncogene, 2015. 
170. Liu, J., et al., The oncogene c-Jun impedes somatic cell reprogramming. Nat Cell Biol, 
2015. 17(7): p. 856-67. 
171. Bain, J., et al., The selectivity of protein kinase inhibitors: a further update. Biochem J, 
2007. 408(3): p. 297-315. 
172. Misale, S., et al., Blockade of EGFR and MEK intercepts heterogeneous mechanisms of 
acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med, 2014. 
6(224): p. 224ra26. 
173. Judd, N.P., et al., ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. 
Cancer Res, 2012. 72(1): p. 365-74. 
174. Weiss, M.B., et al., TWIST1 is an ERK1/2 effector that promotes invasion and regulates 
MMP-1 expression in human melanoma cells. Cancer Res, 2012. 72(24): p. 6382-92. 
175. Smith, M.A., et al., Annotation of human cancers with EGFR signaling-associated protein 
complexes using proximity ligation assays. Sci Signal, 2015. 8(359): p. ra4. 
176. Peng, S., et al., Tumor grafts derived from patients with head and neck squamous 
carcinoma authentically maintain the molecular and histologic characteristics of human 
cancers. J Transl Med, 2013. 11: p. 198. 
177. Siolas, D. and G.J. Hannon, Patient-derived tumor xenografts: transforming clinical 
samples into mouse models. Cancer Res, 2013. 73(17): p. 5315-9. 
178. Wang, K., et al., PEST Domain Mutations in Notch Receptors Comprise an Oncogenic 
Driver Segment in Triple-Negative Breast Cancer Sensitive to a gamma-Secretase 
Inhibitor. Clin Cancer Res, 2015. 21(6): p. 1487-96. 
179. Klinghammer, K., et al., A comprehensively characterized large panel of head and neck 
cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential 
new treatment option. Int J Cancer, 2014. 
180. Schuller, A., et al., The MET inhibitor AZD6094 (Savolitinib, HMPL-504) induces 
regression in papillary renal cell carcinoma patient derived xenograft models. Clin Cancer 
Res, 2015. 
181. Dobbin, Z.C., et al., Using heterogeneity of the patient-derived xenograft model to identify 
the chemoresistant population in ovarian cancer. Oncotarget, 2014. 5(18): p. 8750-64. 
182. Davis, F.M., et al., Targeting EMT in cancer: opportunities for pharmacological 
intervention. Trends Pharmacol Sci, 2014. 35(9): p. 479-88. 
127 
 
183. Leszczyniecka, M., et al., Differentiation therapy of human cancer: basic science and 
clinical applications. Pharmacol Ther, 2001. 90(2-3): p. 105-56. 
184. Sachs, L., Control of normal cell differentiation and the phenotypic reversion of 
malignancy in myeloid leukaemia. Nature, 1978. 274(5671): p. 535-9. 
185. Gupta, P.B., et al., Identification of selective inhibitors of cancer stem cells by high-
throughput screening. Cell, 2009. 138(4): p. 645-59. 
186. Chua, K.N., et al., A cell-based small molecule screening method for identifying inhibitors 
of epithelial-mesenchymal transition in carcinoma. PLoS One, 2012. 7(3): p. e33183. 
187. Hirano, T., et al., Identification of novel small compounds that restore E-cadherin 
expression and inhibit tumor cell motility and invasiveness. Biochem Pharmacol, 2013. 
86(10): p. 1419-29. 
188. Fabbro, D., et al., Targeting cancer with small-molecular-weight kinase inhibitors. 
Methods Mol Biol, 2012. 795: p. 1-34. 
189. Barr, A.J., Protein tyrosine phosphatases as drug targets: strategies and challenges of 
inhibitor development. Future Med Chem, 2010. 2(10): p. 1563-76. 
190. He, R., et al., Small molecule tools for functional interrogation of protein tyrosine 
phosphatases. FEBS J, 2013. 280(2): p. 731-50. 
191. Krishnan, N., et al., Targeting the disordered C terminus of PTP1B with an allosteric 
inhibitor. Nat Chem Biol, 2014. 10(7): p. 558-66. 
192. Li, S., et al., SHP2 positively regulates TGFbeta1-induced epithelial-mesenchymal 
transition modulated by its novel interacting protein Hook1. J Biol Chem, 2014. 289(49): 
p. 34152-60. 
193. Burks, J. and Y.M. Agazie, Modulation of alpha-catenin Tyr phosphorylation by SHP2 
positively effects cell transformation induced by the constitutively active FGFR3. 
Oncogene, 2006. 25(54): p. 7166-79. 
194. Vasilescu, J. and D. Figeys, Mapping protein-protein interactions by mass spectrometry. 
Curr Opin Biotechnol, 2006. 17(4): p. 394-9. 
195. Ren, Y., et al., Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src 
activation in response to epidermal growth factor. J Biol Chem, 2004. 279(9): p. 8497-
505. 
196. Jares-Erijman, E.A. and T.M. Jovin, FRET imaging. Nat Biotechnol, 2003. 21(11): p. 
1387-95. 
197. Piston, D.W. and G.J. Kremers, Fluorescent protein FRET: the good, the bad and the 
ugly. Trends Biochem Sci, 2007. 32(9): p. 407-14. 
198. Soderberg, O., et al., Characterizing proteins and their interactions in cells and tissues 
using the in situ proximity ligation assay. Methods, 2008. 45(3): p. 227-32. 
199. Levy, L. and C.S. Hill, Smad4 dependency defines two classes of transforming growth 
factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-
mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol, 
2005. 25(18): p. 8108-25. 
200. Zhao, S., et al., Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses 
transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer 
cells. Cancer Res, 2008. 68(11): p. 4221-8. 
128 
 
201. Bardeesy, N., et al., Smad4 is dispensable for normal pancreas development yet critical 
in progression and tumor biology of pancreas cancer. Genes Dev, 2006. 20(22): p. 3130-
46. 
202. Doudna, J.A. and E. Charpentier, Genome editing. The new frontier of genome 
engineering with CRISPR-Cas9. Science, 2014. 346(6213): p. 1258096. 
203. Zhang, J., et al., TGF-beta-induced epithelial-to-mesenchymal transition proceeds 
through stepwise activation of multiple feedback loops. Sci Signal, 2014. 7(345): p. ra91. 
 
 
